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A series of twelve 4-amino-7-chloroquinolines containing (N, N-dibenzylmethylamine) 
dibemethin side chains attached to the amino group of the quinoline were synthesized 
by reaction of aminomethyl dibemethins with 4,7-dichloroquinoline to give 
“dibemethinoquines”. The attachment between the quinoline ring and the side chain was 
varied from ortho, to meta to para. The aminomethyl dibemethin side chains were 
synthesized using the Staudinger reduction of azides or the reductive amination via 
oxime of an aldehyde. Derivatives in which the para substituent on the terminal phenyl 
ring were altered from the parent compound (X = H) by replacement with Cl, OCH3 or 
NMe2 group were also synthesized. The choice of substituents was based on the Topliss 
scheme. Analogues of these aminomethyl dibemethins in which their primary amino 
terminus was formylated were also synthesized via a single step reaction with ethyl 
formate to afford amidomethyl dibemethins. Thus, three classes of compounds; 
aminomethyl dibemethins, their formylated derivatives (amidomethyl dibemethins) and 
the proposed “reversed chloroquine” dibemethinoquines were successfully synthesized. 
Their in vitro biological activity was evaluated against chloroquine-sensitive (D10) as well 
as chloroquine-resistant (K1 or in some cases W2) strains of Plasmodium falciparum. In 
vivo activity of these compounds was also tested for two representative compounds 
against P. yoelii nigeriensis. These compounds showed significant in vivo antimalarial 
activity in the mouse model P. yoelii nigeriensis, although neither was as active as 
chloroquine diphosphate when administered by intra-peritoneal injection. This observed 
lower activity relative to chloroquine diphosphate could be ascribed to poor solubility of 
the free bases of these compounds as they were administered as suspensions, whereas 
chloroquine diphosphate was a solution. A preliminary cytotoxicity investigation of the 
prototype compound in Chinese hamster ovarian (CHO) cells showed that it exhibits 
highly selective activity against the malaria parasite. 
 
Dibemethinoquine compounds exhibited activity against both chloroquine sensitive and 
resistant parasites in vitro. Their IC50 values in the K1 strain ranged between 24 nM and 
1 µM, with one compound showing no activity even at 23 µM. These values compared to 
284 nM and 29 nM for chloroquine in chloroquine resistant and chloroquine sensitive 
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parasites respectively. Thus the most active compound had an IC50 almost identical to 
chloroquine in the chloroquine sensitive strain. Two other compounds showed similarly 
strong activity. Structure-activity studies show that, as with other chloroquine analogues, 
the activity of dibemethinoquine compounds results from their ability to accumulate in the 
parasite digestive vacuole and inhibit haemozoin formation. In dibemethinoquines, this 
inherent activity appears to depend on both the site of attachment of the aminoquinoline 
to the dibemethin side chain and the identity of the group on the terminal phenyl ring of 
the dibemethin in a manner that is too complex to rationalize on the basis of the limited 
number of derivatives used in this study. However, correlation analyses using a 
structural descriptor, where the position of attachment of the aminoquinoline to the 
dibemethin side chain was numbered 2, 3 and 4 for ortho-, meta- and para- positions 
respectively showed log IC50 to significantly correlated with position in the order ortho- > 
meta- > para. 
 
Finally, it was found that the aminomethyl dibemethin side chains themselves exhibit 
resistance-reversal activity. Surprisingly, findings in this study show that the 
arrangement of a three carbon aminoalkyl chain positioned between the aromatic rings 
proposed by Bhattacharjee et al (2002), as ideal for imipramine-like resistance reversers 
is not essential for chloroquine resistance reversal. All of the aminomethyl dibemethin 
compounds exhibit stronger activity at 1 µM concentration than their formylated 
derivative. However, at their respective IC10 concentrations, both the aminomethyl and 
amidomethyl dibemethin compounds show chloroquine resistance reversing properties. 
The reduced resistance reversing activity of the formylated compounds can probably be 
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3D-QSAR  Three dimensional quantitative structure-activity relationships 
Ar   Aromatic 
ArH   Aromatic proton 
Arqua   Quaternary aromatic carbon 
BHIA   Beta-haematin inhibitory assay 
BHIA50 50% Inhibitory concentration (molar equivalent relative to 
chloroquine) 
brs.   Broad singlet 
t-BuLi   tert-butyllithium 
CD3OD  Deuteromethanol 
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d   Doublet (in 1H NMR) 
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equiv.   Equivalents  
EI   Electron ionisation 
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EtOAc   Ethyl acetate 
EtOH   Ethanol 
Fe(III)PPIX  Ferriprotoporphyrin IX 
g   Grams 
Hex   Hexane  
hr.   Hour 
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HRMS   High Resonance Mass Spectrometry 
HRP   Histidine rich protein 
IC50   50% inhibitory concentration 
IR   Infra Red spectroscopy 
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J   coupling constants 
K2CO3   Potassium carbonate 
LG   Leaving group 
LiAlH4   Lithium aluminium hydride 
m   Multiplet (in 1H NMR)  
m   Meta 
M+   Molecular ion 
MeOH   Methanol 
m.p.   Melting point 
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MgSO4   Magnesium sulphate 
MHz   Mega hertz (in NMR) 
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mmol   Millimole(s) 
mol   Mole(s) 
MeO   Methoxy 
NaCNBH3  Sodium cyanoborohydride 
NaN3   Sodium azide 
Na2SO4  Sodium sulphate 
NBS   N-bromosuccinimide 
NEt3   Triethylamine   
nM   Nanomolar 
NMe2   Dimethylamino 
NMP   N-methyl-2-pyrrolidine 
NMR   Nuclear magnetic resonance 
o   Ortho 
OPG   O-protecting group 
p   Para 
PFCRT  Plasmodium falciparum chloroquine resistant transporter protein 
Pgh   P-glycoprotein homologue 
PPh3   Triphenylphosphine 
ppm    Parts per million 
QSAR   Quantitative structure-activity relationships 
Rf   Retention factor 
 
viii 
rt   Room temperature  
s   Singlet (in 1H NMR) 
SAR   Structure-activity relationships 
TCTP   Translationally controlled tumor protein 
THF   Tetrahydrofuran 
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CHAPTER 1: INTRODUCTION 
 
1.1 MALARIA AS A GLOBAL PROBLEM 
 
Infectious diseases are today the largest cause of death in developing countries and 
amongst the young.1 Malaria ranks fifth in terms of numbers of deaths due to infectious 
disease. According to the World Health Organization (WHO), between 300 and 500 
million clinical cases of malaria occur every year.2 Malaria is estimated to kill as many as 
1 million people annually, with most of the deaths occurring among children under the 
age of six living in sub-Saharan Africa. It is estimated that over 40% of the world’s 
population lives in malaria endemic areas, which are localized around the tropical and 
subtropical regions (Figure 1.1).  
 
 
Figure 1.1: Global distribution of malaria transmission risk 
(www.cdc.gov/malaria/distribution). 
 
The disease takes an economic toll as well because of reduced productivity, which is 
estimated to be responsible for an estimated average loss of 1.3% of economic growth 
annually in countries with intense transmission.3 
Several organized efforts to control transmission of the disease have been made in the 
last 60 years; these include suppression of vector numbers therefore minimizing the 
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incidents of transmission, preventing contact between the host and an infected vector 
and / or the use of antimalarial drugs both in prophylaxis and treatment of the disease. 
Huge progress was made in reducing the number of malaria cases in the 1950’s using 
these approaches. Coinciding with the discovery of the insecticide 
dichlorodiphenyltrichloroethane (DDT) and chloroquine chemotherapy, World Health 
Organization (WHO) embarked on a Global Malaria Eradication Campaign. The 
remarkable results were that malaria was eliminated completely from Taiwan, the 
Caribbean, the Balkans, parts of North Africa, in most parts of Europe, Northern 
Australia, a large portion of the South Pacific and huge drops in the malaria cases were 
observed in Sri Lanka and India1. By the mid-1960’s however, resistance to DDT and 
chloroquine had emerged. In addition, the indiscriminate use of DDT as an insecticide 
had caused undesirable impacts on the environment; consequently, the eradication 
campaign was put on hold. 
1.1.2 Magnitude of the malaria problem 
Contrary to the rest of the world, the Global Eradication Campaign had very little impact 
in the Amazon basin and Sub-Saharan Africa where social and economic conditions 
meant the program was either not implemented or not sustainable.1 
The downward trend in malaria-related mortality achieved during the 1950’s has 
undergone a reversal since the late 1980’s. This resurgence is confined mainly to 
underdeveloped countries where inadequate health systems are unable to provide rapid 
diagnosis and treatment. In Africa, malaria is the world’s most important parasitic 
disease as it is directly responsible for one in five childhood deaths and indirectly 
contributes to illness and deaths from respiratory infections, diarrhoeal disease and 
malnutrition.1 
The seriousness of the disease has been exacerbated by several factors, these include 
amongst others; the spread of the disease into areas previously free of malaria mostly 
as a result of changing land utilization.4 Failure to implement control measures in conflict 
regions particularly in Africa and Southeast Asia has also contributed to the upsurgence 
of the disease in areas that it was previously under control.4 Most of the antimalarial 
drugs available currently have been in use for decades, but their use is now severely 
limited by the emergence and spread of drug resistance, especially chloroquine. Hence, 





1.1.3 History of malaria 
The disease supposedly has its origins in the jungles of Africa, where it remains 
prevalent. The Romans named the disease “mal’ aria” as at that time the disease was 
attributed to the “bad air” surrounding stagnant waters.1 Scientists were to later confirm 
that mosquitoes transmit the malaria parasite through their bite. Today, the malaria 
parasite is known to be transmitted by the female Anopheles mosquito; furthermore, of 
about 400 species of the Anopheles mosquito known, only about 60 transmit the 
disease.5 
The antiquity of Malaria, which is caused by the protozoan parasites of the genus 
Plasmodium, is demonstrated by the host specificity of over 100 parasite species found 
in reptiles, birds and mammals. Of the four species of plasmodia that infect man; P. 
vivax, P. malariae, P. ovale and P. falciparum; it is P. falciparum that is the most 
dangerous and is responsible for almost all fatalities.6 
1.2 Life cycle of the malaria parasite 
 
The life cycle of Plasmodium falciparum is divided into 2 basic cycles, an asexual cycle 
in man and a sexual cycle in the Anopheles mosquito. In man the cycle can further be 
divided into a liver stage and a blood stage. The life cycle of the malaria parasite is 
illustrated in Figure 1.2 below. In the gut of an infected mosquito, sexual reproduction 
occurs where male and female gametes fuse to form a zygote that develops into an 
oocyst, and later into sporozoites. These sporozoites travel to the salivary glands where 
they wait to be discharged into the human host when the mosquito takes its blood meal. 
When an infected Anopheles mosquito bites, it releases malaria sporozoites into the 
blood stream of the human host. These sporozoites rapidly pass to the liver and 
penetrate its parenchymal cells where they multiply asexually 30 000 fold and form liver 
schizonts. The schizonts burst open the host cells and enter the blood stream as 
merozoites after a period known as the liver stage in the parasite’s life cycle in a process 
that takes 7-12 days.7 The merozoites invade red blood cells and over the next 48 hours, 
develop into small rings contained within a parasitophorous vacuole (ring stage); they 
will metabolize haemoglobin (trophozoite stage) and replicate asexually (schizont stage) 
with subsequent rupturing of the cells.8 Rupturing of the cells leads to further release of 
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merozoites into the blood stream hence increased parasitemia. While most of the 
trophozoites develop into blood schizonts during the blood stage of the parasites life 
cycle; some of the trophozoites develop into male and female gametocytes that may 




Figure 1.2: Life cycle of P.falciparum. (A) Mosquito bites human passing sporozoites 
into the human’s bloodstream. (B) Sporozoites travel to the liver and undergo asexual 
reproduction forming merozoites. (C) Merozoites enter the bloodstream and infect red 
blood cells. (D) In red blood cells merozoites grow and divide (E) some merozoites 
develop into male and female gametocytes. (F) Another mosquito bites the infected 
human ingesting the gametocytes. (G) In the mosquito’s stomach, the gametocytes 
mature to form sporozoites which travel to the mosquito’s salivary glands. (H) If this 
mosquito bites another human, the cycle begins again (www.cdc.gov/malaria/biology). 
 
1.3 CLASSES OF ANTIMALARIALS 
 
Antimalarial drugs can best be classified according to their mode of action as 
compounds acting on haem-detoxification, drugs generating an oxidative stress 
(endoperoxides), nucleic acid inhibitors or inhibitors of protein metabolism. These drugs 
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act by targeting different stages of the malaria life cycle,9 although most of them act on 
the blood stage of development of the malaria parasite. 
1.3.1 Inhibitors of protein synthesis 
In this group are found the antibiotics (Figure 1.3), which have a long history in the 
treatment of malaria. Interest in the use of antibiotics to treat malaria re-emerged with 
the appearance of chloroquine-resistant and multi-drug resistant strains of P. falciparum. 
The tetracyclines cannot not be used alone for initial treatment of malaria, even when 
the parasite is sensitive towards them because their antimalarial activity is delayed. This 
delay is related to their mechanism of action. The tetracyclines act by inhibiting protein 





















1.1      1.2 
Figure 1.3: Chemical structure of tetracycline (1.1) and doxycycline (1.2).  
 
1.3.2 Nucleic acid inhibitors 
Nucleic acid inhibitors are anti-folates and atovaquone. They exert their effect by 
inhibiting synthesis of parasitic pyrimidines and thus of parasitic DNA.11 
1.3.2.1 Folate antagonists 
Some of the most widely used antimalarial drugs belong to the folate antagonist class. 
This class of compounds act by inhibiting enzymes of the folate pathway, which 
consequently results in decreased pyrimidine synthesis, hence reduced DNA, serine, 
and methionine formation. They exerted their activity at all growing stages of the asexual 
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red blood cell cycle and on young gametocytes. Conventionally, antifolates are classified 















   1.3     1.4  
Figure 1.4: The DHPS inhibitors sulfadoxine (1.3) and dapsone (1.4).    
 
Type-1 antifolates are sulfonamides and sulfones (Figure 1.4). They prevent the 
formation of dihydropteroate from hydroxymethyldihydropterin, itself a pyrophosphate 
derivative, in a process that is catalyzed by a bifunctional enzyme in Plasmodia known 
as dihydropteroate synthase (DHPS) by competing for the active site of this enzyme. 









Figure 1.5: The DHFR inhibitor pyrimethamine (1.5). 
 
Type-2 antifolates include pyrimethamine (Figure 1.5), quinazolines, biguanides and 
triazine metabolites. They act by inhibiting dihydrofolate reductase (DHFR), also a 
bifunctional enzyme in Plasmodia coupled with thymidylate synthase [TS]), thus 
preventing the NADPH-dependent reduction of H2folate (DHF) to H4folate (THF) by this 
enzyme. THF is a necessary cofactor for the biosynthesis of thymidylate, purine 
nucleotides, and certain amino acids. Unfortunately, resistance to these drugs is now 
widespread in Asia, India and Africa,12,13. Due to noticeable synergistic effects, a type-1 
drug is usually used in combination with a type-2 drug with pyrimethamine-sulfadoxine 
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(SP) being the most widely used combination. The mechanism of resistance has been 
shown to be due to mutations in the genes of DHFR,14 and DHPS.15 
1.3.2.2 Atovaquone and proguanil 
Atovaquone (Figure 1.6) is used in both treatment and prophylaxis of malaria. Despite a 
novel mode of action, resistance occurs readily when atovaquone is used alone, thus, it 
is used in a fixed-ratio combination with proguanil (Figure 1.6) as Malarone®. 
Atovaquone is thought to act on dihydroorotate dehydrogenase (DHODase), a critical 
enzyme in electron transport. Inhibition of DHODase blocks pyrimidine synthesis,16,17. 
Proguanil on the other hand is a pro-drug that inhibits parasite dihydrofolate reductase 















   1.6     1.7 
Figure 1.6: The DHFR and DHODase inhibitors proguanil (1.6) and atovaquone (1.7) 
respectively. 
 
It is generally agreed that atovaquone acts on the mitochondrial electron transfer chain 
although more recently its activity and synergy with proguanil has been ascribed to its 
interfering with mitochondrial membrane potential. The two proposed mechanisms of 
action although not fully understood, are linked as the mitochondrial electron transport 
chain serves to generate this membrane potential.10 
The combination of atovaquone and proguanil is very effective,18 but the mechanism of 
such interaction remains largely unknown. One seemingly obvious explanation of 
synergy is that both atovaquone and cycloguanil act on enzymes involved in pyrimidine 
synthesis (DHODase and DHFR, respectively), however, this does not appear to be the 
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case because the combination is highly effective both in patients who do not convert 
proguanil to cycloguanil19 and against highly cycloguanil-resistant parasites.20 
 
1.3.3 Endoperoxides 
This class of compounds comprises artemisinin, a sesquiterpene lactone that is naturally 
occurring in Artemisia annua 21 and its derivatives, which include artemether and sodium 
artesunate (Figure 1.10). Artemisinin has been used historically in China as a treatment 
of malaria 22. Artemisinin-type compounds have activity throughout the phases of the 






















OR      
R = H, Dihydroartemisinin
R = Me, Artemether
R = Et, Arteether
R = OCO(CH2)2COONa
       Sodium artenuate  
         1.15              1.16  
Figure 1.10: Artemisinin (1.15) and its semi-synthetic derivatives. 
 
They achieve higher reduction rates of parasitemia per-cycle than any other drug known 
to date.23 The semi-synthetic derivatives artemether and arteether are effective against 
both chloroquine-sensitive and chloroquine-resistant P. falciparum strains and are 
clinically used for cerebral malaria. 
 
Although their mechanism of action is not fully understood, the prevailing hypothesis is 
that reductive cleavage of the O-O bond by Fe(III)-haem generates C-centred radicals 
which in turn would alkylate biomolecules leading to the death of the parasite.24 Whilst it 
is generally accepted that Fe(II)PPIX induces extensive decomposition of artemisinin, 
there is no unequivocal evidence that this can occur in the highly oxidizing and acidic 
environment of the food vacuole. Early studies indicated that an “oxidative stress” could 
be involved,25 but the nature of the oxidative stress remains unclear. The theory that 
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artemisinin acts by invoking oxidative stress is substantiated by observations of 
synergism with other oxidant drugs and antagonism by agents that lower oxidative stress 
26. However, peroxide-bridge compounds do not usually induce oxidative stress. For this 
type of compounds to induce oxidative stress they need to undergo a two step process 



























































Scheme 1.1: Hypothetical mechanism for the radical alkylation of haem by artesunate.24 
 
The first step would be the “activation” of the molecule via homolytic cleavage of the 
peroxide-bridge. This step presumably occurs in the presence of transition metal ions 
such as Fe(II)PPIX, although it is unclear whether haem iron alone is sufficient or 
whether additional reduced iron is needed. The second step would be the alkylation of 
putative protein target(s). The “cleavage” of the peroxide bond gives rise to the formation 
of an oxygen-centred and then a carbon-centred radical, followed by a ferryl-
protoporphyrin IX=O species, and finally, an epoxide, which is a highly active alkylating 
27 (Scheme1.1).The carbon-centred radicals28 may alkylate either haem itself or some 
other proteins, such as translationally controlled tumor protein (TCTP)29 or histidine-rich 
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protein. Translationally controlled tumor protein binds haem, hence possibly bringing 
artemisinin into the vicinity for reaction. It is not known whether the alkylation is specific 
for the TCTP homologue or whether any protein that binds haem can be similarly 
alkylated. It is also unclear whether haem-bound artemisinin can react with proteins that 
do not bind haem. This “carbon-centred radical theory” is not universally accepted.30 
Eckstein-Ludwig et al., (2003) have reported compelling evidence that artemisinins act 
via a Fe2+-dependent activation mechanism.31 In studies conducted on Xenopus 
oocytes, they demonstrated that PfATP6, the sarco / endoplasmic reticulum Ca2+-
ATPase (SERCA) orthologue of Plasmodium falciparum is inhibited by artemisinin with 
potency similar to that of thapsigargin (another sesquiterpene lactone and highly specific 
SERCA inhibitor) but not by quinine or chloroquine. The most probable answer as to why 
resistance has not developed for endoperoxide compounds is therefore that artemisinin 
compounds do not exert their antimalarial effects by hitting a single biological target but 
rather by simultaneously hitting several targets with very high precision and efficiency.32 
Hence, their mode of action could involve enzyme inhibition, lipid peroxidation, 
membrane damage through vital enzymes and some effect on haem detoxification. 
1.3.4 Compounds acting on haem detoxification 
This class of compounds includes some of the most common and widely used 
antimalarial drugs and can be separated into two types. Type-1 drugs, (Figure 1.7), are 
the 4-aminoquinolines (chloroquine), and Mannich-base (amodiaquine). Chloroquine 
was introduced in 1944-1945 and soon became the mainstay of malaria treatment and 
prevention because it was cheap, non-toxic and active against all strains of the malaria 
parasite 11. Since two decades ago, the emergence and spread of the malaria parasite 
resistant strains has limited its use. Primaquine has been used with chloroquine against 
resistant strains of P. vivax, while amodiaquine due to its superior efficacy has been 




























      1.10 
Figure 1.7: Chemical structures of chloroquine (1.8) amodiaquine (1.9) and primaquine 
(1.10). 
 
Type-2 drugs are the aryl-amino alcohols (quinine and quinidine, mefloquine and 
halofantrine). Quinine and its isomers including quinidine (Figure 1.8) are found in the 
bark of the cinchona tree35 and for almost three centuries quinine in its purified form or 
as a component of the cinchona bark extract was the only widely available medication 













   1.11     1.12 




Mefloquine (Figure 1.9) is structurally related to quinine and its long half-life (14-21 days) 
has contributed to the rapid development of parasite resistance to this drug. Halofantrine 
(Figure 1.9) is effective against chloroquine-resistant parasites;11 however, cardiotoxicity 
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Figure 1.9:  Chemical structures of mefloquine (1.13) and halofantrine (1.14). 
 
In general, the two classes of drugs differ in that type-1 drugs are weak bases, can be 
diprotonated and are hydrophilic at neutral pH, whereas type-2 drugs are weaker bases 
and lipid soluble at neutral pH. In addition, the two groups appear to interact differently 
with their putative target36 and show an inverse relationship with respect to parasite 
sensitivities. Various mechanisms have been proposed for the action of quinoline-based 
and related compounds. These include inhibition of protein synthesis,37 inhibition of food 
vacuole lipase38 and aspartic proteinase,39 and inhibition of DNA and RNA synthesis.40 
The commonly accepted hypothesis is that quinoline-containing drugs act primarily in the 
food vacuole by preventing the detoxification of haem (a product of the digestion of 
haemoglobin - the parasites food source in the host red blood cells) and that chloroquine 
selectively accumulates in the parasite food vacuole due to its weak base properties. 
There is conflicting data as to whether such a mechanism would explain the mode of 
action of both chloroquine and the quinoline / phenanthrene methanols.41 However, 
recent experiments using proteinase inhibitors and quinoline-containing drugs 







1.4 HAEMOGLOBIN AND HAEMOZOIN FORMATION 
During the blood stage of the malaria parasite’s life cycle, the parasite utilizes host 
haemoglobin as its main food source43 obtaining amino acids required for protein 
synthesis from degrading 25-75% of host haemoglobin in the occupied red blood cells.44 
In this process, large quantities of red blood cell cytoplasm are ingested by fluid phase 
endocytosis and transported in vesicles to a secondary lysosome known as the food 
vacuole.6 The food vacuole contains at least three classes of proteinase enzymes, these 
are the three cysteine proteases, falcipain 1, 2 and 345 the four aspartic proteases 
plasmepsins I, II,46 IV47 and histoaspartic protease (HAP)48,49,50 and a metallo 
pepetidase, facilysin51 which break down haemoglobin. This haemoglobin degradation 
process is complicated by the release of ferrous haem which is rapidly oxidised to the 
ferric form known as haematin (aquaferriprotoporphyrin IX or H2O-Fe(III)PPIX) (Figure 
1.11). Solubilized haematin is cytotoxic and has been shown to damage biological 

















Figure 1.11: Chemical and molecular structure of haematin.58 
 
In mammals Fe(III)PPIX is degraded via the haem-oxygenase / biliverdin reductase 
pathway.59 The malaria parasite however, has evolved a pathway to detoxify haematin 
by conversion to the insoluble, black, granular substance known as malaria pigment or 
haemozoin (Figure 1.12). It has been shown that at least 95% of the haem released 
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Figure 1.12: The haemoglobin degradation pathway and generation of haemozoin.61 
 
Haematin crystallization is thought to occur when the negatively charged propionate 
group of one is drawn to the positively charged Fe(III) centre of the next producing the β-
haematin precursor,62 this initiates the assembly of the haemozoin crystal by the 
recurring assembly of haematin molecules in his manner. 
 
Slater and Cerami suggested that haemozoin formation is enzyme catalysed in vivo and 
demonstrated P. falciparum trophozoites extracts promoting formation of its synthetic 
counterpart β-haematin,63 However, this was questioned by Dorn et al. who noted that 
heat treatment of the extracts had little effect on the reaction and suggested the initiator 
to be some haem-derived material associated with haemozoin.64 Bendrat et al. 
suggested that this reaction promoting material is a lipid contaminating the haemozoin 
extracts.65 Sullivan et al. managed to identify and clone two histidine-rich proteins (HRP 
II and HRP III) in purified digestive vacuoles, which are similar to human histidine-rich 
glycoprotein (HRG) and are composed of histidine (34%), alanine (37%) and aspartic 
acid (10%).66 These authors claim all the ferrihaems in the HRP II-Fe(III)PPIX complex 
are low spin and six coordinate with a two histidine ligands and that this complex is 
stable between pH 5.5 and 7.0. These results are at odds with the findings of Choi et al., 
who observed two types of haem-binding within HRP-II which causes conformational 
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changes around pH 6.67 This protein has been found to promote β-haematin formation 
under physiological conditions when Fe(III)PPIX binding is weakened at low pH. These 
authors attributed this weak Fe(III)PPIX binding to a change in conformation of the 
protein which results in possible coordination of a carboxylate group from an aspartate 
amino acid. 
 
Since findings on the mechanism of β-haematin formation have compared this process 
to biomineralisation, it is possible that the role of HRP in vivo will be to provide a scaffold 
on which nucleation and growth of the crystal can occur. However, recent findings show 
that parasite clones lacking the gene for HRP-1 or 2 form haemoglobin normally, ruling 
out a role for this protein. Haemozoin formation is not unique to the malaria parasite but 
has also been identified in other organisms that lack HRP but degrade haemoglobin 
where presumably it serves the same purpose. These organisms include amongst 
others, Shistosoma mansoni a worm in humans causing bilharzia68 and Haemoproteus 
colombae a protozoan parasite common in birds. 69 
 
The weight of evidence has recently shifted away from histidine-rich protein II or III to 
lipid initiation.70,71,62,72 Bendrat et al., (1995) initially proposed possible polar lipid 
initiation,65 this hypothesis was substantiated by Dorn et al. (1995) and (1998).64,73 Fitch 
also proposed a role for neutral lipids, but was not able to identify digestive vacuolar 
lipids,70 while Tripathi and coworkers suggested a combination of proteins and lipids.71,74 
Recent work in Plasmodium linked neutral lipid bodies on both the interior and the 
exterior of digestive vacuoles with haem crystallization.75,76,77 Based on the published 
electron micrographic evidence of intra-vacuolar lipid bodies, Pisciotta identified neutral 
lipids closely associated with hemozoin.78 In vitro growth of β-hematin under biomimetic 
conditions indicate that this crystalline solid forms exceptionally efficiently in a lipid 
environment, 78,62 especially when Fe(III)PPIX is directly introduced at or near the 
interface between the lipid and aqueous solution.62 The high rate at which solid 
crystalline β-hematin forms suggests that the lipid / water interface itself is probably 







1.5 MECHANISM OF ACTION OF QUINOLINE ANTIMALARIALS 
Quinoline antimalarial drugs are widely used in chemotherapy of the disease. However, 
their effectiveness particularly that of chloroquine has been considerably reduced due to 
the advent of resistant strains of the parasite. Although the mechanism of action of this 
class of drugs is not unequivocally known, these drugs are believed to accumulate by a 
weak base mechanism in an acidic compartment found inside the parasite within the 
infected red blood cell known as the food vacuole. The currently held hypotheses, 
although not without its flaws, is that chloroquine interferes with conversion of haem into 
haemozoin thereby causing an accumulation of the potentially toxic haematin. However, 
the accumulation of haematin alone cannot be viewed as fatal to the parasite as the 
excess haematin could presumably be disposed by diffusion from the cell or possibly by 
reduced glutathione-mediated degradation80 although there is no evidence that this 
actually occurs. The toxic event would therefore be the formation of a haem-chloroquine 
complex that would prevent haem degradation. Based on the morphological changes 
and specific drug accumulation within the food vacuole upon chloroquine administration, 
it would appear that the food vacuole is the primary site of drug activity. Various 
intravacuolar theories have been brought forward and shall be discussed. These include 
inhibition of enzymes inside the food vacuole, an increased vacuolar pH, and other 
hypotheses on interference with haematin detoxification. 
1.5.1 INTRAVACUOLAR HYPOTHESES 
1.5.1.1 Inhibition of Protease enzymes 
It has been shown that chloroquine binding to Fe(III)PPIX decreases protein synthesis 
since Fe(III)PPIX  was shown to stimulate  protein synthesis in a trophozoite extract.37 
However, no evidence of haem involvement in protein synthesis in the parasite has been 
presented. Furthermore, the parasite could not possibly withstand the high 
concentrations of haem required to stimulate protein synthesis. Chloroquine has also 
been shown to inhibit partially purified aspartic protease activity from P. falciparum 
extracts57 but again only at concentrations above the therapeutic range. Furthermore, 
haematin itself is a very good inhibitor of acid proteases (roughly 10 µM) and this activity 
is unchanged in the presence of chloroquine.39 
 
17 
The hypothesis that chloroquine interferes with the parasite’s feeding mechanism have 
further been questioned by Ginsburg and Krugliak who noted that treatment of 
chloroquine-treated parasites with membrane permeable amino-acids, were unable to 
alleviate inhibition of parasite growth.81 
1.5.1.2 Inhibition of Phospholipase enzymes 
Vacuolar phospholipase enzymes have been identified within the food vacuole and are 
responsible for degrading endocytic vesicle membranes in order to release their 
haemoglobin content into the food vacuole. Chloroquine has been shown to inhibit 
phospholipase activity in vitro,81 but at concentrations substantially higher than those 
likely to occur in the vacuole. 
1.5.1.3 Increased vacuolar pH 
A number of authors have suggested that chloroquine raises the pH of the food vacuole 
because of it weak base properties.81 This would result in a homeostatic change in the 
food vacuole; consequently, the normal functions of the enzymes within this normally 
acidic compartment are disrupted. 
This hypothesis is no longer accepted because it has been shown that not all weak 
bases are antimalarials, a case in point is the intrinsic antiplasmodial inactivity of 9-
epiquinine, a stereoisomer of the potent antimalarial drug quinine in spite of both 
compounds possessing virtually identical weak base properties. 
Further experiments using fluorescent dextrans to monitor the vacuolar pH have shown 
that alkalization is only observed at levels above the therapeutic concentration range of 
the antimalarial drugs.82,83,84 This is presumably due to the ability of the vacuolar proton 
pumps to maintain an acidic pH even in the presence of a weak base such as 
chloroquine.85 Nonetheless, weak base properties probably account in part for 
accumulation of drugs in the food vacuole. 
1.5.1.4 Interference with haematin detoxification 
Haemozoin inhibitors are thought to act at the formation of the unit head-to-tail haem 
crystal dimer by drug–haem complex competition or at the growing face of a large 
haemozoin crystal by drug–haem complex binding to prevent addition of more haem 
crystal dimers.79 First indications of haem-drug complex formation were reported by 
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Cohen et al., (1964).86 Later reports by other workers would suggest that chloroquine 
and related drugs act by forming a complex with haematin and in so doing inhibit the 
conversion of the toxic haematin to non-toxic haemozoin; a process developed by the 
parasite as part of its natural defence.64,87,88,89 Additional interest in the haemozoin 
formation theory was centred on the fact that drugs such as chloroquine inhibit its 
formation under synthetic conditions, 88, 90,87,63 demonstrating that inhibition of haemozoin 
formation may be the basis of activity of these drugs. 
Slater and Cerami put forward a proposal that a haem polymerase enzyme91 catalyses 
haemozoin formation. It was further proposed that inhibition of this enzyme by 
chloroquine would result in a build up of the potentially toxic haem in the parasites food 
vacuole. However, Dorn et al., (1995) showed that haemozoin formation is not enzyme 
catalysed but is instead autocatalytic.64 They also confirmed earlier observations by 
Egan et al., (1994) that haemozoin formation could be directly inhibited by chloroquine 
and suggested that this process is the target for chloroquine in vivo.87 
Ginsburg et al., (1998) also proposed that chloroquine competitively inhibits degradation 
of haem by glutathione, thus allowing haem to accumulate in membranes.92 Tilley and 
co-workers (1999) demonstrated the rapid decomposition of haem in the presence of 
H2O2 and suggested that chloroquine and quinacrine are efficient inhibitors of the 
peroxidative destruction of haem by complex formation.93 
1.5.2 EXTRAVACUOLAR HYPOTHESES 
Despite the background that the food vacuole appears to be the primary site of drug 
action. Various extravacuolar theories have also been brought forward and 
unsurprisingly, none has found widespread approval. These include DNA binding and 
inhibition of polyamine synthesis. 
1.5.2.1 DNA binding 
Chloroquine was originally thought to exert its antimalarial activity through DNA 
intercalation and hence inhibition of DNA replication and RNA synthesis ultimately 
leading to cell death. This hypothesis is no longer accepted on the basis that it has been 
demonstrated in vitro that chloroquine binds to DNA but at concentrations much higher 
(100 µM) than the pharmacological concentration (typically 10 nM).91 Furthermore, this 
hypothesis does not explain why the quinoline antimalarial, mefloquine, which does not 
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bind to DNA,94 is active. It has also been shown that there is no selectivity between the 
chloroquine-DNA interactions of host and that of parasite DNA. 
1.5.2.2 Inhibition of Polyamine Synthesis 
Quinoline antimalarial drugs have been reported to inhibit ornithine decarboxylase 
activity in trophozoite extracts of infected red blood cells.95 Since ornithine 
decarboxylase enzymes are important in polyamine synthesis, it has been suggested 
that chloroquine may exert its antiplasmodial activity this way. There have been no 
further experiments pertaining to the effects of quinolines on this class of enzymes to 
give credence to this hypothesis. However, existing information does not explain why 
chloroquine is only active on the blood stage parasites as liver stage parasites also 
presumably have ornithine decarboxylase. Furthermore, using a functional proteomics 
approach to understand how quinoline drugs function and to provide a comprehensive 
description of quinoline-interacting proteins; Graves et al., (2001)96 demonstrated 
several quinoline compounds to specifically target two human proteins, aldehyde 
dehydrogenase 1 (ALDH1) and quinone reductase 2 (QR2) but not to interact with P. 
falciparum proteins. These findings may well provide new insights into the mechanism of 
action of quinoline drugs. 
1.6 STRUCTURE-ACTIVITY RELATIONSHIPS IN QUINOLINES 
 
Various studies have shown that the activity of quinoline-based antimalarials is 
dependent on haemoglobin degradation.97,98 This class of compounds is thought to act 
by complexing with haematin thus preventing the formation of haemozoin. A number of 
studies have shown that a wide range of quinoline and phenanthrene antimalarials and 
antiplasmodials inhibit synthetic haemozoin (β-haematin) formation in vitro.73,64,87,89-104 
Recent studies have thus investigated the structural requirements for association of 
quinolines with haematin. Egan et al., (2000) investigated structure-activity relationships 
in 21 chloroquine analogues and showed that the minimum structural requirements for 
drug association with haematin is substitution of the 2 or 4 position of the quinoline ring 
with an amino group (Figure 1.14).102 Quinoline itself does form a complex with haematin 





Attachment of an alkyl side-chain to the 2- and 4-amino group of aminoquinolines 
resulted in only a small change on the association constant. It was demonstrated that 
compounds that do not bind with haematin do not inhibit β-haematin formation and have 
essentially no antiplasmodial activity. Thus, the 4-aminoquinoline nucleus of chloroquine 
was identified to be a necessary requirement for antiplasmodial activity in this class of 
compounds. The molecular basis of specific interactions remains unknown, although it 
was proposed to be due to the ability of partial charges on quinoline to form strong 
interactions with opposite charges on haematin. Portela et al., (2003) supported this idea 
using molecular orbital calculations and suggested that the amino group connected to 
the quinolic ring corresponding to a positive electrostatic potential, interacts with the 
central negative zone of the haematin dimmer.105 The negative potential located over the 
aromatic area of the quinoline ring also interacts with the peripheral positive area of the 
putative µ-oxo-dimer (Figure 1.13). 
 
 
Figure1.13: (a) The side on view of the lowest energy complex of haematin with 
chloroquine showing the π-stacking interaction between the porphyrin ring of haematin 
and the quinoline ring of chloroquine. (b) The top down view of the chloroquine haematin 
interaction with all atoms of haematin displayed in red for clarity.106 (c) The mode of 
interaction between haemozoin and chloroquine is illustrated with chloroquine interacting 
with the growing face of haemozoin.107 
 
However, it is now clear that inhibition of β-haematin formation is not only a result of 
association with haematin. Quinolines including 9-epiquinine as well as certain 4-
aminoquinolines have been shown not to inhibit β-haematin formation despite forming 
 
21 
complexes with haematin.101,102 Egan et al., (2000) and Vippagunta et al., (1999) have 
shown that the key feature for inhibition of β-haematin formation for 4-aminoquinolines 
appears to be the presence of the 7-chloro group.101,102 The identity of the group at this 
position was found to be the critical feature in determining the strength of inhibition of β-
haematin formation. This conclusion has recently been supported by Cheruku et al., 
(2003) who have confirmed that the 4-amino-7-chloroquinoline substructure of 
chloroquine is essential for inhibition of β-haematin formation.108 Replacement of the 7-
chloro group with a bromo or nitro has been shown to result in complexes that are still 
active, while 7-amino and 7-hydro are not. This seems to suggest that groups that are π-
electron withdrawing are successful inhibitors 101. This is consistent with a recent report 
on the antiplasmodial activity of aminoquinolines with fluoro-, chloro-, bromo-, iodo-, 
trifluoromethyl-, and methoxy- substituents in the 7-position.109 The fluoro- and methoxy- 
derivatives were found to be less active than chloro-, bromo-, iodo- and trifluoromethyl- 
derivatives. The efficacy of 4-aminoquinolines depends both on the strength of β-
haematin inhibition and on the extent of accumulation of the drug in the food vacuole 
through pH trapping. The extent of pH trapping depends on the basicity of the quinoline 
ring and the side-chain amino group. 
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Figure 1.14: A selection of 2-, and 4-aminoquinolines used to investigate SARs for 
haematin-quinoline association.102 
 
Kaschula et al., (2002) reported that the pKa is strongly dependent on the nature of the 
group at the 7-position on the quinoline ring in short chain analogues of chloroquine 110. 
Groups that are electron-releasing such as NH2 and OCH3 raise pKa1 relative to that of 
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the 7-H derivative. By contrast, strongly electron-withdrawing groups such as NO2 cause 
considerable decrease in pKa1.  
 
De et al., (1998) also found that the most active aminoquinolines were those with two or 
three carbon diaminoalkane side-chains especially those that have chloro-, bromo- or 
iodo- groups in the 7-position.109 The authors also found that these aminoquinolines are 
active against chloroquine resistant P. falciparum because they avoid the mechanism 
responsible for resistance to chloroquine.109 They suggested that the side-chain length 
(carbons between the two nitrogens in the diaminoalkane side-chain of 7-bromo- and 7-
iodo- of 4-aminoquinolines) is the major determinant of activity against chloroquine 
resistant P. falciparum as it is with 7-chloro-4-aminoquinoline. The proposed structure 







Amino alkyl side chain - length and shape 
generally causes only small changes in haematin 
association strength, has no effect on inhibition 
of ß-haematin formation and has limited influence 
on antiplasmodial activity
Terminal amino group required for strong 
activity - basic, possibly enhances vacuolar
drug accumulation through ph trapping. Not
required for haematin association or inhibition 
of ß-haematin.
7-chloro group required for inhibition of
ß-haematin formation. Quinoline nitrogen - basic, possibly enhaces vacuolar drug accumulation  
through pH trapping
4-aminoquinoline nucleus minimun requirement
for haematin association
 
Figure 1.15: The proposed structure-activity relationships for chloroquine.102 
 




In general, resistance to a drug can be due to several mechanisms. Changes to the drug 
may make it less potent.  Changes to the drug target may result in the drug not being 
able to exert its effect on the modified target. The target may be over-expressed thereby 
reducing the effect of the toxin. The drug may be denied access to its target by either a 
reduction in its accumulation or an increase in its efflux out of the cell or its site of action. 
In order to understand the occurrence of resistance towards quinoline drugs in P. 
falciparum, one needs to look at the problem of resistance from three fundamental 
points: Firstly, the physiological changes to the cell that give rise to resistant strains; 
secondly, the genetic mutations that cause resistance; and thirdly, the structure-activity 
relationships between chloroquine analogues and cross-resistance in chloroquine. 
Current evidence supports reduced accumulation as a basis of resistance to 
chloroquine. However, the manner in which this is achieved is widely debated and 
remains unresolved. 
1.7.1 The physiological basis of chloroquine resistance 
Chloroquine resistant strains of the malaria parasite accumulate less chloroquine than 
do sensitive parasites.111,112 It is thought that this reduced accumulation is either a result 
of reduced uptake of the drug or an enhanced efflux of the drug from parasitized cells. 
The enhanced efflux hypothesis has found considerable support.113,114 
The efflux mechanism has been shown to be influenced by glucose and thus proposed 
to be energy dependent.115-118 However, this appears to be disproved by the observation 
by Bray et al. (1996) that deoxyglucose also stimulates chloroquine efflux, despite being 
unable to generate ATP.119  
 
An alternative to the efflux mechanism is a decrease of drug uptake in the food vacuole 
as a result of an increase in pH at this site. An increase in food vacuole pH would be 
expected to cause a decrease in pH trapping of the drugs in the food vacuole. Early 
evidence suggested that chloroquine resistant parasites do indeed exhibit an increased 
digestive vacuole pH120 but later studies could provide no definitive evidence to support 
this theory. Other studies have suggested that there is in fact a decrease in food vacuole 
pH in resistant parasites resulting in a decrease in haematin available as a target for 
chloroquine as a result of haematin aggregation and precipitation.121 The latter study has 





Suggestions that a Na+ / H+ exchanger is involved in drug uptake123,124 or that a Cl- / 
HCO3
- antiporter is responsible for maintaining pH gradients in the food vacuole125 
appear to have been disproved,98, 126or do not find strong support.98 
In addition, general changes in pH are difficult to reconcile with the observation that 
closely related dibasic 4-aminoquinolines, differing only in side-chain length exhibit major 
differences in activity against chloroquine-resistant parasites.  
 
The structural specificity of the resistance mechanism, for example, the well-known 
increased parasite sensitivity to quinine but decreased sensitivity to its enantiomer 
quinidine, suggests that a specific transporter-mediated mechanism is involved.8  
1.7.2 The genetic basis of chloroquine resistance 
Recently, mutations in the pfcrt gene of P. falciparum have been identified as the major 
player in the phenomenon of chloroquine resistance. The protein product of this gene, 
Plasmodium falciparum Chloroquine Resistant Transporter (PfCRT) is located primarily 
in the food vacuole membrane and is thought to be responsible for chloroquine 
resistance by transporting chloroquine out of its site of action. Mutations at codon 86 
were found to be associated with chloroquine resistance in a number of isolates.128-132 
Later, little support for this correlation could be found in epidemiological studies 133-139 
and a genetic cross between chloroquine-resistant and sensitive parasites showed no 
evidence of association with mutations in this gene at all.140  
 
Plasmodium falciparum was also found to express a homologue of the human multi-drug 
resistant protein refered to as Plasmodium falciparum P-glycoprotein homologue-1 
(PfPgh 1) coded for by the pfmdr 1 gene.127 Although mutations in PfPgh 1 cannot confer 
chloroquine resistance alone, they can lead to increased chloroquine resistance through 
decreased drug accumulation.141 Thus, PfPgh 1 mutations do appear to have a role in 
modulation of chloroquine resistance in at least some strains of P. falciparum.142 
 
Martin and Kirk (2004) conducted a bioinformatics analysis of the pfcrt gene. This study 
indicates that the normal function of the protein products of this gene may be to export 
peptides from the food vacuole.143 Recently, Zhang et al., (2004) have demonstrated that 
chloroquine binds directly to the transmembrane transporter protein PfCRT.144 However, 
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no strong evidence has been brought forward to show that quinine is also bound 
although PfCRT is able to modulate quinine resistance. Cooper et al. (2002) have 
demonstrated that point mutations in PfCRT are associated with chloroquine 
resistance.145 It has now been established that chloroquine resistant strains share a 
common K76T mutation in the pfcrt gene. The mutant (K76T) is characterized by a 
change of the charged amino acid, lysine, to an uncharged amino acid, threonine. This 
mutation is predicted to permit the positively charged diprotonated chloroquine molecule 
to pass through the food vacuole membrane down its concentration gradient. Another 
mutation associated with resistance involves a change in an asparagine to a serine 
(A220S) although this mutation does not confer resistance in the absence of the K76T 
mutation. 
 
There is some evidence that mefloquine resistance may be related to an increase in 
pfmdr1 copy number,146-149 while mutations at codon 86 are associated with increased 
sensitivity to Mefloquine.147 Thus, there is evidence that multi-drug resistance to 
quinoline methanols may also be associated with the Pgh 1 protein.150 
Interestingly, there have been reports of chloroquine resistant field isolates that do not 
possess the K76T mutation151 and also some evidence has been reported of patients 
harboring the parasites with the K76T mutation that nonetheless respond to chloroquine 
treatment 152. This may indicate that other proteins, including Pgh 1,142 as well as patient 
immunity may also play a role in clinical failure of chloroquine. 
1.8 Structure-activity relationships between chloroquine analogues and cross-
resistance in chloroquine 
 
Although the chloroquine resistance mechanism remains a subject of debate, resistance 
certainly arises from reduced drug accumulation rather than modifications to the target 
haem.141 Various SARs between chloroquine analogues and drug resistance have been 
reported and it appears that the resistance mechanism is structure specific and seems to 
recognize the aminoalkyl side-chain of chloroquine. This was demonstrated by Krogstad 
et al. (1998) who showed that analogues of chloroquine with shortened (2-3 carbons 
long) or lengthened (10-12 carbons long) side-chains maintain full activity against 
chloroquine resistant parasites153  (Figure 1.16), while those with chain lengths close to 




It appears that a high degree of variability can be tolerated in the side-chain as can be 
seen from the diversity of the nature of side-chains (Figure 1.16).154-157 In contrast, 
structural changes to the quinoline ring have shown little or no effect on the activity of 
chloroquine against both sensitive and resistant parasites.109,121 Cross-resistance 
between chloroquine and quinoline methanols such as mefloquine is not ruled out,146 but 
often an inverse relationship is observed with chloroquine-resistant parasites showing 
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Figure 1.16: A selection of chloroquine analogues that are active against chloroquine-
resistant parasites including short chain (1.21) and long chain (1.23) analogues, 
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analogues with side-chains containing bulky groups or aromatic rings [ amodiaquine 
(1.24) and isoquine (1.25)] and metallated analogues [feroquine(1.22)]. 
 
These findings support proposals that resistance mechanisms in quinoline methanols 
are different to that of chloroquine resistance. The question as to whether structural 
changes to mefloquine can circumvent this type of resistance does not appear to have 
been investigated.158 
1.9 Approaches to combat drug resistance 
1.9.1 Drug rotation 
There is evidence that parasites with the critical PfCRT K76 mutation are at a fitness 
disadvantage. For example, in Malawi where chloroquine had been replaced with 
sulfadoxine-pyrimethamine as a first-line therapy drug, it has been shown that after a 
sufficient period of nonuse the parasite’s susceptibility to chloroquine is restored.159 
Similar observations have been made in Gabon, Vietnam, China and Thailand.160 This 
could indicate that drug rotation is a useful approach to reversing resistance in a certain 
geographical location. However, there is evidence that recovery of chloroquine 
sensitivity arises from expansion of wild-type PfCRT in the population, rather than back-
mutation.161 This merely implies that re-expansion of resistant forms of the pfcrt gene is 
likely to spread rapidly upon resumption of drug pressure.162 Furthermore, such reversal 
has not been seen in any South American strains.163 
1.9.2 Combination therapy 
The use of combination antimalarial therapy offers two important potential advantages. 
Firstly, the combination should improve efficacy providing additive or synergistic activity. 
Secondly, the combination should slow the progression of parasite resistance to the new 
drugs. Combination therapy is based on the assumption that while a mutation conferring 
resistance to a single drug might occur, the probability of simultaneous mutations 
conferring resistance to two drugs active against different targets is highly unlikely. 
Examples of successful combinations are sulfadoxine-pyrimethamine, chlorproguanil-
dapsone (Lapdap)164 and atovaquone-proguanil (Malarone®).165 Attempts at combining 
chloroquine with other drugs, for example chloroquine-sulfadoxine-pyrimethamine has 
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been less successful.166 However, combinations of other quinolines and related 
compounds have thrived. These include, mefloquine-artesunate (in Southeast Asia)167 
and lumefantrine-artemether (in Africa).168 Combination therapy suffers a drawback 
when the elimination half-life of one member of the combination drug is very long or 
when the pharmacokinetics of the two drugs are not well matched.169 Hastings and 
Watkins have described the process of resistance development as first passing through 
a stage of drug tolerance.169,170 Further mutations then lead from tolerance to resistance. 
There is recent evidence that such a process could be unfolding with respect to 
artemisinin combination therapy. Sisowath et al., (2005) have investigated lumefantrine-
artemether in Zanzibar and have reported a significant increase in pfmdr1 86N following 
drug treatment which may be a sign of developing lumefantrine tolerance.168 
1.9.3 Redesigning of existing drugs 
In this approach to combat emergence and spread of existing drug resistance, 
analogues of existing drugs are used in chemotherapy. The findings by Krogstad et al., 
(1998)153 rationalize this approach. In their studies, Krogstad et al., (1998) showed that 
the chloroquine resistance mechanism is structure specific and appears to recognize the 
aminoalkyl side-chain of chloroquine.153 In addition, Yuthavong and co-workers have 
shown that analogues of pyrimethamine in which the para-chloro group is moved to the 
meta-position are active against resistant strains of the parasite.171 Increasing the 
flexibility of antifolate drug analogues also restores sensitivity of resistant strains as this 
allows the compound to again be able to fit into the drug binding site.171 Furthermore, it 
has been pointed out that mutations occurring on enzymes are finite as many mutations 
will tend to reduce activity or result in an unstable protein.171 In the case of quinoline 
compounds, analogues with shortened side-chains154,155 or substantially altered side-
chains containing a ferrocene group156 have been shown to restore activity against 








1.9.4 RESISTANCE-REVERSING AGENTS 
The use of resistance reversing agents has generated interest in malaria chemotherapy 
following the discovery of the chloroquine resistance-reversing properties of verapamil. 
172 Since then, a wide and diverse range of compounds that also demonstrate the ability 
to reverse chloroquine-resistance and mefloquine-resistance has been described. These 
include other calcium channel blockers,174-176 some tricyclic antidepressants177-180 and 
antihistamines181-183 (Figure 1.17). 
 
 A chloroquine resistance-reversing agent is a compound that lowers the IC50 value of 
chloroquine in chloroquine-resistant parasites to a value comparable to that of 
chloroquine-sensitive parasites. The substance is in itself not active against the parasite 
at the concentration at which it restores activity and it does not alter activity against 
chloroquine sensitive parasites. Chloroquine resistance-reversal in Plasmodium 
falciparum is therefore characterized by both a reduction of the chloroquine IC50 and the 
increased accumulation of chloroquine into chloroquine resistant strains 
specifically,113,173.  
 
Interestingly, chloroquine resistance-reversers seem to induce only a partial reversal of 
the resistant phenotype in the parasite. While they decrease the IC50 values in resistant 
strains to those found in sensitive strains, chloroquine never accumulates in resistant 
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Figure 1.17: A representative selection of compounds with reported chloroquine 
resistance-reversing activity. The compounds include known calcium channel blockers 
(1.26) and (1.27), antidepressants (1.28) and (1.30), antipsychotics (1.29) antihistamines 





1.9.4.1 Mechanism of action of chloroquine resistance-reversers 
Recent work has indicated that chloroquine resistance-reversal may involve direct 
competition of the resistance reverser for the chloroquine-binding site in PfCRT. A recent 
report by Lakshmanan et al., (2005) on the effects of pfcrt on chloroquine resistance, 
verapamil reversibility and activities of chloroquine analogues with shortened and 
lengthened side-chains has further elucidated these issues.185 It appears that most 
chloroquine resistance-reversers bind to the same site on PFCRT as chloroquine, 
effectively blocking chloroquine binding by competition. The close structural relationships 
between chemosensitizors and chloroquine have been highlighted by Kalkinidis et al., 
(2002).186 Further support for a direct competition is the fact that the aromatic nucleus of 
chloroquine, 4-amino-7-chloroquinoline is itself a resistance reverser.186 
 
The binding site proposed by Alibert et al., (2002)184 appears to have strict structural 
requirements. It readily accommodates chloroquine, but not analogues with shortened 
side-chains that are active against chloroquine-resistant parasites.184 This is consistent 
with the observation that side-chain length of chloroquine analogues is important in 
determining the resistance profile to these drugs.154 There are key mutations in pfcrt 
which appear to result in the formation of this binding site and of these mutations K76T 
is the most important. The K76T mutation is also shown to be the decisive factor in 
determining susceptibility to chloroquine analogues with different chain lengths. Overall 
accumulation of chloroquine and haem-binding to chloroquine could also be directly 
correlated with this key mutation.  
 
A puzzling aspect of the study by Alibert et al. is that chloroquine resistance-reversal 
activity and increased chloroquine accumulation in the parasite do not appear to be 
directly correlated.184 A possible explanation of this is that some dihydroanthracenes 
may interact with haem without inhibiting haemozoin formation, but competing with 
chloroquine and hence reducing its overall accumulation. In this regard, it is known that 
some quinolines can bind haem without inhibiting haemozoin formation.102 It is also 
important to note that most resistance reversers work at micromolar concentrations 
which are much higher than the expected amount of free, non-haem bound chloroquine. 
A reason for this disparity is not clear but could be related to the reverser affinity for the 
chloroquine-binding site. Interestingly, some compounds are able to reverse the 
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resistance to both chloroquine and mefloquine, which is not consistent with the proposed 
strict structural specificity of the chloroquine-binding site. Furthermore, some compounds 
that reduce intracellular glutathione levels are also able to sensitize the parasites to 
chloroquine.92 
1.9.4.2 Structure-activity relationships in chloroquine resistance-reversers 
Previously, structure-activity relationship studies in chloroquine resistance-reversers 
were an area that was largely unexplored. However, in the last few years several articles 
have been published on SARs in resistance reversing agents.184,187,188 A recent study by 
Lakshmanan et al., (2005) also throws some light on the relationship between resistance 
reversal activity and PfCRT structure.185  
Bhattacharjee et al., (2002) conducted a 3D-QSAR study of 17 imipramine analogues.187 
The study revealed that the basic features for a compound to act as a resistance 
reverser are two hydrophobic aromatic rings and a hydrogen bond acceptor, preferably 
secondary or tertiary nitrogen in a specific geometric orientation (Figure 1.18). A two or 
three carbon bridge from the heterocyclic 7-membered ring to the N atom was shown to 
be optimal for activity. Nitrogen basicity, frontier orbital energies and lipophilicity were 
found to correlate with resistance reversing activity.  
 
 
Figure 1.18:  A schematic presentation of the pharmacophore for chloroquine 
resistance-reversal proposed by Bhattacharjee et al., (2002) together with a series of 
representative compounds of various classes to illustrate the proposed pharmacophore. 
These include imipramine (a), chlorpromazine (b), a dihydroanthracene derivative (c), 




The study by Alibert et al., (2002) conducted using a series of 28 novel rigid 
dihydroanthracene derivatives aided in establishing some possible characteristics of the 
binding site for resistance reversers.184 Using a molecular modeling approach, the 
authors defined a putative interaction site for the N atom in which there is hydrogen 
bonding to a hydroxyl group of a serine residue and a salt bridge formed between the 
same protonated, positively charged N and an aspartate residue. The findings from this 
study are highlighted in Figure 1.19.  
 
 
Figure 1.19: Schematic presentation of the SARs conducted by Alibert et al., (2002) and 
the proposed chloroquine resistance-reverser-binding site. The SARs were conducted 
using the rigid 9, 10-dihyro-9, 10-ethano and etheno-anthracenes (a). Ethano- 
compounds were better resistance reversers than the etheno- compounds (b). 
Secondary amines were more active than tertiary amines while the N atom preferred the 
β-position in the chain (c). Cyclic amines were more active than acyclic structures (d). 
The binding site is depicted in (e). The amino group was proposed to hydrogen bond 
(blue dashes) to the hydroxyl group of a serine (or threonine) residue and to interact 
electrostatically (red dashes) with the carboxylate group of an aspartate (or glutamate) 
residue. The two residues were proposed to be 9.2 Å apart (dotted line). 
 
The mandatory requirement for the aromatic rings was illustrated by the inactivity of 
mecamylamine, which contains the bicyclic saturated ring system with a secondary N 
function, but lacks any aromatic rings. The authors suggested that the proposed binding 
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site is consistent with mutant PfCRT in chloroquine-resistant parasites that have alleles 
encoding a CVIET haplotype at residues 72–76. The functional groups on the glutamate 
and threonine residue side-chains would presumably form a site resembling that 
produced by the putative aspartate and serine residues in the hypothetical binding site 
generated by this study. 184 
1.9.4.3 “Reversed chloroquine” compounds 
Burgess et al. (2006)189 reported a highly innovative hybrid molecule that combines the 
pharmacophore of a 4-amino-7-chloroquinoline antimalarial with a resistance reversing 
group and called this class of compounds “reversed chloroquine”. Such a design will 
deliver the resistance-reversing agent in a 1:1 ratio with the quinoline moiety. Thus, 
“reversed chloroquine” compounds provide the pharmacophore for haem-binding (4-
aminoquinoline), inhibition of haemozoin formation (4-amino-7-chloroquinoline) and drug 
accumulation by pH trapping (a tertiary amino group in the side-chain) as well as the 
pharmacophore for a resistance reverser,189 namely two suitably positioned aromatic 
groups with an amino group separated by a short chain.191 
 
In addition to promoting drug accumulation in the food vacuole, it was speculated that 
the reversal agent component would interfere with export of the chloroquine moiety from 
the food vacuole by the mutated chloroquine-resistant PFCRT alluded to in Chapter 
1.7.2. Together, these effects would allow a curative dose against chloroquine-resistant 
strains to be lower than that of its components given separately. These so-called 
“reversed-chloroquine” compounds demonstrated high potency against both sensitive 
and resistant strains of the malaria parasite in vitro and were shown to be active against 
P. chabaudi in mice with no signs of toxicity, although they have not yet been 
demonstrated to exhibit chloroquine resistance-reversal activity. Nonetheless, the 
approach is a novel one and could result in new active antimalarials that are not 
susceptible to development of chloroquine-like resistance. It must be emphasized 
conversely that in many cases alterations of the chloroquine side-chain has result in 
compounds that are active against chloroquine resistant strains of P. falciparum.185 A 
representative selection of the “reversed chloroquine” compounds reported by Burgess 




























    1.37    1.38 
Figure 1.20: A selection of “reversed chloroquine” compounds reported by Burgess et al 
(2006). All of the compounds shown exhibit activity against chloroquine-sensitive as well 
as resistant parasites.189, 190 
 




The drug optimization process usually involves changing several characteristics of a 
compound, such as its shape, functionality (hydrogen bonding or ion pair interactions), 
lipophilicity and electronic characteristics. Historically, the experience and insight of the 
researcher as well as availability of starting material drove drug design. However, in the 
1960’s and 1970’s, following the development of the Hansch method of structure-activity 
correlations, a more rational approach to drug design was employed and the method 
also brought the ability to generate Quantitative Structure-Activity Relationships (QSAR) 
with in analogue series.192, 193  
 
The QSAR approach aims to take a set of analogues of an active compound, identify 
and quantify their physicochemical properties and determine which properties have a 
significant input to the activity of the molecule. Commonly used property descriptors are 
the substituent hydrophobicity constant, π (a measure of the substituent’s hydrophobicity 
relative to hydrogen), the Hammett constant, δ (a measure of the substituent’s electron 
withdrawing or donating characteristics) and the Taft’s steric factor, Es.
194 Through an 
appropriate mathematic derivation of a relationship between these and / or other 
properties and the level of activity, it should be possible to predict the biological activity 
of analogues. However, to generate a reliable correlation a relatively large number of 
compounds should be used in the initial analysis. Furthermore, it is not always easy to 
separate the significance of different parameters e.g., if activity varies across a 
homologous series of compounds in which an alkyl side-chain length is increased, it is 
difficult to decide whether this is due to the increase in chain length or lipophilicity or 
both.193 
 
The optimization process therefore is a multifactorial process and needs to be broken 
down into a stepwise approach to provide focus for synthetic activities. One such step 
commonly faced is the identification of optimum substitution patterns on phenyl or hetero 






1.10.1 Topliss schemes 
In the 1970’s Topliss addressed some of the concerns arising form QSAR using non-
mathematical schemes for analogue design.195-197 The fundamental basis of the methods 
was the concept pioneered by Hansch,192,193 that the primary influences on activity 
following introduction of a substituent resulted from lipohilic (π), electronic (δ) and steric 
(Es) properties of the substituent. The first of these schemes used a decision tree 
approach which later became known as the Topliss tree.194 
 
 
Figure 1.21: A simplified version of the Topliss tree.194 
 
A stepwise procedure is used starting with the unsubstituted phenyl compound and 
proceeding first to the 4-chloro analogue. This substituent is lipophilic (+π) and electron 
withdrawing (+δ). The potencies of the two are compared and if the 4-chloro analogue is 
more active, this improved potency can the ascribed to a +π effect and a +δ effect or a 
combination of both. Then the 3, 4-dichloro compound is synthesized since in this 
analogue the summed +π and +δ values would be larger with prospects for improved 
potency. If the 4-chloro compound was equipotent, this could be due to a favorable +π 
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effect offset by an unfavorable -δ dependency. Then the 4-methyl analogue would be 
synthesized as this group possess both lipophilic and electron withdrawing properties. 
Similarly, if the 4-chloro analogue is less potent than the parent compound, one may 
conclude that activity is -π or -δ controlled. Then the 4-methoxy analogue would have to 
be made owing to the electron-releasing and marginal hydrophilic nature of this 
substituent. 194 
 The Topliss scheme can also be applied in a batch wise manner in which the parent 
drug together with the 4-chloro, 3, 4-dichloro, 4-methyl and the 4-methoxy are all 
synthesized and their potency order compared to the order of the Topliss tree. From this 
activity pattern analysis a new selection can be made for the synthesis of potentially 
potent analogues.194 
Both the stepwise and batchwise procedures have been successfully used in synthesis 
of more potent analogues including in the synthesis of a series of sulphonamide with 
carbonic anhydrase inhibitory activity198 and a series of anti-inflammatory aryltetrazolyl 
propionic acids.199  
1.11 AIMS 
 
The overall aim of this project is to synthesize 4-amino-7-chloroquinoline antimalarials of 
high potency against chloroquine-resistant parasites, which possess potential 
resistance-reversing properties. Therefore, the target compounds are proposed to 
function as hybrid molecules (“reversed chloroquines”) which provide both the potent 
antimalarial activity of chloroquine-like compounds with the added advantage of 
possessing chloroquine resistance-reversing properties. 
1.12 OBJECTIVES 
 
The design of the target compounds will be facilitated by 3 models that have been 
reviewed extensively above being; (i) The 3D-QSAR pharmacophore model for 
chloroquine resistance-reversal proposed by Bhattacharjee et al., (2002); (ii) The SAR 
model based on findings by Egan et al., (2000) that depicts the pharmacophore for 
antimalarial activity of quinoline antimalarials, and (iii) the Topliss scheme in an attempt 




Based on delineations from these three models, the target compounds will be 
synthesized, purified and characterized.  
 
Their in vitro and in vivo antimalarial activity and cytotoxicity will be evaluated against 
chloroquine-sensitive as well as chloroquine-resistant strains of P. falciparum. 
Furthermore, the chloroquine resistance-reversing properties of the target compounds 
will also be evaluated 
.
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CHAPTER 2: SYNTHESIS 
2.1 RATIONALE AND DESIGN  
 
In the study described in this thesis, the model proposed by Egan et al., (2000)102 
together with work published by Bhattacharjee et al., (2002)187 and Alibert et al., 
(2002)184 facilitated the design of “reversed-chloroquine” compounds. The proposals 
made in these three models have been extensively reviewed above (Chapter 1.6 and 
Chapter 1.9.4).  
 
In summary, Egan et al., (2000) highlighted the essential structural features in 
chloroquine-like compounds to be the 4-aminoquinoline nucleus, which was identified as 
the minimum requirement for haematin association; the 7-chloro group, which is optimal 
for inhibition of haemozoin formation; and the need for an amino group as a basic site in 
the side-chain to facilitate drug accumulation by pH trapping.102  
For resistance reversal, Bhattacharjee et al., (2002) proposed the need to have two 
hydrophobic aromatic rings fused to a 7-membered ring containing a nitrogen atom 
bearing a three-carbon chain with a hydrogen-bond acceptor group at the terminal, 
preferably an amino group in imipramine-like resistance reversers.200 It is interesting to 
note, as highlighted in Chapter 1.9, that other non imipramine-like resistance reversers 
were shown to contain many of the same features, typically the two aromatic rings and 
the chain with a basic N atom at the terminal and Alibert et al., (2002) gave an insight 
into the possible characteristics of the binding site for resistance reversers.  
 
For this study, a comparison of the structures of chloroquine resistance-reversers shows 
that the linkage between the two aromatic rings is quite permissive and can range from a 
direct bond between rings to long flexible chains of six or seven atoms (1.26-1.33) 
(Chapter 1.94). Indeed, some resistance reversers such as primaquine (1.10) possess 
only a single aromatic ring system. Based on the resistance-reverser imipramine (1.28) 
in which the H-bond acceptor group (terminal N-atom) is linked to a ring system 
containing two hydrophobic aromatic rings via a 3-carbon chain (Figure 2.1), the target 
compounds (dibemethinoquines) were thus designed with a dibemethin side-chain linked 
to a hydrogen bond acceptor (quinoline N-atom) via a three-carbon linker involving the 
pyridine ring of the quinoline (Figure 2.1). In this manner, the target compounds were 
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perceived to meet the requirements for chloroquine resistance-reversal as proposed by 
Bhattacharjee et al., (2002). Thus, it was proposed in the current work that the 








(1.28) (6, 43 - 53)  
Figure 2.1: Chemical structure of imipramine (1.28) and the generic structure of 
dibemethinoquines (6, 43 – 53). 
 
In order to better understand the structure–activity relationships between resistance 
reversal and structure, the point of attachment of the Quinoline aminomethyl linker to the 
dibemethin was varied between ortho-, meta- and para- positions. Three different 
substituents (X) were introduced into the para position of the terminal aromatic ring in 
dibemethinoquines to investigate the effect of electronic and hydrophobic properties of 
groups attached to the dibemethin nucleus. The para position for the X-substituent was 
preferred over ortho- and meta- in order to minimize steric effects, while retaining 
mesomeric (hyper-conjugative) and inductive communication between X and the tetha 
joining the two aromatic rings. The selection of substituents (X) was based on the 
Topliss Scheme in which groups selected were Cl (hydrophobic/electron-withdrawing), 
OMe (electron-releasing, similar hydrophobicity to H) and NMe2 (strongly electron-
releasing/hydrophobic).  
 
To investigate whether the side-chain itself might exhibit resistance-reversing activity 
and to probe structure–activity relationships between resistance reversal and side-chain 
structure, the dibemethin side-chain was designed with an aminomethyl chain on one 
phenyl ring. The primary amino terminal was also formylated to probe the effect, if any, 
of the basicity of this group (Figure 2.2). 









   (4, 21 – 31)                               (5, 32 – 42)  
Figure 2.2: Generic structures of aminomethyl dibemethins (4, 21 – 31) and 
amidomethyl dibemethins (5, 32 – 42). 
 
The basis of the “reversed chloroquine” idea reported by Burgess et al., (2006) is that 
the fundamental pharmacophore for haem-binding (4-aminoquinoline), inhibition of 
haemozoin formation (4-amino-7-chloroquinoline) and drug accumulation by pH trapping 
(a tertiary amino group in the side-chain) is preserved as is the pharmacophore for a 
resistance-reverser190 (Figure 2.3), namely two suitably positioned aromatic groups with 

















(6, 43 – 53) 
 
Figure 2.3: Chemical structure of some reversed chloroquine compounds reported by 
Burgess et al., 2006 (1.33 and 1.36) and the generic structure of the target compounds 
(6, 43 – 53). 
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The target compounds in the current study would similarly possess the following 
characteristic features: 
 
(i) A 4-amino-7-chloroquinoline antimalarial pharmacophore important for haem-
binding and inhibition of haemozoin formation. 
(ii) A dibemethin scaffold coupled with the H-bond acceptor (quinoline N-atom) for 
providing the resistance-reversing moiety. 
(iii) Protonatable N atoms in the quinoline ring and the dibemethin side-chain for 
increasing drug accumulation in the food vacuole by pH trapping. 
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2.2 Retro-synthesis of the dibemethinoquines 
 





















X = H (1b)
   =  Cl (7a)
   =  MeO (8a)


















































X = H (1a)
   = Cl (7)
   = MeO (8)
   =NMe2 (9)
(10 - 20)








Scheme 2.1: Retro-synthesis of the target compounds. 
 
The synthesis of dibemethinoquines was envisaged as attainable by considering a 
convergent synthetic route (route A) or a divergent synthetic route (route B) as outlined 
in Scheme 2.1 above. The convergent synthesis involved coupling of two pieces in 
which the side-chain aminomethyl group would be obtained via reductive amination of an 
aldehyde or the Staudinger reduction of an azide to give aminomethyl dibemethins (4, 21 
- 31). On the other hand, a divergent synthesis would involve alkylation of a suitably p-
substituted benzyl-N-methylamine (1a, 7 – 9) with a respective 4-aminoquinoline-N-
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benzyl-halide (2.2). In this study, the convergent synthetic route was preferred as it 
entails considerably more reaction steps as shown in Scheme 2.1. Prior knowledge that 
incorporation of the quinoline moiety in chloroquine-like compounds is better achieved 
via nucleophilic substitution on the quinoline ring supported the resolute choice of 4, 7-
dichloroquinoline (2.1) as the precursor to the quinoline moiety of dibemethinoquines.  If 
quinoline is considered as a fused benzo[b]pyridine according to Hantzsch-Widman 
fusion nomenclature, its chemistry can be rationalised in terms of that of benzene and 
pyridine from which it is derived. Like pyridine, the quinoline pyridine ring is π-deficient 
due to the electron-withdrawing inductive and mesomeric effects of the nitrogen atom. 
These effects are pronounced at positions 2 and 4 (Figure 2.4). The reactivity of these 
positions is further increased by the presence of electron-withdrawing groups; for 
example, a halogen group at position 2 or 4 further activates these positions towards 
nucleophilic attack. 4, 7-Dichloroquinoline is therefore more reactive towards 
nucleophiles as a result of resonance stabilization of the reaction intermediate via the 








8 N N  
Figure 2.4: Resonance structures of quinoline ring, illustrating mesomeric effects with 
resulting preferred sites for nucleophilic attack. 
 
Since changes at the 7-position of the quinoline nucleus of chloroquine have been 
shown not to produce compounds that are active against chloroquine-resistant parasites,  
the 7-chloroquinoline moiety of chloroquine was retained in dibemethinoquines (6, 43 – 
53) and commercially available 4, 7-dichloroquinoline (2.1) fulfilled this identity. Against 
this background, the key methodological challenge in the synthesis of 
dibemethinoquines was the synthesis of the side-chains (4, 21 – 31). Aminomethyl 
dibemethins can be viewed as unsymmetrical bis-aminomethyl phenyldiamines with 
different substituents on each N (see (2.7) in Figure 2.5). The main challenge in their 
synthesis would be the timing and methods of forming the new C-N bonds. 
 






    4, 21 - 31                                 2.7 
 
Figure 2.5: General structure of dibemethins (4, 21-31) and their condensed structure 
(2.7) 
2.3 General routes to bis-aminomethyl phenyldiamines 
A number of classical methods have been employed in the formation of new C-N bonds. 
These include but are not restricted to: i) synthesis via azides by the Staudinger 
reaction; ii) from carboxylic acids in the Schmidt reaction; iii) from halides and hexamine 
in the Delepine reaction; iv) from primary halides using potassium phthalimide in the 
Gabriel synthesis; v) from primary alcohols using Mitsunobu and Staudinger reactions 
and via reductive amination of aldehydes and ketones. Evidently, the methods and 
precursors are diverse. In the literature, bis-aminomethyl phenyldiamines have been 
prepared by a variety of methods. Of particular importance to this project are the 





















Scheme 2.2: Route by Blackie et al., to the synthesis of bis-aminomethyl arylamines.  
 
The first step in the method by Blackie et al. for synthesizing bis-aminomethyl 
phenyldiamines (Scheme 2.2) requires the synthesis of 2-
dimethylaminomethylbenzaldehyde (2.11), which was prepared using tert-butyllithium (t-
BuLi) and dimethylformamide (DMF) in a directed metallation / quenching sequence as 
shown in Scheme 2.2 above. Compound (2.11) was then reductively aminated via its 
benzylic oxime (2.12). Reductive amination is an important method in organic synthesis 
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in which a carbonyl group is aminated. As illustrated in Scheme 2.3 below, the prototype 
reaction involves reaction of an aldehyde with ammonia to form an imine intermediate. 
Subsequent reduction of the imine by H2, a Friedel catalyst or using a metallohydride 
yields a primary amine. Similarly, the reaction performed using a primary amine in place 
of ammonia yields a secondary amine while if a secondary amine is used the reaction 



























Scheme 2.3: General mechanism for reductive amination. 
 
The formation of primary amines via reductive amination of aldehydes using ammonia in 
the presence of the reductant is complicated by a competing reaction. As the primary 
amine begins to build up, it may react with the aldehyde to give an imine which is 
subsequently reduced to a secondary amine. For this reason, reductive amination via an 
oxime in which the condensation and reduction steps are separate is often the preferred 
route to the synthesis of primary amines from aldehyde or ketone sources. 
An alternative to the method by Blackie et al., (2007)200  is the method by Rinke et al., 











(2.14) (2.15) (2.16) (2.17)  
Scheme 2.4: Route by Rinke et al, to the synthesis of bis-aminomethyl phenyldiamines. 
 
Synthesis: Results and discussion 
48 
In this method, o-xylene was used as a starting point for the synthesis. Benzylic 
bromination with N-bromosuccinimide using benzoyl peroxide as radical initiator was 
followed by the substitution of the benzylic bromides with azide using sodium azide (2 
equiv.). A degree of selective mono-substitution by azide can be achieved using a 
stoichiometric amount of azide. Other alkali azides, tetraalkylammonium azides, 
polymer-bound azides or silver azide have also been used to generate aliphatic or 
benzylic azides in the literature. Finally, reduction of the diazides using catalytic 
hydrogenation with Pd/C gave the desired diamines. LiAlH4 or triphenylphosphine and 
H2O (Staudinger process) have also been used to reduce azides to amines. 
2.4 Synthesis of dibemethinoquines 
 
In this study, o-aminomethyl dibemethin (4) was synthesized in four steps using the 
method by Blackie et al. The first step in the synthetic route requires the synthesis of 
dibemethin (1) which was achieved via a nucleophilic substitution of benzyl bromide by 
N-benzyl-methylamine (1a) in CH2Cl2 (Scheme 2.5). Compound (1) is known, and was 
previously prepared by a similar method. Confirmation of the structure of (1) was 
provided by its 1H NMR spectrum which revealed the following resonances: a 10-proton 
multiplet at δ 7.57 - 7.38 ppm assigned to the aromatic protons, a 4-proton singlet at δ 
3.70 ppm for the symmetrical phenyl CH2 and a 3-proton singlet at  δ 2.37 ppm for the 
methyl protons. The correct number of carbons [as six] based on symmetry was 
observed in the 13C spectrum of (1). As indicated in Scheme 2.5 below, o-formylation of 










Scheme 2.5: Preparation of o-(N-benzyl-N-methylamino)methyl-benzaldehyde (2) . 
Reagents and conditions: (i) benzyl bromide, NEt3, CH2Cl2, 2hrs, 67%; (ii) t-BuLi, Et2O, -
78 ºC, 30 minutes; DMF, r.t, 3h, 77%. 
 
The mechanistic events that lead to the o-formylation of dibemethin are worthy of 
mention and are depicted in Scheme 2.6 below. 


















Scheme 2.6: The mechanistic events involved in the o-formylation of dibemethin (1) to 
afford (2). Reagents and conditions: (i) t-Butyllithium, anhydrous Et2O, -78 ºC, 30 
minutes; 0 ºC, 30 minutes. (ii) anhydrous DMF, rt, 3h, 77%. 
 
The proton at the o-position of dibemethin (1) is the most acidic owing to the presence 
and position of a nitrogen atom in this compound. t-Butyllithium was used to abstract the 
ortho-proton via an ortho-directed metallation involving the nitrogen resulting in the 
formation of an anionic intermediate which precipitated as a yellow lithio-salt. Caution 
was taken in this reaction as t-butyllithium reacts explosively with water. Consequently, 
anhydrous reagents and anaerobic conditions using a Schlenk line were employed. 
Subsequent addition of anhydrous DMF to the anion produced the benzaldehyde (2) in 
good yield (77%) following work-up and colunm chromatography. Its 1H NMR and 13C 
NMR spectra revealed peaks that were consistent with the target compound. Thus, a 
noteable change in the 1H spectrum of (2) relative to (1) was the downfeild (deshielded) 
aromatic proton ortho to the newly inserted carbonyl group which was split into a dd, J = 
1.5, 7.5 Hz, with ortho and meta aromatic couplings. Similarly, a formyl CHO proton 
appeared down-field as a singlet at  δ 10.42 ppm. The IR spectrum of (1) also confirmed 
insertion of the carbonyl group by revealing a band at vmax 1690 cm
-1 due to (C=O), 
which was corroborated by a downfield resonance in the 13C spectrum at δ 192.0 ppm 













Scheme 2.7: Preparation of o-aminomethyl dibemethin (4). Reagent and conditions: (iii) 
NH2OH.HCl, NaOH(aq), EtOH, reflux, overnight, 85%; (iv) LiAlH4, Et2O, reflux overnight, 
89%. 
 
Subsequent reductive amination of the aldehyde (2) via its oxime according to the 
method by Blackie et al., (2007)200 afforded  o-aminomethyl dibemethin (Scheme 2.7). 
Thus, hydroxylammonium hydrochloride (NH2OH.HCl) was basified with aqueous NaOH 
in ethanol. Subsequently, the free base was condensed in situ with the aldehyde (2) to 
afford oxime (3) in 85% yield after column chromatography (Scheme 2.7) as a mixture of 
geometrical isomers (~ 10: 1, with the anti assumed to be the major). The 13C and 1H 
NMR spectra of (3) revealed peaks that were consistent with the target compound. A 
noteable change in the 1H NMR spectrum of (3) relative to (2) was the identity of a 1-
proton broad-singlet at δ 1.29 ppm assigned to the OH group. Also, the oxime proton 
appeared less downfield compared to the formyl proton of (2), consistent with the 
substitution of oxygen with the less electronegative nitrogen  The change in functionality 
at the ortho-position of dibemethin from aldehyde (2) to oxime (3) was confirmed in the 
IR spectrum of the latter by disappearance of the C=O band (vmax1690 cm
-1) and the 
emergence of a new C=N band at vmax1600 cm
-1. Reduction of the oxime was achieved 
by refluxing (3) in anhydrous diethylether in the presence of LiAlH4 (Scheme 2.7). After 
the reaction had gone to completion, a saturated solution of aqueous Na2SO4 with a few 
drops of triethylamine was added to the reaction mixture and stirred for 30 minutes. The 
resultant precipitate was filtered through Celite and the residue washed with a solution of 
5% triethylamine in THF. A small volume of toluene was used to facilitate the azeotropic 
removal of any water. This intricate work-up procedure was necessitated on account of 
the polar nature of o-aminomethyl dibemethin (4) owing to its primary amino terminus as 
revealed by TLC. This meant that a typical extractive work-up using an organic solvent 
and aqueous medium would not extract the organic product, as primary amines are 
known to be water-soluble. In this way, o-aminomethyl dibemethin (4) was afforded in 
89% yield after purification by column chromatography using 100% ethyl acetate 
followed by EtOAc: MeOH: NEt3 (95: 5: 5) as the mobile phase . To fulfill the aim of  
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probing the effect of the basicity of the amino terminus of (4), a formyl derivative (5) was 
prepared lacking the basic primary amino group, this also served the purpose of 
characterization of (4). This was achieved by refluxing a solution of (4) in excess ethyl 
formate under an inert atmosphere overnight (Scheme 2.8). Unreacted ethyl formate 
was removed under reduced pressure to give a crude residue, which was purified by 
flash chromatography directly to afford o-amidomethyl dibemethin (5) as a formate ester 
in 92% yield and predominantly as an s-trans rotamer according to 1H NMR and on 
steric grounds. Confirmation of the structure of (5) was provided by an additional 
downfield carbonyl carbon in its 13C NMR, a formyl proton (singlet) in its 1H NMR and an 
IR amide carbonyl stretch at vmax 1656 cm
-1 The proposed “reversed chloroquine” 
compound, o-dibemethinoquine (6), was also afforded as a colourless crystalline solid in 
27% yield following coupling (4) to 4, 7-dichloroquinoline (2.1) (DCQ coupling) (Scheme 
2.8). 1H NMR, 13C NMR, HSQC, HMBC and IR spectroscopy were used to fully 
characterize (4), whose microanalytical (CHN) data confirmed molecular composition as: 
Found C, 74.56; H, 6.07; N, 10.08% when C25H24N3Cl requires C, 74.71; H, 6.02; N, 
10.45%. Crystallographic analysis unequivocally confirmed attainment and structure of 

















Scheme 2.8: Synthesis of o-amidomethyl dibemethin (5) and o-dibemethinoquine (6). 
Reagents and conditions: (i) ethyl formate, reflux overnight, 92%; (ii) 4, 7-DCQ, K2CO3, 
NEt3, NMP, 90 ºC, 48h, 27%. 
 
The DCQ coupling was carried out in a cyloaddition tube via reaction at 90°C over 48 
hours. The reaction was facilitated by the use of triethylamine and K2CO3 bases. The 
particular use of K2CO3 served to tweak the NH2 protons which are acidic in nature 
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owing to their bonding to the more electronegative N atom. This increases the 
nucleophilicity of the nitrogen atom and augments DCQ couplings. The use of N-methyl-
2-pyrrolidone (NMP) as a solvent has special place in these types of reactions as NMP 
is thought to propagate DCQ coupling by also H-bonding with the NH2 hydrogens. The 
importance of this solvent is highlighted by the fact that attempts to perform the DCQ 
coupling using alternative high boiling solvents such as DMF or dioxane were 
unsuccessful. The high boiling point of NMP means that it cannot be removed on the 
rotorevaporator. However, it is miscible with water, hence a work-up was used involving 
extracting with ethyl acetate and washing the organic extracts several times with 
saturated brine to remove the NMP. Under these conditions, the product could still be 
extracted. Possibly the low yield reflected losses into the water. The mechanism of 











Scheme 2.9: General mechanism of DCQ couplings. 
 
As discussed earlier, the C-2 and C-4 positions of quinoline are more susceptible to 
nucleophilic attack, which is enhanced by electronegative groups at these positions. The 
mechanism involves a classical aromatic nucleophilic substitution (SNAr) mechanism in 
which nucleophilic attack by the primary amino nitrogen at the 4-position of 4, 7-
dichloroquinoline is followed by elimination of the chloride anion. The observed 
regioselectivity is facilitated by the influence of the nitrogen atom via resonance 
stabilization of the intermediate.  
 
Although the procedure by Blackie et al., (2007) had been successfully employed in the 
synthesis of o-aminomethyl dibemethin (4) and subsequently (5) and (6), it could not be 
applied in the synthesis of p- and m-aminomethyl dibemethins owing to the 
regioselective nature of the formylation reaction (see Scheme 2.6). Furthermore, an 
alternative pathway to aminomethyl dibemethins that would avoid the complex reaction 
work-up associated with the LiAlH4 reduction of oximes to amines discussed above was 
preferable. For these reasons, meta and para-aminomethyl dibemethin compounds (24, 
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28) were prepared in three steps based on modification to the method by Rinke et al.  
starting with a nucleophilic mono-substitution of commercially available meta- or para-α, 
α'- dibromoxylenes (2.15) with sodium azide ion as shown in Scheme 2.10 below. Owing 
to the structural similarities of the target compounds, characterization of all the 
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Meta (35) Para (39) (iv)
 
Scheme 2.10: Preparation of m- and p-aminomethyl dibemethin (24 and 28) and their 
respective amidomethyl dibemethins (35) and (39) Reagents and conditions: (i) NaN3 
(1.0 equiv.), DMF, rt, overnight; (ii) K2CO3, CH3CN, reflux overnight (1a); (iii) PPh3, THF, 
H2O, reflux overnight; (iv) ethyl formate, reflux overnight. 
 
The drawback of the substitution reaction by azide is that using one equivalent of azide 
results in a mixture of the desired mono-substitution product (2.15a) as well as the di-
substitution product (2.15b) and unreacted m, or p-dibromoxylene (2.15) as illustrated in 













(2.15) (2.15a) (2.15b) (2.15)  
Scheme 2.11: Mixture of products formed in the reaction of α, α'-dibromoxylene with 
NaN3. 
 
Based on TLC analysis, the mixture contained (2.15a), (2.15b) and (2.15) in a ratio of 
approximately (0.70): (0.15): (0.15) respectively. Separation of the products by column 
chromatography was complicated by the non-polar nature of these compounds. 
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Therefore, the crude product of this reaction was used in the subsequent alkylation 
reaction by heating to reflux a solution of N-benzyl-methylamine (1a) in acetonitrile and 
the appropriate crude m, or p-α, α'-azido-bromoxylene overnight using K2CO3 as base 
(Scheme 2.10). After this reaction, the polarities of the products were significantly altered 
to permit purification by column chromatography since each product contained 0, 1, or 2 





(2.15b) (2.15b)Meta (13) Para (17)  
Figure 2.6: General structures of the products in the alkylation reaction of N-benzyl-
methylamine (1a) and the mixture of products formed in the reaction of α, α'-
dibromoxylene with NaN3-see Scheme 2.11 above. 
 
Yields of the azidomethyl dibemethins (13) or (17) were 57% and 59% respectively, 
which is in agreement with the observed yield for the mono-substituted azido-
bromoxylenes (2.15a) on TLC in the azide substitution step assuming a high yield for the 
subsequent substitution reaction with (1a). Staudinger reduction of (13) or (17) gave the 
desired m-aminomethyl dibemethin (24) or p-aminomethyl dibemethin (28). This reaction 
involves nucleophilic attack on an organic azide by triphenylphosphine (PPh3) to produce 
an iminophosphorane after nitrogen evolution (Scheme 2.12). 










Scheme 2.12: General scheme of the Staudinger reduction of azides to primary amines. 
 
The procedure involved adding PPh3 to a solution of the respective azidomethyl 
dibemethin in THF and stirring for 30 minutes at room temperature. Water was then 
added and the reaction heated and allowed to reflux overnight. After the reaction had 
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gone to completion, water was removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography to afford (24) and (28) in 88% and 89% 
yields respectively without the need for an extractive work-up, which was important in 
view of polarity. The mechanistic details of the Staudinger reduction of alkyl azides to 




















































Scheme 2.13: General mechanism of the Staudinger reaction. 
 
The resonance-stabilized azide is attacked by the lone pair of electrons on the 
phosphorus atom to give (ii) which cyclizes to intermediate (iii). Loss of a molecule of N2 
produces iminophosphorane intermediate (iv), which is hydrolysed to the product to yield 
amine and triphenylphosphine oxide as a by-product. 
Subsequently, formylated derivates of aminomethyl dibemethins (35) and (39) (Scheme 
2.10) were prepared as with compound (5) using excess ethyl formate and as 
predominantly s-trans rotamers according to 1H NMR and on steric grounds in 95% and 
89% yield respectively. Finally, m-dibemethinoquine and p-dibemethinoquine were 
afforded in 27% and 24% yield respectively following DCQ coupling of their respective 
aminomethyl dibemethins at 120 °C overnight. The azide strategy applied to the 
synthesis of m-dibemethinoquine and p-dibemethinoquine provided good overall yields, 
and its versatility meant that it could be applied to the synthesis of the 4-chloro-, 4-
methoxy- and 4-dimethylamino- analogues of  the parent compounds (Scheme 2.16) by 
simply changing the 4-substitutent of N-benzyl-methylamine (1a). For synthesis of these 
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amines, a nucleophilic substitution reaction between methylamine and the respective 4-
chlorobenzyl chloride or 4-methoxybenzyl chloride (7a, 8a) furnished the respective p-
substituted N-benzyl-methylamine (7) and (8) as shown in Scheme 2.14 in good yields of 
81% and 87% respectively. By comparison, (9) had to be prepared via a reductive 
amination sequence involving reaction of N, N-dimethylaminobenzaldehyde (9a) in 
acetonitrile with a 40% v/v methylamine solution in water followed by addition of 








X = Cl (7a)
   = MeO (8a)
X = Cl (7)
    = MeO (8)





Scheme 2.14: Preparation of p-substituted benzyl-N-methylamine (7 – 9). Reagents and 
conditions: (i) 40% MeNH2 / H2O, THF, rt, overnight; (ii) 40% MeNH2 / H2O, CH3CN, 0 
°C, 2h; NaCNBH3, r.t ,4hrs. 
Reductive amination of (9a) to (9) was necessary because synthesis via nucleophilic 
substitution as was done in the X = Cl and MeO analogue was not viable because p-
dimethylaminobenzyl chloride is unstable. An OPG or LG group in place of an aldehyde 
functionality results in the chemically unstable quinone-like intermediates as shown in 






Scheme 2.15: Formation of quinone-like compounds in dimethylamino benzyl halides. 
The 4-chloro-, 4-methoxy- and 4-N,N-dimethylamino- analogues of the parent 
aminomethyl dibemethins (21 – 23, 25 – 27 and 29 – 31) were thus synthesized using 
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the modified method by Rinke et al., as outlined in Scheme 2.16 to afford the target 
compounds in good yield (Table 2.1). Of note was the use of the azide strategy 
throughout without having to use the directed ortho-metallation strategy. 
Table 2.1: Yields of compounds synthesized using the modified method of Rinke et al. 
 
Reaction Step X Ortho Meta Para 
Cl 58% (10) 61% (14) 63% (18) 




(7) –(9) NMe2 57% (12) 61% (16) 63% (20) 
Cl 93% (21) 93% (25) 93% (29) 
MeO 83% (22) 88% (26) 89% (30) Staudinger 
reduction 
NMe2 83% (23) 81% (27) 89% (31) 
Cl 89% (32) 84% (36) 86% (40) 
MeO 79% (33) 76% (37) 79% (41) Formylation 
NMe2 82% (34) 89% (38) 78% (42) 
Cl 31% (43) 27% (47) 21% (51) 
MeO 21% (44) 20% (48) 24% (52) 
DCQ 
coupling 




























X = Cl (7)
    = MeO (8)
    = NMe2 (9)
Ortho
X = Cl (10)
    =MeO (11)
    =NMe2 (12)
Meta 
X  =Cl (14)
    =MeO (15)
    =NMe2 (16)
Para
X  = Cl (18)
    =MeO (19)
    =NMe2(20)
Ortho
X = Cl (21)
    =MeO (22)
    =NMe2 (23)
Meta
X =Cl (25)
    =MeO (26)
    =NMe2 (27)
Para
X = Cl (29)
    =MeO (30)
    =NMe2(31)
Ortho
X = Cl (32)
    =MeO (33)
    =NMe2 (34)
Meta
X =Cl (36)
    =MeO (37)
    =NMe2 (38)
Para
X =Cl (40)
    =MeO (41)
    =NMe2(42)
Ortho
X = Cl (43)
    =MeO (44)
    =NMe2 (45)
Meta
X =Cl (47)
    =MeO (48)
    =NMe2 (49)
Para
X  = Cl (51)
    =MeO (52)







Scheme 2.16: Route to the synthesis of 4-Cl, 4-MeO and 4-NMe2- analogues of the 
parent dibemethinoquines. Reagents and conditions: (i) NaN3, DMF, r.t, overnight (ii) 
K2CO3, CH3CN, reflux overnight; (iii) PPh3, THF, H2O, reflux overnight; (iv) ethyl formate, 
reflux overnight; (v) 4, 7-DCQ, K2CO3, NEt3, NMP, 120°C overnight. 
2.5 CHARACTERIZATIONS 
2.5.1 Characterisation of azidomethyl dibemethins 
N N3
X  
Figure 2.7: Generic structure of azidomethyl dibemethins (X = H, Cl, MeO and NMe2). 
 
The intermediates from each step were characterised using NMR, IR, CHN and / or high 
resolution mass spectrometry. The 1H NMR spectra obtained for the azidomethyl 
dibemethins were consistent with the proposed structures. In this regard, three 
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methylene singlets were observed throughout with the one for H-1 (see Figure 2.8) 
always downfield to those of H-8 and H-10 owing to the deshielding effect of the azido 
group. The most notable differences between the parent compounds (4-H) and their 4-
Cl, 4-MeO, and 4-NMe2 substituted analogues were the changes in chemical shift and 
the multiplicities of the four protons in the p-substituted aromatic ring bearing X. In the 4-
MeO and 4-NMe2 substituted derivatives (11, 12, 15, 16, 19, 20), the two pairs of protons 
appeared as AB doublets. For example, in (19), the four protons in the p-methoxybenzyl-
N-methylamine ring appeared as a 2-proton doublet at δ 7.43 ppm (J = 8.4 Hz) assigned 
to H-12 / 16 and a 2-proton doublet at δ 6.92 ppm (J = 8.4 Hz) assigned to H-13 / 15. 
The same protons appeared as part of an 8 or 9-proton multiplet in the 4-Cl and 4-H 


























































      (17)           (19)     (15)  
Figure 2.8: Structure and numbering of compounds (15, 17 and 19). 
 
Differences were also noted in the protons on the ring bearing the azidomethyl group 
depending on whether the azidomethyl group was on the ortho-, meta- or para-position. 
In meta compounds e.g. (15), H-3 of the azidomethyl-benzyl-ring was the most 
deshielded of the aromatic rings protons owing to the inductive effect of the two ortho 
groups. 
 





































































Figure 2.9: 1H NMR spectra of compound 17 (CDCl3, 400 MHz) and its 4-MeO analogue 
19 (CDCl3, 400 MHz). 
 
The aromatic region in the spectrum of (17) and (19) have been expanded in Figure 2.9 
above to highlight the typical differences caused by the nature of the substituent (X) at 
the para-position of the ring of azidomethyl dibemethins. The upfield shielding seen in H-
13 / 15 of X = MeO and NMe2 compounds was due to the mesomeric releasing effect of 
these groups.  A summary of the different chemical shifts, multiplicities and coupling 
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constants of H-12 / 16 and H-13 / 15 in azidomethyl dibemethins is shown in Table 2.2 
below. 
 
Table 2.2: Chemical shifts multiplicities and coupling constants of H-12 / 16 and H-13 / 
16 in azidomethyl dibemethins 
 
Compound X Position H δ ppm multiplicity J (Hz) 
12/16 
10 Cl o 
13/15 
7.39-7.26 m  
12/16 7.29 d 8.9 
11 MeO o 
13/15 6.92 d 8.9 
12/16 7.53 d 8.7 
12 NMe2 o 
13/15 6.90 d 8.7 
12/16 
13 H m 
13/15 
7.40-7.14 m  
12/16 
14 Cl m 
13/15 
7.36-7.31 m  
12/16 7.28 d 8.4 
15 MeO m 
13/15 6.87 d 8.4 
12/16 7.22 d 8.9 
16 NMe2 m 
13/15 6.73 d 8.9 
12/16 
17 H p 
13/15 
7.43-7.28 m  
12/16 
18 Cl p 
13/15 
7.44-7.31 m  
12/16 7.44 d 8.4 
19 MeO p 
13/15 6.92 d 8.4 
12/16 7.23 d 8.6 
20 NMe2 p 
13/15 6.72 d 8.6 
 
The 13C NMR data of all the compounds was in agreement with the expected values for 
the different types of carbon atoms. A notable observation in the 13C spectra of these 
compounds is that C-12 and C-16 have the same chemical shift and appear as a single 
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peak as do C-13 and C-15, owing to C-2 symmetry. Thus, three high-field methylenes 
and one methyl resonance were always observed, as well as four quaternary carbons 
regardless of substitution patterns. Unambiguous assignments were made for all the 
alkyl protons and carbons as well as most carbons of the p-substituted benzyl-N-
methylamine ring using HSQC and HMBC. High resolution mass spectrometry confirmed 
the molecular formulae of the proposed structures. 







                   (4, 21 – 31)                                     (5, 32 – 42) 
Figure 2.10: Generic structures of aminomethyl dibemethins and amidomethyl 
dibemethins (X = H, Cl, MeO and NMe2). 
 
These target compounds were also fully characterised by NMR, IR and high resolution 
mass spectrometry. The IR spectra of the aminomethyl dibemethins (21 – 31) indicated 
a characteristic peak for a primary amine (NH2) at vmax 3200 cm
-1. By comparison, the IR 
spectra of amidomethyl dibemethins (32 – 42) revealed the emergence of a 
characteristic band for C=O (1660 cm-1) and the disappearance of the NH2 band. The 
1H 
NMR of a representative compound ((30) see Figure 2.11) reveals the following key 
signals: a 4-proton multiplet at δ 7.32 - 7.27 ppm assigned to ArH-3, 4, 6 and 7 (see 
Figure 2.10), a 2-proton doublet at δ 7.23 ppm (J = 8.8 Hz) assigned to H-12 / 16, and a 
corresponding 2-proton doublet at δ 6.85 ppm (J = 8.8 Hz) assigned to H-13 / 15. A 2-
proton singlet at δ 3.83 ppm was assigned to H-1 and a 3-proton singlet at δ 3.77 
assigned to OMe. The identities of H-8 and H-10 were unequivocally assigned using 
HMBC as a 2-proton singlet at δ 3.46 ppm for H-8 and a 2-proton singlet at δ 3.43 ppm 
for H-10. The 3-proton singlet at δ 2.13 was assigned to H-9 and a broad singlet at δ 
4.53 ppm to NH2. 











































   (30)     (41) 
Figure 2.11: Structure and numbering of compound (30) and (41). 
 
Conversely, the 1H NMR of the formylated derivative of this compound, (41) showed the 
emergence of two new signals being a 1-proton broad singlet at δ 8.21 ppm assigned to 
H-1 and a 1-proton broad singlet at δ 6.06 ppm assigned to the amide NH group. It is 
also interesting to note that H-1, which appeared as a 2-proton singlet at δ 3.83 ppm in 
(30) now numbered H-2 in (41) had shifted further downfield owing to the deshielding 
effect of the adjacent amido group  and was now observed as a 2-proton doublet at δ 
4.44 ppm (J = 5.7). The characteristic splitting patterns and chemical shifts that were 
observed for protons in azidomethyl dibemethins (10 – 20), which were discussed 
previously were also largely maintained in aminomethyl dibemethins (21 – 31), and 
amidomethyl dibemethins (32 – 42). The 13C data of the target compounds were 
consistent with the proposed structures. The major difference between the 13C spectra of 
aminomethyl dibemethins and their corresponding formamides as expected was an 
additional peak in the spectra of the latter owing to the newly inserted C-1. C-1 was 
characteristically observed downfield around δ160.0 ppm. A conspicuous observation in 
both the 13C NMR and 1H NMR of amidomethyl dibemethins were the presence of minor 
isomer peaks in the spectra as shown in an expanded insert of compound (41) in Figure 
2.12 below. This observation is attributed to the presence of non-interconverting cis and 
trans isomers around the amide bond as rotamers, with the trans dominating on steric 
grounds (ratio ~ 1: 8 for cis: trans isomers) see H-2 in compound (41) in Figure 2.12. 
This pattern of differences and similarities was generally observed between aminomethyl 
dibemethins and their corresponding amidomethyl dibemethins. 
 
 






























































































Figure 2.12: 1H NMR spectra of compound (30) (CDCl3, 300 MHz) and its formylated 
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Figure 2.13: Generic structure of dibemethinoquines (X = H, Cl, MeO and NMe2). 
 
These target compounds were also fully characterised by NMR, IR and high resolution 
mass spectrometry where oils were obtained, or microanalysis (CHN) for solid 
compounds. Representative coupling patterns were observed in the 1H NMR spectrum 
of (52) (Figure 2.14) for the quinoline ring. Thus, H-1 and H-2 appeared as an AB 
doublet pair with a coupling constant of 5.7 Hz, while in the benzene quinoline ring, H-5, 
H-6 and H-8 gave rise to a distinctive triad of d, dd, d respectively with ortho and meta 
coupling constants of J = 9.0 Hz and 2.4 Hz respectively. H-8 always resonated 
downfield to the other two owing to the deshielding effect of the pyridine nitrogen The 
NH proton appeared as a broad singlet at δ 5.77, while  H-10 split into a doublet with J = 
4.8 Hz by coupling to this proton. From the HSQC spectrum, the quinoline CH carbons 
could be assigned and the quaternary carbons were also identified (eight in total) based 
on reduced size due to relaxation. The characteristic splitting patterns and chemical 
shifts of the H and C atoms in the aminomethyl dibemethin side-chain of 
dibemethinoquines appeared as discussed above. The correct number of carbons for 






























































Figure 2.14: 1H NMR (CDCl3, 400 MHz) spectra of compound (52)  
 
High resolution mass spectrometry (EI or ESI) or microanalysis (CHN) was sucessfuly 
used to confirm the molecular formulae and composition of the proposed structures 
except for compound (47) and (51) where there was not enough material to run a full 
CHN analysis. Where possible, i.e. in solid cases, CHN on a crystallized sample was 
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(EtOAc:Hex) Microanalysis (C.H.N) 
  Found (%) Calculated (%) 
  C H N C H N 
6 101-103 74.56 6.07 10.08 74.71 6.02 10.45 
46 103-104 74.53 5.86 9.87 74.71 6.02 10.45 
50 120-122 74.35 5.88 10.0 74.71 6.02 10.45 
                                              HRMS (M+) (g mol-1) 
43 oil 436.1344 436.1347 
44 oil 432.1860 432.1860 
45 oil 445.2172 445.2159 
47 oil 436.1335 436.1347 
48 oil 432.1825 432.1843 
49 oil 445.2138 445.2159 
51 oil 436.1335 436.1347 
52 oil 432.1835 432.1843 










Synthesis: Results and discussion 
68 
2.6 Crystallographic analysis 
Crystals of prototype compound (6) were grown for structure determination and its 













Figure 2.15: An ORTEP drawing of the molecular structure with ellipsoidal model at 
50% probability level, showing the atomic numbering scheme.   
 
Compound (6) crystallises in a monoclinic unit cell in the space group P21/c with two 
crystallographically independent molecules per unit. The plane of the o-benzyl-N-
methylamine- ring (aromatic ring A) (see Figure 2.16) is almost perpendicular to the 
plane of the quinoline ring at an angle of 88.1° (torsion angle C9-N2-C10-C11) while the 
plane of aromatic ring B is off the plane of aromatic ring A at an angle of 70.6° (torsion 
angle C16- C17-N3-C19). Aromatic ring B is bent towards the quinoline ring where the 
plane of the former ring is off the plane of the quinoline ring at an angle of 49° (Figure 
2.16). The bond angle of N3-C17-C16 is 114.9° while N3-C19-C20 has a bond angle of 
113.7°. The syn-like conformational arrangement of the quinoline and terminal aromatic 
ring is significant, suggesting intramolecular communication (via π-π stacking), as 
opposed to a sterically more favoured anti-arrangement. This could have implications for 
the biological activity and physicochemical properties of this compound. 
 










~ 88 ° ~ 70 °
~ 49 °
Quinoline ring Aromatic ring B
Aromatic ring A
 
Figure 2.16: Edge-on view of the planes of aromatic ring A relative to quinoline ring and 















Figure 2.17: A projection viewed down [010]. All hydrogens except the amino hydrogens 
are omitted for clarity. The N-H⋅⋅⋅N hydrogen bonds are shown as dotted lines. 
Hydrogen bonding in the crystal structure of (6) is illustrated in Figure 2.17 above which 
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H⋅⋅⋅N, formed between the donor secondary amino group NH and the quinoline nitrogen 
atom. Thus one-dimensional hydrogen bonding networks are formed via N2A-H2A⋅⋅⋅N1B 
and N2B-H2B⋅⋅⋅N1A interactions. Hydrogen bond distances are indicated in Table 2.4. 
 
Table 2.4: Hydrogen bond distances and angles in the crystal structure of (6) 
Atoms D⋅⋅⋅A (Å) D-H (Å) H⋅⋅⋅A (Å) D-H⋅⋅⋅A (Å) 
N(2B)-H(2B)...N(1A) 2.938 1.01 1.98 158.0 
N(2A)-H(2A)...N(1B) 2.972 1.05 1.95 164.9 
 
Since the essential pharmacophore for chloroquine resistance-reversal in imipramine-
like compounds was proposed to be two aromatic rings at a specific geometric 
orientation together with a nitrogen atom. To obtain a spatial delineation of this 
configuration, the bond lengths between the terminal amino-group in imipramine and the 
two aromatic rings as well as the distance between aromatic rings themselves was 
measured and compared with those in compound (6). Significantly, it was found that the 
bond length between the respective terminal amino group and the centre of the 
corresponding aromatic ring A was fairly similar in imipramine and compound (6), 
differing by about 0.3 Å (Figure 2.18). A comparable bond length between the respective 





























Figure 2.18: Comparison of bond lengths between the two aromatic rings and the 
respective N-atom in imipramine (1.28) and (6) and the two aromatic rings in verapamil 
(1.26). 
Although the distance between the centres of the respective two aromatic rings A and B 
differed significantly between imipramine (1.28) and compound (6), it is important to note 
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that in the chloroquine resistance-reverser verapamil, the distance between the centres 
of the two aromatic rings is larger than in both imipramine and compound (6). This 
suggests that a variable spatial arrangement of the two aromatic rings is tolerated at the 
active site of chloroquine resistance-reversing agents, and that compound (6) may well 
indeed possess the necessary properties for chloroquine resistance-reversal. The crystal 
data of (6) is tabulated in Table 2.5 below. 
Table 2.4: Crystal data of compound (6) 
Empirical formula C25 H24 Cl N3 
Formula weight 401.92 
Crystal system, space group Monoclinic, P21/c 
a (Å) 13.1065(2) 
b (Å) 15.7570(3) 
c (Å) 21.7792(5) 
α (°) 90 
β (°) 90.5650(10) 
γ (°) 90 
V (Å)3 4497.60(15) 
Z 8 
λ (Mo-Kα) (Å) 0.71073 
F (000) 1696 
Crystal size (mm) 0.16 x 0.11 x 0.09 
Range scanned θ (°) 3.02 - 25.37 
h: ±15 
k: ±18 Range of indices 
I: ±26 
No. reflections collected 60271 




∆ρ excursions /e.Å3 -0.2, 0.242 
 




Three classes of compounds, the proposed side-chains of the resistance reversering 
quinolines (aminomethyl dibemethins), their formylated derivatives (amidomethyl 
dibemethins) and the proposed “reversed chloroquine” compounds (dibemethinoquines) 
have been successfully synthesized.  
Aminomethyl dibemethins were synthesized using the Staudinger reduction of azides or 
the reductive amination via oxime of an aldehyde in good yields. The precursors to these 
compounds were also successfully synthesized and purified in good yields.  
Amidomethyl dibemethins were all synthesized via a single-step reaction, which involved 
refluxing the respective aminomethyl dibemethins in excess ethyl formate to obtain the 
product in near quantitative yield, albeit as rotamers. Dibemethinoquines were also 
obtained, although in low yields, by DCQ coupling reactions. All the target compounds 
were fully characterized using NMR, IR and high resolution mass spectrometry or 
microanalysis. The crystal structure of a representative compound (6) was also 
elucidated. A syn-like conformational arrangement of the quinoline and terminal aromatic 
ring was observed and thought to have implications in biological activity of 
dibemethinoquine compounds, as the conformation appears to conform to the resistance 
reverserpharmacophore 
.
Quantitative SAR in dibemethinoquines 
73 




The advent of drug resistant strains of P. falciparum has reduced the efficacy of current 
antimalarial drugs including some mainstay compounds like chloroquine. Since the 
emergence of resistant strains of the malaria parasite, scientists have tried with limited 
success to produce cheap and effective 4-aminoquinoline alternatives to chloroquine. 
The discovery of the chloroquine resistance-reversing properties of the calcium channel 
blocker verapamil opened up interest in a new class of compounds known as resistance 
reversing agents. Since then, more compounds of diverse chemical structures have 
been identified as chloroquine resistance-reversering agents. However, the usefulness 
of these agents as chemosensitizers is impaired by their profound antipsychotic, 
antihistaminic or cardiovascular effects. This is further complicated by the fact that the 
effective dose of these compounds as chemosensitizers is generally close to or higher 
than their other clinical applications 188. Against this background, there is an urgent need 
to find new and innovative drugs to combat chloroquine resistance in P. falciparum. In 
this regard, chloroquine analogues which are active against chloroquine-resistant 
parasites including short chain (1.21) and long chain (1.23) analogues, analogues with 
side-chains containing bulky groups or aromatic rings (1.24) and isoquine (1.25) and 
metallated analogues (1.22) have been synthesized,154-157 but most have not found use 
in malaria chemotherapy. The introduction of advanced techniques such as molecular 
modeling and 3D-QSAR as tools in the search for new drugs has proved supportive in 
this drive. Using these methods, SAR models have been established based on the 
structures and activities of known chemosensitizers as well as existing chloroquine 
analogues. SAR models help identify essential features in a class of compounds. These 
findings have found particular application in the synthesis of highly potent drug targets.  
In this study, a novel class of analogous compounds (dibemethinoquines, Figure 3.1) 
hypothesized to be potent antimalarial compounds against both sensitive and resistant 
strains of P. falciparum coupled with the added advantage of potentially being able to 
reverse resistance was synthesized. 
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Figure 3.1: Chemical structure of dibemethinoquines (6, 43 - 53). 
 
By varying the point of attachment of the dibemethin side-chain to the quinoline ring 
between ortho, meta and para and also introducing three different substituents (X = Cl, 
MeO and NMe2) to the side-chain of the parent compounds (X = H), a quantitative 
structure-activity relationship could be elucidated based on physicochemical properties 
and biological activities of these compounds. 
3.2 EXPERIMENTAL METHODS 
3.2.1 Synthesis of dibemethinoquines 
The target compounds were synthesized in a single step by reaction of the appropriate 
dibemethin with excess commercially available 4, 7-dichloroquinoline in anhydrous N-
methyl-2-pyrrolidone as outlined in Chapter 2.4. All the compounds were fully 
characterized by infrared, 1H and 13C NMR and mass spectrometry when oils and 
elemental combustion analysis when solids. Melting points of solid compounds were 
also determined. Experimental details of the compounds are outlined in Chapter 6. 
3.2.2 β-haematin inhibition 
The IC50 values for β-haematin inhibition were determined by the method of Ncokazi and 
Egan using a pyridine based 96-well plate assay method 202. The method relies on the 
fact that 5 % aqueous pyridine dissolves haematin, but not β-haematin at pH 7.5. The 
extent of inhibition is then characterized by measuring the intensity of the monomeric 
pyridine-haematin complex at 405 nm. 
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3.2.3 pKa determinations 
The pKa values of compounds (6, 43– 53) were determined by pH titration. The values 
were determined by Dr Kanyile Ncokazi (Department of Chemistry, University of Cape 
Town). 
3.2.4 Calculations of log P and log D 
Log P and log D at the physiological pH (7.4) and vacuolar pH (5.0) were calculated from 
the observed pKa values using the ClogP computer program. 
3.2.5 Antiplasmodial and cytotoxicity testing 
Antiplasmodial and cytotoxicity tests were conducted by the division of Pharmacology, 
Department of Medicine, University of Cape Town (courtesy of Prof. P Smith).The in 
vitro antiplasmodial activities of the compounds were tested against the chloroquine 
sensitive D10 and chloroquine resistant K1 strains of parasite. The prototype (6) was 
subjected to cytotoxicity testing in Chinese hamster ovarian (CHO) cells. Compounds (6) 
and (50) were also tested against P. yoelii nigeriensis in a mouse model by intra-
peritoneal injection at 5 and 20 mg/kg and compared to chloroquine diphosphate at the 
same doses. 
3.2.6 Statistical correlations 
The statistical correlations were performed using the computer programs EXCEL and 
GPAPHPAD PRISM 3.0. In all cases where the p value was < 0.05, the correlations 
were considered to be significant. 
3.3 RESULTS 
The biological results obtained for dibemethinoquines are presented in Table 3.1 below. 
The table shows resonance constants (R), measured acid dissociation constant (pKa) 
values, β-haematin inhibitory activities (BHIA50) and in vitro antimalarial activities (IC50) 
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Table 3.1: The resonance constants (R), measured acid dissociation constant (pKa) 
values, β-haematin inhibitory activities (BHIA50), in vitro antimalarial activities (IC50) 
versus the D10 and K1 strains of P. falciparum and resistance index (RI) of compounds 
6, 43 – 53. 
 
 Code R pKa1 pKa2 BHIA50





6 VZ1 0 7.57 9.85 1.12 138.3 187.9 1.4 
46 VZ2 0 7.63 9.77 0.69 53.3 65.0 1.2 
50 VZ3 0 7.56 9.90 0.32 26.5 24.5 0.9 
43 2VZ1 −0.15 7.44 9.60 1.35 NDb 1127.5 − 
47 2VZ2 −0.15 7.55 9.89 0.66 131.4 84.9 0.6 
51 2VZ3 −0.15 7.44 9.74 0.34 NDb NDc − 
44 3VZ1 −0.51 7.47 9.85 0.46 175.2 134.3 0.8 
48 3VZ2 −0.51 7.38 9.67 0.52 90.5 116.8 1.3 
52 3VZ3 −0.51 7.44 9.70 1.44 129.9 87.8 0.7 
45 4VZ1 −0.92 7.40 9.71 0.48 177.7 153.3 0.9 
49 4VZ2 −0.92 7.36 9.67 0.45 NDb 280.9 − 
53 4VZ3 −0.92 7.33 9.66 0.41 47.8 37.0 0.8 
CQe  − 8.4 10.8 1.91 29.4 285 9.7 
a Equivalents relative to haematin, b not determined, IC50 > 100 ng/ml, 
c not determined, 
IC50 > 10 µg/ml, 
d RI = IC50 (K1) / IC50 (D10), 
e chloroquine. 
 
The pKa1, which corresponds to the quinoline heteroaromatic N atom, was found to lie in 
a narrow range from 7.33 (53) to 7.63 (46) while pKa2 which corresponds to the basic 
tertiary amino group in the dibemethin side-chain ranged from 9.6 (43) to 9.9 (50). The 
IC50 values for β-haematin inhibition covered a somewhat larger range, with the most 
potent inhibitor (50) having an IC50 of 0.32, while the least active (52) exhibited a value 
of 1.44. 
 
In the D10 strain, activities were not determined above 100 ng/ml while in the K1 strain 
measurements were not performed above 10 µg/ml. With these cutoff values, three 
compounds (43, 51 and 49) were inactive against the D10 strain, while one (51) was 
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inactive in the K1 strain. Of the remaining compounds (43) and (49) had the weakest 
measured IC50 values in the K1 strain. The IC50 values ranged from 27 nM (50) to 178 
nM (49) in the D10 strain and from 24 nM (50) to 1178 nM (43). The resistance index, a 
ratio of IC50 in the K1 strain to that in the D10 strain ranged between 0.7 (52) and 1.4 (6). 
This variation is probably not statistically significant and reflects the essentially complete 
retention of activity in resistant parasites by these compounds.   
3.3.1 Determination of log P and log D 
The accumulation of an ionizable compound in cells is determined by its partition 
coefficient (P) or distribution coefficient (D) and is usually expressed as logarithms (log P 
and log D respectively). Calculations of log P and log D are useful as measures of 
hydrophilicity or hydrophobicity of a compound and aid in estimating distribution of a 
compound within the cell or the body. The partition coefficient is a ratio of concentrations 
of un-ionized compound between two immiscible solvents normally aqueous (water) and 
organic (octanol). For partially ionized compounds, the partition coefficient between two 
phases at any fixed pH is called the distribution coefficient (D). It is therefore the ratio of 
the sum of the concentrations of all forms of the compound (ionized plus neutral) in each 
of the two phases. The difference between log P and log D is therefore determined by 
the percentage of the drug ionized at different pH values and is given by Equation 1 for a 
basic compound 203. 
  
log D = log P – log [1 + 10(pKa–pH)]                          (Equation 1) 
 
When the difference between pKa and pH is more than 1.0 log
 unit, subtraction of this 
difference from log P will furnish log D (Hansch and Leo, 1995). This makes it possible to 
calculate204 log D from knowledge of log P, pKa and pH. 
In the case of a drug possessing two basic centres, as in the case of dibemethinoquines, 
the correction needed in log P to obtain log D at a given pH involves the additive 
contribution of both ionized species, and Equation 1 must be modified to Equation 2.205 
 
log D = log P – log [1 + 10(pKa1 – pH) + 10(pKa1 + pKa2 – 2pH)]        (Equation 2) 
 
In this study Log P values were obtained using the ClogP program and the log D 
calculated using Equation 2. The program provides a useful method of computing 
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approximate log P values for compounds of known structure. This program is widely 
used in approximating log P values although it has limitations in that it does not take into 
account some differences due to conformational isomerism.206  
The Log P and Log D values of dibemethinoquines are listed in Table 3.2 below. 
 
Table 3.2: The calculated log P and log D values of dibemethinoquines 
 
Compound 
Code log P log D5.0 log D7.4 
6 VZ1 5.01 -2.41 2.39 
46 VZ2 4.90 -2.50 2.30 
50 VZ3 4.90 -2.56 2.24 
43 2VZ1 5.61 -1.43 3.36 
47 2VZ2 5.50 -1.94 2.86 
44 3VZ1 4.93 -2.39 2.41 
48 3VZ2 4.82 -2.23 2.57 
52 3VZ3 4.82 -2.32 2.48 
45 4VZ1 5.12 -1.99 2.81 
49 4VZ2 5.01 -2.02 2.78 
53 4VZ3 5.01 -1.98 2.81 
 
No quantitative relationships were found between log D and antiplasmodial activity in 
dibemethinoquines due to their similar pKa and hence log D values. However, in 
agreement with the occurrence of aromatic hydrophobic rings in their side-chain 
structure, all dibemethinoquine compounds showed the expected enhanced hydrophobic 
properties based on the calculated log P (5.06 ± 0.2) compared with chloroquine (4.72). 
The greatly increased lipophilicity of dibemethinoquine compounds compared to 
chloroquine is demonstrated by their higher log D7.4 (2.64 ± 0.3) relative to chloroquine
 
(0.96). The distribution coefficient (log D) at pH 7.4 affords some insight into the potential 
membrane transfer capabilities of these drugs. Significantly, chloroquine-resistance 
mechanisms have been shown to be related to drug lipophilicity, less lipophilic 4-
aminoquinolines being relatively less effective against resistant strains 119. 
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3.3.2 Dependence of pKa on the identity of the terminal group on the side-chain.  
Although the pKa values for compounds (6, 43 – 53) vary over only a very small range of 
about 0.3 log units, a statistically significant correlation with the physical characteristics 
of the functional group attached to the terminal phenyl ring of the side-chain is observed 
(Figure 3.2). Unexpectedly, both pKa1 and pKa2 increase as the functional group 
becomes less resonance releasing (i.e. as the parameter R becomes more positive). 
One would expect that an electron-releasing group would strengthen the N–H+ bonds, 
making deprotonation more difficult and raising rather than decreasing the pKa. 
Furthermore, the quinoline N atom is separated from the functional group on the terminal 
phenyl ring by fifteen bonds and even the dibemethin N atom is separated from this 
group by six bonds. This means that the influence of the group on pKa must be a through 
space interaction. The crystal structure of (6) illustrates that these molecules can adopt a 
folded structure in which the quinoline comes into relatively close contact with the 
terminal phenyl ring of the side-chain. Although less-likely, the observed drop in pKa1 in 
dibemethinoquines by ~1 unit compared to the reported pKa1 of chloroquine can be 
thought to be due to increased steric hindrance to protonation of the heteroaromatic 









Figure 3.2: Correlations between pKa values and resonance constants (R) of the group 
attached to the terminal phenyl ring (see Table 3.1). (a) Statistically significant 
correlation for the quinoline N, pKa1 (r
2 = 0.69, P = 0.0008). (b) Correlation for the 
dibemethin tertiary amino group, pKa2. In this case the correlation is not as good, but is 
still statistically significant if all of the data points are included (r2 = 0.35, P = 0.042). 
Omission of a single data point (open circle) for compound (43) improves the fit 
considerably (r2 = 0.65, P = 0.0028). 
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Without a more detailed investigation of such intramolecular interactions, the trend in pKa 
values is unlikely to be rationalized. 
Using Equation 3 the predicted accumulation ratio of (6, 43 – 53) in the digestive vacuole 


















==  Equation 3 
 
Here [Q]v is the concentration of the compound in the digestive vacuole of the parasite, 
[Q]e is its concentration in the extracellular medium, pHv is the digestive vacuole pH 
(taken as 5, the midpoint between two recent estimates of 4.8 and 5.2) and pHe is the pH 
of the external medium (7.4). Values are given in Table 4. An accumulation normalized 
IC50 for antimalarial activity can be calculated by multiplying the observed IC50 by the 
VAR value for each compound. As 4-aminoquinolines are believed to act by inhibiting 
haemozoin formation in the digestive vacuole, these numbers may be more relevant 
than the observed IC50. They are therefore reported in Table 3.3 below. 
 
Table 3.3: Calculated vacuolar accumulation ratio (VAR) and vacuolar accumulation 
normalized IC50 against the K1 strain of P. falciparum in vitro (VAR⋅IC50). 
 
 VARa VAR⋅IC50 / mM 
6 15029 2.82 
46 15843 1.03 
50 14892 0.37 
43 13173 14.85 
47 14753 1.25 
44 13620 1.83 
48 12318 1.44 
52 13181 1.16 
45 12608 1.93 
49 12031 3.38 
53 11601 0.43 
      a according to eq. 1, assuming a vacuolar pH of 5.0 
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3.3.3 Correlations of biological activity and β-haematin inhibition.  
In the case of compounds (6), (43), (46), (47), (50) and (51) the β-haematin inhibition 
activity increases markedly in going from the ortho- to meta- to para- derivatives. 
However, this pattern is reversed in the series (44), (48) and (52) and no significant 
differences are seen in compounds (45), (49) and (53). Thus, the abilities of these 
compounds to inhibit haemozoin formation appears to depend on both the site of 
attachment of the aminoquinoline to the dibemethin side-chain and the identity of the 
group on the terminal phenyl ring of the dibemethin in a manner that is too complex to 
rationalize on the basis of the limited number of derivatives used in this study. 
 
As IC50 values were not determined for three of the compounds against the D10 strain of 
parasite, while values were obtained for eleven of the twelve compounds against the K1 
strain, the K1 IC50 data has been used for structure-activity relationship analysis. Plots of 
log IC50 for in vitro antimalarial activity versus log IC50 for inhibition of β-haematin 
formation (log BHIA50) indicate that there is a general decrease in biological activity as β-
haematin inhibition activity decreases (Figure 3.3a). However, the trend is not 
statistically significant unless the data for compound (52) is omitted. The correlation is 
only marginally improved if the antimalarial activity is normalized for accumulation in the 
digestive vacuole (Figure 3.3b). The correlation is again only statistically significant if 
compound (52) is omitted. While this may suggest that either the BHIA50 or the IC50 
value for (52) is an outlier, it is more likely an indication that other factors play a role in 
biological activity in addition to vacuolar accumulation and haemozoin inhibition. By 
contrast to a previous study of short-chain analogues of chloroquine in which vacuolar 
accumulation and β-haematin inhibition alone correlated with activity,208 in the present 
study the structure of the side-chain is not kept constant. Therefore, a correlation 
analysis in which a structural descriptor (the position number 2, 3 and 4 for ortho-, meta- 
and para- positions respectively) was incorporated. The log IC50 is significantly 
correlated with position in the order ortho- > meta- > para (Fig. 3.3c). This correlation 
improves slightly if the accumulation normalized IC50 is used (r
2 = 0.55 and P = 0.0087 
versus r2 = 0.52 and P = 0.012 without normalization). When the structural descriptor 
was used in the correlation together with the log BHIA50 the correlation with 
accumulation normalized log IC50 is greatly improved (Figure 3.3d). When vacuolar 
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accumulation is treated as a third variable in multiple correlation analysis with the 

























Figure 3.3: Correlations of biological activity (IC50) with vacuolar accumulation ratio 
(VAR), IC50 for β-haematin inhibition activity (BHIA50) and a molecular structure 
descriptor (ortho-, meta- or para- indicated by 2, 3 or 4 respectively and referring to 
compounds (6), (43), (44), and (45 – 49); and (50 – 53) respectively). (a) Linear 
correlation between log IC50 and log BHIA50 is not statistically significant (r
2 = 0.30, P = 
0.083) unless the point for compound (52) is omitted (open circle) which considerably 
improves the correlation (r2 = 0.50, P = 0.021). (b) Linear correlation between the 
vacuolar accumulation normalized log IC50 (log VAR⋅IC50) and log BHIA50 is also not 
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statistically significant (r2 = 0.33, P = 0.064) unless the point for compound (52) is 
omitted (open circle) which again considerably improves the correlation (r2 = 0.51, P = 
0.012). (c) Statistically significant linear correlation between log IC50 and the structural 
descriptor (r2 = 0.52, P = 0.012). (d) Multiple linear correlation between the log of the 
vacuolar accumulation normalized IC50 (log VAR⋅IC50) and both log BHIA50 and the 
structural descriptor conform to the equation log VAR⋅IC50 = 0.84 × log BHIA50 − 0.34 × 
position descriptor − 1.65. F = 10.3 > Fcrit = 8.65 at the 99% confidence level. (e) Multiple 
linear correlation of log IC50 with VAR, log BHIA50 and position descriptor. Here the data 
conform to the equation log IC50 = 0.95 × log BHIA50 – 0.35 × position descriptor – 3.87 × 
log VAR + 10.24. F = 9.70 > 8.45 at the 99 % confidence level. 
 
The factors affecting the biological activities of this series of compounds are in 
agreement with previous studies on short chain chloroquine analogues, 110 with the 
additional observation of an independent influence of side-chain structure. The origin of 
this latter effect is unknown. It could indicate enhanced uptake of the para- substituted 
compounds, or more likely there is a decrease in the concentration of the quinoline 
available to inhibit haemozoin formation arising from interaction with constituents of the 
cell or culture medium which binds the ortho- compounds most strongly. In any event, 
both haemozoin inhibition and vacuolar accumulation are confirmed to be significant for 
biological activity. 
 
It is noteworthy that there is no indication of any significant cross-resistance with 
chloroquine in this series of compounds in the K1 strain of parasite. When the available 
IC50 values are plotted on the same correlation graph as those of the K1 strain (Figure 
3.3e) the points clearly fall on the same correlation line. The maintenance of activity 
against chloroquine resistant parasites could be a result of the resistance reversing side-
chain, or merely owing to the altered structure of the side-chain, which makes it no 




Quantitative SAR in dibemethinoquines 
84 
3.3.4 Cytotoxicity of (6) and evaluation of compounds (4) and (6) against 
Plasmodium yoelii nigeriensis (NS) in vivo in adult BalbC white mice  
The prototype compound (6) was subjected to cytotoxicity testing in Chinese hamster 
ovarian (CHO) cells. The IC50 in this system was found to be 32 µM which is 232 times 
higher than the IC50 in the D10 strain of P. falciparum and 170 times greater than that in 
the K1 strain. Thus, compound (6) exhibits highly selective activity against the malaria 
parasite.  
Compounds (6) and (50) were also tested against P. yoelii nigeriensis in a mouse model 
by intra-peritoneal injection at 5 mg/kg and 20 mg/kg and compared to chloroquine 
diphosphate at the same doses. These doses were chosen since the compound proved 
as effective as chloroquine in vitro and thus the same test doses as chloroquine were 
used in vivo. Typically, with Plasmodium yoelii (NS), a 5 mg/kg dose of chloroquine in 
100µl phosphate-buffered saline (PBS) produces a moderate parasite clearance in the 
bloodstream; a 20 mg/kg dose produces an almost complete clearance of circulating 
parasites.  Each test group (5 mice) was challenged using the 4-day suppressive test as 
described by Peters et al, (1975) with modifications. Identical procedures were used for 
both the 5 mg/kg and 20 mg/kg experiments. The results of the in vivo antimalarial 
activity of compounds (6) and (50) are tabulated in Table 3.4 below.   
 
Table 3.4: In vivo antimalarial activities of suspensions of compounds (6) and (50) 
administered to adult BalbC white mice infected with P. yoelii nigeriensis by intra-
peritoneal injection. 
 








CQa 6.1% 4-8 <1% ND 
6 23.45% 8.75-34.72 2.76%* 1.30-4.05* 
50 20.07% 17.71-32.85 3.13% 1.99-3.86 
*Total range from 4 mice only, following one death overnight after infection on Day 0. 
 
As indicated in Table 3.4, both compounds were less effective than chloroquine, 
although substantial activity is observed at 20 mg/kg. As both compounds were 
administered as suspensions of their free bases rather than solutions, as opposed to the 
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chloroquine salt which was fully dissolved, the somewhat lower activity of these two 
compounds in vivo may just reflect lower bioavailability owing to the method of 




The series of novel 4-amino-quinolines with chloroquine resistance-reversing dibemethin 
side-chains attached via a methylene bridge at the ortho-, meta- or para- position on the 
dibemethin exhibit activity against chloroquine-sensitive and resistant parasites. Three 
compounds, (46), (50) and (53) show promising levels of in vitro antimalarial activity, 
with compound (50) in particular being more active than chloroquine against 
chloroquine-sensitive parasites. Both the prototype compound (6) and compound (50) 
have been shown to have significant in vivo antimalarial activity in the mouse model P. 
yoelii nigeriensis, although neither was as active as chloroquine diphosphate when 
administered intra-peritoneal. Preparation of salts of these compounds and improved 
formulation would probably improve in vivo activity considerably, as both (6) and (50) 
were administered as suspensions, whereas chloroquine diphosphate was a solution. A 
preliminary cytotoxicity investigation of compound (6) suggests that toxicity is acceptably 
low relative to antimalarial activity. Structure activity studies show that, as with other 
chloroquine analogues, the activity of this class of compound results from their ability to 
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CHAPTER 4: RESISTANCE REVERSING POTENTIAL OF THE AMINOMETHYL 
DIBEMETHIN SIDE-CHAIN OF DIBEMETHINOQUINE COMPOUNDS 
4.1 BACKGROUND 
 
The structural makeup of the “reversed chloroquine” hybrid compounds reported by 
Burgess et al., (2006),189 helped shape the structural delineation of dibemethinoquines. 
As discussed earlier, “reversed chloroquine” compounds combine the fundamental 
pharmacophore for haem-binding and inhibition of haemozoin formation (4-amino-7-
chloroquinoline) and the pharmacophore for a resistance reverser.  
 
Since dibemethinoquines are proposed to fall in the class of “reversed chloroquine” 
compounds, then the earlier observed antimalarial activity of these compounds against 
resistant strains of P. falciparum could possibly be ascribed to their aminomethyl 
dibemethin side-chains whose two aromatic hydrophobic ring structure coupled with the 
presence of protonatable N-atoms in the side-chain, although not inline with the spartial 
delinations proposed in the Bhattacharjee et al., (2002) model, had successfully 
conferred the chloroquine resistance-reversing entity of this type of compounds. If this 
hypothesis is true, then aminomethyl dibemethins can be viewed as a new class of 
chloroquine resistance-reversing agents.  
 
A chloroquine resistance-reversing agent should restore chloroquine activity at 
concentrations at which it has little or no inherent biological activity. To explore the 
potential of aminomethyl dibemethins as chloroquine resistance-reversing agents, in 
vitro chloroquine resistance-reversing activity was tested against the W2 chloroquine 
resistant strain of the malaria parasite. Furthermore, to probe the effect, if any, of the 
primary amino group of these compounds, their formylated analogues were prepared 
and tested similarly. β-haematin inhibitory activity tests were also conducted to 
determine if the mode of action of the weak antimalarial activity of these compounds is 
via interference with the haem detoxification pathway of the malaria parasite as has 
been reported in some resistance modulating agents,209 
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4.2 EXPERIMENTAL METHODS 
4.2.1 Synthesis of aminomethyl and amidomethyl dibemethins 
As discussed in Chapter 2, o-aminomethyl dibemethin (4) was synthesized in four steps 
through a reductive amination via the oxime route using the method by Blackie et al., 
(2007).200 All the other aminomethyl dibemethins were synthesized via the Staudinger 
reduction of azides using a modified synthetic route to the method by Rinke et al., 
(2001).201 The formylated derivatives of aminomethyl dibemethins (amidomethyl 
dibemethins) were all synthesized in a single step reaction of the appropriate 
aminomethyl dibemethin with excess ethyl formate. All the target compounds were fully 
characterized by infrared, 1H and 13C NMR and mass spectrometry. Experimental details 
of the compounds are outlined in Chapter 6. 
4.2.2 β-haematin inhibition 
The IC50 values for β-haematin inhibition were determined by the method of Ncokazi and 
Egan (2005) using a pyridine based 96-well plate method.202 
4.2.3 Antiplasmodial and chloroquine resistance-reversal testing 
The antiplasmodial and chloroquine resistance-reversal activity of aminomethyl and 
amidomethyl dibemethins was tested against the chloroquine resistant W2 strain of 
parasite with the compound concentration fixed at 1 µM and also with each fixed at its 
individual IC10. This work was conducted at the Division of Pharmacology, Department of 
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4.3 RESULTS 
4.3.1 β-haematin formation 
All the aminomethyl dibemethin compounds and their formylated derivatives were tested 
for their β-haematin inhibitory activity using 96-well plate method of Ncokazi and Egan 
(2005).202 None of the compounds demonstrated β-haematin inhibitory activity in vitro.  
4.3.2 Antimalarial activity 
Since a chloroquine resistance-reversing agent restores chloroquine activity at 
concentrations where it has little or no inherent biological activity itself, it was necessary 
to first test the in vitro antimalarial activities of aminomethyl dibemethin compounds (4, 
21 – 31) and amidomethyl dibemethin compounds (5, 32 – 42) against the chloroquine 
resistant W2 strain of parasite. The IC50 and IC10 values are reported in Table 4.1 below. 
Each compound was then tested in combination with chloroquine. In each case, testing 
was carried out with the compound concentration fixed at 1 µM and also with each fixed 
at its individual IC10. This permits both direct comparison of the relative resistance 
reversing activities of the compounds as well as providing information on the maximal 
resistance reversing activity under conditions in which the compound has little inherent 
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Table 4.1: The in vitro IC50 and IC10 values of aminomethyl dibemethin compounds (4, 
21 – 31) and amidomethyl dibemethin compounds (5, 32 – 42), against the chloroquine 
resistant W2 strain of P. falciparum. 
 
Compound Number Compound Code IC50 / µM 
4 VZ1A 4.2 
24 VZ2A 3.4 
28 VZ3A 39.0 
21 2VZ1A 6.1 
25 2VZ2A 27.9 
29 2VZ3A 59.8 
22 3VZ1A ND 
26 3VZ2A 5.3 
30 3VZ3A 50.5 
23 4VZ1A 21.0 
27 4VZ2A 30.4 
31 4VZ3A 14.5 
5 VZ1F 10.1 
35 VZ2F 25.5 
39 VZ3F 5.4 
32 2VZ1F 4.8 
36 2VZ2F 18.4 
40 2VZ3F 27.2 
33 3VZ1F 31.6 
37 3VZ2F 45.7 
41 3VZ3F 43.7 
34 4VZ1F 53.9 
38 4VZ2F ND 
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Table 4.2: The IC50 of chloroquine (nM) in the presence of 1 µM concentration and the 
IC10 of aminomethyl dibemethin compounds (4, 21 – 31) and amidomethyl dibemethin 
compounds (5, 32 – 42) and the corresponding resistance modification index in the 
chloroquine resistant W2 strain. 
 
Compound Code 
At 1 µM 
compound 
RMIa At the IC10 RMI
a 
− − 165.9b 1.00 144.9 - 
4 VZ1A 4 0.024 ND - 
24 VZ2A -c - 3.70 0.0255 
28 VZ3A 26.8 0.162 ND - 
21 2VZ1A 4 0.024 4.53 0.031 
25 2VZ2A 44.3 0.267 64.05 0.442 
29 2VZ3A 29.7 0.179 83.66 0.577 
22 3VZ1A 47.1 0.284 95.61 0.660 
26 3VZ2A 36.9 0.222 38.38 0.265 
30 3VZ3A 36.9 0.222 52.40 0.362 
23 4VZ1A 45.7 0.275 59.91 0.413 
27 4VZ2A 29.7 0.179 4.53 0.031 
31 4VZ3A 27.1 0.163 8.44 0.058 
5 VZ1F 114 0.687 68.49 0.473 
35 VZ2F 115 0.693 41.96 0.290 
39 VZ3F 166 1 59.91 0.413 
32 2VZ1F 138 0.832 43.87 0.303 
36 2VZ2F 138 0.832 24.59 0.170 
40 2VZ3F 138 0.832 24.59 0.170 
33 3VZ1F 134 0.808 5.90 0.041 
37 3VZ2F 164 0.989 51.26 0.354 
41 3VZ3F 162 0.976 40.13 0.277 
34 4VZ1F 146 0.880 61.26 0.423 
38 4VZ2F -c - ND - 
42 4VZ3F 187 1.127 70.02 0.483 
a IC50 of CQ in presence of compound/IC50 of CQ in its absence, 
b in presence of CQ 
alone, c compound too toxic to parasite to test. 
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The data shows (Table 4.1) that none of the dibemethins tested exhibit in vitro 
antimalarial IC50 values at concentrations below 1 µM. On the other hand, all show 
significant resistance reversing activity. With most compounds bringing about restoration 
of chloroquine activity in the W2 strain of chloroquine resistant parasite at their IC10 
values to within about 2 – 3 times the IC50 in the D10 strain. Only compounds 22 and 29 
show weak resistance reversing activity at their IC10 values, restoring chloroquine activity 
to about 5 – 6 times the IC50 in the D10 strain. 
 
Among compounds (4, 21 – 31), there is little difference in their chemosensitizing activity 
except for compounds (4) and (21) which are exceptionally active, probably because 
they possess some direct toxicity to the parasite. When comparing the chemosensitizing 
activities of the whole set of these compounds at the same concentration (1 µM), the 
dominant effect appears to be formylation of the primary amino group. At this 
concentration the activity of the formylated compound is almost abolished. Only (5) and 
(35) retain any resistance reversing activity. By contrast, all of the compounds with a 
basic primary amino group exhibit strong activity at this concentration. The likely 
explanation for this observation is that the dibasic compounds (4, 21 – 31) accumulate in 
the digestive vacuole of the parasite, the site of drug action of chloroquine 210 through pH 
trapping to a far higher concentration than the monobasic compounds (5, 32 – 42). 
Comparing the activities of the dibemethin compounds at their respective IC10 
concentrations shows that all, including the formylated series (5, 32 – 42) are active 
chloroquine resistance-reversers. The fact that formylation of the amino group does not 
abolish the resistance reversing properties of these compounds demonstrates that the N 




The data obtained in this study gives an insight into the structural characteristics that are 
associated with chloroquine resistance-reversing activity. The ability to interact with 
haem was shown not to be a necessary feature of resistance reversing activity. As 
expected, this confirms that haem-binding is not directly related to resistance reversing 
activity. By contrast to the proposal by Bhattacharjee et al., (2002) 187, the two aromatic 
rings linked by a 1-carbon chain to an N atom provide resistance reversal activity 
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although the position of the N atom appears to be less critical than earlier studies 
suggest. Furthermore, all of the compounds with a basic primary amino group exhibit 
stronger activity at this concentration than their formylated derivative. Indeed, it has 
previously been shown that accumulation at the site of action is critical for resistance 
reversing activity.  
 
A possible explanation for the observed resistance reversing properties of these 
compounds is that the aromatic rings in aminomethyl dibemethins may function by 
mimicking the molecular structure of the chloroquine ring system in a manner that allows 
specific interaction with the resistance apparatus in chloroquine resistant parasites. This 
would be consistent with a model in which the chemosensitizer binds directly to the 
chloroquine resistance transporter PfCRT on the vacuolar side of the membrane, 
competing with chloroquine.61 Alternatively, the aminomethyl dibemethins may bind to 
the chloroquine resistance transporter protein and indirectly affect chloroquine 
accumulation by altering the proton gradient across the food vacuole membrane 211, 155. 
Yet a third possibility is that if the resistance transporter functions by exporting 
chloroquine from its site of action, aminomethyl dibemethins may bind closely with the 
quinoline ring of chloroquine via π-π interactions. The resultant compound is more 
hydrophobic than chloroquine and may be less efficiently exported from the food vacuole 
although this seems less likely. In this light, it is interesting to note that a direct 
correlation has been observed between hydrophobicity and activity against chloroquine 
resistant parasites in a series of quinoline antimalarials.207 
4.5 CONCLUSIONS 
 
The aminomethyl derivatives of dibemethin represent a new class of chloroquine 
resistance-reversing agent in Plasmodium falciparum. A significant finding is that the 
need for a three-carbon aminoalkyl chain positioned between the aromatic rings as 
proposed by Bhattacharjee et al., (2002),187 is not essential for resistance reversal. 
Finally, ability to pH trap in the digestive vacuole appears to greatly enhance resistance-
reversing activity, while stereospecific factors seem to play an important role in the 
relative activities of closely related compounds. 
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CHAPTER 5: OVERALL CONCLUSCIONS AND FUTURE WORK 
5.1 Overall conclusions 
 
The principle aim of this project was to synthesize chloroquine-like antimalarial 
compounds of high potency with the inherent ability to switch-off drug resistance should 
it develop, based on the principle of the “reversed chloroquine” hybrid molecule reported 
by Burgess et al (2006).189 The structural makeup and synthesis of the target 
compounds (dibemethinoquines) was guided by 3 models being; (i) a SAR model based 
on findings by Egan et al., (2000),102 (ii) a 3D-QSAR pharmacophore model for 
chloroquine resistance-reversal proposed by Bhattacharjee et al., (2002)187 and (iii) the 
Topliss scheme193 to select suitable substituents in an attempt to synthesize analogues 
of superior activity to the parent compounds.  
 
By possessing two hydrophobic aromatic rings (the aminomethyl dibemethin side-chain) 
and a hydrogen bond acceptor (quinoline N-atom) in agreement with the requirements of 
the proposal by Bhattacharjee et al., (2002), dibemethinoquines were hypothesized to 
act as resistance-reversing compounds. Furthermore, the 4-amino-7-chloroquinoline 
moiety provided the focus for haem-binding and inhibition of haemozoin formation thus 
fulfilling the requirements in the SAR model proposal by Egan et al., (2000) for the 
activity of chloroquine-like compounds (Figure 5.1) and the Topliss scheme was used in 









    
NH2N
X  
   (6, 43 – 53)     (4, 21 – 31) 
Figure 5.1: Chemical structures of dibemethinoquines (6, 43 – 53) and aminomethyl 
dibemethins (4, 21 – 31). 
 
To better understand the structure–activity relationships of resistance reversal on side-
chain structure, the influence of the position of connection between the 4-amino-7-
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chloroquinoline moiety and the dibemethin side-chain was probed by varying the 
connection between ortho-, meta- and para- positions. Furthermore, analogues of the 
parent dibemethinoquine compounds (X = H) were prepared by introducing substituents 
on the para position of the benzyl-N-methylamine ring of the side-chain. The choice of 
substituents was based on the Topliss Scheme where the Cl (hydrophobic/electron-
withdrawing), OMe (electron-releasing, similar hydrophobicity to H) and NMe2 (strongly 
electron-releasing/hydrophobic) groups were selected.  
 
The IC50 values of dibemethinoquine compounds were almost identical in the 
chloroquine-sensitive D10 and chloroquine-resistant K1 strains of malaria parasite in 
vitro. Three compounds, (46), (50) and (53) showed promising levels of in vitro 
antimalarial activity, with compound (50) having an IC50 almost identical to chloroquine in 
the chloroquine sensitive strain. Compound (6) and (50) were tested in a mouse model 
for in vivo activity against P. yoelii nigeriensis. Although active, they were less active 
than chloroquine. However, as they were administered by i.p. injection of the free bases 
(versus the diphosphate salt of chloroquine), the lower activity can be ascribed to poor 
water solubility. Indeed, these compounds were noted to be suspensions, whereas 
chloroquine diphosphate was clearly a solution. No obvious acute adverse effects were 
observed in the mice and cytotoxicity tests on the prototype compound (6) showed that 
this class of compound is selectively active against malaria parasites. All the 
dibemethinoquines were shown to inhibit β-hematin (synthetic haemozoin) formation in 
vitro and a quantitative structure activity relationship between digestive vacuole 
accumulation normalized IC50 (determined from pKa values and the Henderson-
Hasselbach equation) and both β-hematin inhibition strength and a structural descriptor 
of the dibemethin moiety (taking into account ortho-, meta- or para-substitution) was 
found. This strongly supports the hypothesis that dibemethinoquines act by inhibiting 
haemozoin formation in the parasite. 
 
Somewhat surprisingly, the aminomethyl dibemethin compounds used as side-chains all 
showed strong chloroquine resistance-reversing (chemosensitizing) activity in the 
chloroquine resistant W2 strain of Plasmodium falciparum cultured in vitro when present 
at 1 µM concentration or at their IC10 concentration. Their N-formylated derivatives 
(amidomethyl dibemethins) also showed resistance reversing activity, but only at their 
significantly higher IC10 concentrations. The fact that formylation of the terminal amino 
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group does not abolish the resistance reversing properties of these compounds 
demonstrates that the N atom at this position does not need to be basic in order to 
exhibit chloroquine resistance-reversing activity. However, the fact that the aminomethyl 
dibemethin compounds exhibit stronger activity at 1 µM concentration than their 
formylated derivatives highlights the observation that the ability to accumulate in the 
digestive vacuole by pH trapping enhances resistance-reversing activity. The resistance 
reversing activity observed in aminomethyl and amidomethyl dibemethins demonstrates 
that the amino group need not be attached to the two aromatic rings via a three or four 
carbon chain for a compound to exhibit chloroquine resistance-reversing properties as 
has been suggested by previous QSAR studies.  
 
5.2 FUTURE WORK 
 
An extensive study of the magnitude of chemosensitization of chloroquine resistant 
parasites by these novel classes of resistance reversers and “reversed chloroquine” 
compounds will have to be performed by isobologram analysis. This will aid in 
establishing whether the interaction of these new compounds with chloroquine is 
synergistic, additive or antagonistic and hence to establish whether the active quinoline 
derivatives themselves actually reverse chloroquine resistance. 
 
In view of the fact that free-bases of dibemethinoquines showed solubility problems both 
in the in vitro and in the in vivo antimalarial tests, preparation of salts of these 
compounds and / or improved formulation is essential to improve biological tests results 
and to determine their potential as new drugs. 
 
In this study, it was found that aminomethyl dibemethin compounds exhibit chloroquine 
resistance-reversing activity. In future studies, it would be worthwhile synthesizing 
analogues of these compounds with longer alkyl chains separating the two aromatic 















Where n = 1, 2, 3 e.t.c  
Figure 5.2: Chemical structures of proposed new aminomethyl dibemethin synthetic 
targets with elongated alkyl chains between N and the two aromatic rings. 
 
Synthesis of such compounds would afford the opportunity to further explore structure-
activity relationships in this class of compounds with regard to resistance reversal. 
 
Basicity of aminomethyl dibemethin compounds was identified as having a bearing on 
activity by improving accumulation via pH trapping. It would be interesting to observe 
resistance reversing properties of analogues of these compounds where one or both of 




















Where n = 1, 2, 3 etc  
 
Figure 5.3: Chemical structures of proposed new aminomethyl dibemethin synthetic 
targets with elongated alkyl chains between N and the two aromatic rings and with one 
or both or the benzene rings replaced by pyridine. 
 
Such compounds would in essence retain the aromatic nature of these regions while 
more importantly increasing both the overall basicity of the compound and the number of 
H-bond acceptors within the molecule. The improved H-bond acceptor properties of this 
type of compound may possibly assist in the drug binding to the resistance transporter 
protein. 
 
Similar changes to aminomethyl dibemethins can be effected to the side-chains of a new 
class of potential “reversed chloroquine” compounds (Figure 5.4).This will offer novel 
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Figure 5.4: Chemical structures of proposed new dibemethinoquine synthetic targets 
with elongated alkyl chains between N and the two aromatic rings and / or with one or 


















CHAPTER 6: EXPERIMENTAL 
6.1 General Procedure 
 
All solvents were freshly distilled. Dichloromethane was distilled over phosphorus 
pentoxide under nitrogen. Tetrahydrofuran was distilled under nitrogen and dried over 
sodium wire with benzophenone. Other reagents were purified according to standard 
procedures.317 All reagents were purchased from Aldrich or Merck. Low temperature 
reactions were carried out using liquid nitrogen in acetone (-78 ºC) or a slurry of water 
and ice (0 ºC). 
 
Thin layer chromatography (TLC) was used to monitor reactions using aluminium-
backed Merck silica-gel 60 F254 plates. Compounds on TLC were observed by a 
combination of ultra-violet light, iodine vapour, or by spraying with a 2.5% solution of 
anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v) and then heating at 150 
ºC. Column chromatography was performed using silica-gel 60 mesh (Merck 7734).  
 
Melting points were measured on a Reichert-Jung Thermovar hot-stage microscope and 
are uncorrected. Infrared spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR 
spectrometer on sodium chloride plates. Elemental analyses were performed using a 
Fisons EA 110 CHN elemental analyzer. High-resolution mass spectrometry was 
performed at The University of the Witwatersrand using a VG70-SEQ micromass 
spectrometer or at The School of Chemistry, University of Stellenbosch on an API Q-
TOF Ultima machine. All spectra were recorded in Electron Ionisation mode, unless 
otherwise stated. 
 
Nuclear Magnetic Resonance spectra were recorded on either a Varian Unity 400 (at 
399.95 MHz for 1H and 100.58 MHz for 13C) or a Varian VXR-300 (at 300.08 MHz for 1H 
and 75.5 MHz for 13C) spectrometer in deuterated chloroform unless otherwise stated. 
Chemical shifts (δ) were recorded using residual chloroform (δ 7.26 in 1H NMR and δ 
77.00 in 13C NMR) as internal standards. All chemical shifts are reported in ppm and J 











To a stirred solution of N, N-benzylmethylamine (10.6 ml, 82.5 mmol) in DCM (50 ml) 
and triethylamine (17.2 ml, 124 mmol) at 0 ºC under an atmosphere of nitrogen, was 
added benzyl bromide (9.80 ml, 82.5 mmol) slowly and the reaction allowed to progress 
for 2 hours after which time a white precipitate had formed. The reaction mixture was 
worked up by the addition of a saturated solution of aqueous Na2CO3 and the product 
extracted into ethyl acetate (3 × 50 ml), the organic extracts dried over anhydrous 
MgSO4 and the solvent removed under reduced pressure to give a crude product (17 g), 
which was chromatographed on silica-gel (170 g) using 10% ethyl acetate in hexane as 
eluent. The product was dried in vacuo to give 1 (11.6 g, 67%) as a pale yellow oil; δH 
(300 MHz, CDCl3) 7.57 - 7.38 (10H, m, ArH), 3.70 (4H, s, CH2), 2.37 (3H, s, CH3); δC 
(CDCl3, 75.5 MHz) 139.2 (Arqu), 128.8 (Arortho ), 128.1 (Armeta ), 126.8 (Arpara ), 61.8 (CH2), 
42.1 (CH3). 
 






















t-Butyllithium (10.0 ml, 1.7 M, 17.0 mmol) was slowly added dropwise to a stirred 
solution of 1 (3.00 g, 14.2 mmol) in anhydrous diethyl ether (100 ml) at -78 ºC under an 
atmosphere of nitrogen. The mixture was warmed up to 0 ºC and allowed to stir until the 
colour of the mixture turned from orange to pale-yellow and a white precipitate of the 
lithio-salt had formed. Anhydrous DMF (1.10 ml, 14.3 mmol) was then slowly added 
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dropwise at 0 ºC and the reaction allowed to progress to room temperature while stirring 
for 3 hours after which time the reaction mixture was clear of precipitate. Diethyl ether 
was evaporated off on the rotary evaporator, the resulting solid was worked up with 
deionised water and the product extracted into ethyl acetate (3 × 100 ml). The organic 
extracts were dried over anhydrous MgSO4 and the solvent removed under reduced 
pressure to give a crude product (3.20 g), which was chromatographed on silica-gel 
using mixtures of ethyl acetate: hexane (0:100) to (5: 95) as eluent. The product was 
dried in vacuo to give 2 (2.61 g, 77%) as a yellow oil; vmax/cm
-1 (CHCl3) 3066, 3029, 
3010, 2949, 2880, 2843, 2793, 1689, 1600; δH (CDCl3, 300 MHz) 10.42 (1H, s, H-1), 
7.92 (1H, dd, J = 1.5, 7.5 Hz, H-7), 7.50 - 7.23 (8H, m, ArH), 3.84 (2H, s, H-8), 3.53 (2H, 
s, H-10), 2.13 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 192.0 (C-1), 141.7 (Arqu), 138.5 (Arqu), 
134.9 (Arqu), 133.0 (ArC-H), 130.4 (C-4), 128.9 (C-7), 128.8 (C-12 / 16), 128.1 (C-13 / 15),  
127.6 (ArC-H), 127.0 (ArC-H), 61.8 (C-10), 58.9 (C-8), 41.6 (C-9); HRMS (ES): Found 
239.13034 (M+). C16H17NO (M

























To a stirred solution of 2 (2.50 g, 10.4 mmol) in absolute ethanol (50 ml), was added 
hydroxylammonium chloride (1.97 g, 28.3 mmol) followed by a solution of NaOH (2.26 g, 
56.5 mmol) in deionised water(3 ml). The reaction was allowed to reflux overnight under 
an atmosphere of nitrogen. The mixture was then worked up with deionised water and 
extracted with ethyl acetate (3 x 50 ml). The organic extracts were dried over anhydrous 
MgSO4 and the solvent evaporated under reduced pressure. The crude product was 
chromatographed on silica-gel using a mixture of ethyl acetate: hexane (10:90) as 
eluent. The product was dried in vacuo to give 3 (2.25 g, 85%) as a pale-yellow oil; 
vmax/cm
-1 (CHCl3) 3305, 3065, 3028, 3011, 2950, 2881, 2841, 2791, 1601; δH (CDCl3, 
300 MHz) 8.69 (1H, s, H-1), 7.80 (1H, dd, J = 1.7, 6.5 Hz, H-7), 7.35 - 7.25 (8H, m, ArH), 
3.64 (2H, s, H-8), 3.54 (2H, s, H-10), 2.15 (3H, s, H-9), 1.29 (1H, br s, OH); δC (CDCl3, 
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75 MHz) 149.2 (C-1), 138.8 (Arqu), 137.7 (Arqu), 131.4 (Arqu), 130.7 (ArC-H), 129.4 (ArC-H), 
129.1 (C-12 / 6), 128.3 (C-13 / 15), 127.6 (ArC-H), 127.0 (ArC-H), 126.4 (C-7), 62.1 (C-10), 

























To a stirred solution of 3 (1.00 g, 3.90 mmol) in anhydrous diethyl ether (10 ml), was 
added LiAlH4 (75 mg, 1.96 mmol) slowly and the reaction allowed to reflux overnight 
under an atmosphere of nitrogen. After the reaction mixture was allowed to cool to room 
temperature, a saturated solution of aqueous Na2SO4 (10 ml) with a few drops of 
triethylamine was added to the reaction mixture. This mixture was stirred for 30 minutes 
and the resultant precipitate filtered through Celite, the residue washed with a solution of 
5% triethylamine in THF (100 ml). The solvent was removed under reduced pressure 
with a small volume of toluene being added to facilitate the azeotropic removal of any 
water. The crude product was purified by column chromatography using 100% ethyl 
acetate followed by EtOAc: MeOH: NEt3 (90: 5: 5) as eluent to give 4 (0.83 g, 89%) as a 
dark-orange oil; vmax/cm
-1 (DMSO) 3523 - 3422, 3287, 2791, 2143, 2050, 1973, 1711, 
1663, 1579, 1491; δH (CDCl3, 300 MHz) 7.32 - 7.23 (9H, m, ArH), 6.88 (2H, br s, NH2), 
3.94 (2H, s, H-1), 3.58 (2H, s, H-8), 3.57 (2H, s, H-10), 2.07 (3H, s, H-9); δC (CDCl3, 75.5 
MHz) 137.5 (Arqu), 137.1 (Arqu), 136.8 (Arqu), 131.3 (C-7), 130.7 (C-4), 129.5 (C-12 / 16); 
128.5 (C-13 / 15); 128.4 (ArC-H), 128.0 (ArC-H), 127.4 (ArC-H), 62.3 (C-10), 60.8 (C-8), 43.0 




































A stirred solution of 4 (0.35 g, 1.46 mmol) in excess ethyl formate (5.75 ml, 72.5 mmol) 
under N2 was refluxed overnight. The excess ethyl formate was removed under reduced 
pressure and the crude product purified by column chromatography using mixtures of 
ethyl acetate: hexane (50:50) to (95:5) as eluent to give 5 (0.36 g, 92%) as a thick-yellow 
oil and predominantly (> 90%) as a s-trans rotamer; vmax/cm
-1 (DMSO) 3621 - 3211, 
2595, 2148, 2059, 1979, 1907, 1656; δH (CDCl3, 300 MHz) 8.33 (1H, br s, NH), 8.08 (1H, 
s, H-1), 7.41 - 7.22 (9H, m, ArH), 4.44 (2H, d, J = 5.7 Hz, H-2), 3.58 (2H, s, H-9), 3.55 
(2H, s, H-11), 2.12 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 160.3 (C-1), 137.9 (Arqu), 137.8 
(Arqu), 136.7 (Arqu), 131.7 (C-8), 130.6 (C-5), 129.4 (C-13 / 17); 128.6 (ArC-H), 128.5 (C-
14 / 16); 127.7 (ArC-H), 127.6 (ArC-H), 62.2 (C-9), 61.4 (C-11), 42.0 (C-10), 41.3 (C-2); 
HRMS (ES): Found 268.15875 (M+).  C17H20N2O (M



































To a stirred solution of 4 (0.42 g, 1.73 mmol) in anhydrous N-methyl-2-pyrrolidone (2 ml) 
under N2, were added triethylamine (1.21 ml, 8.67 mmol), K2CO3 (0.48 g, 3.47 mmol) 
and 4, 7-dichloroquinoline (1.72, 8.67 mmol) and the mixture was heated at 90 °C for 48 
Experimental 
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Hours. After the mixture was allowed to cool to room temperature it was poured into 
saturated brine (20 ml) and extracted with ethyl acetate (3 × 50 ml). The combined 
organic extracts were further washed 5 times with saturated brine to ensure removal of 
any traces of the pyrrolidone, before being dried over anhydrous Na2SO4 and filtered. 
Following solvent removal, the resulting crude product was dried under reduced 
pressure and purified by silica-gel chromatography using mixtures of ethyl acetate: 
hexane (30:70) to (80:20) as eluent to give 6 (0.26 g, 37%) as a white crystalline solid,  
m.p. (EtOAc:Hex) 101-103 ºC; vmax/cm
-1 (DMSO) 3583, 3384 - 3256, 2595, 2140, 2050, 
1975, 1659, 1580; δH (CDCl3, 300 MHz) 8.53 (1H, d, J = 5.1 Hz, H-1), 7.89 (1H, d, J = 
2.0 Hz, H-8), 7.49 - 7.19 (10H, m, Ar H and H-5), 6.85 (1H, dd, J = 2.0, 9.0 Hz, H-6), 
6.52 (1H, d, J = 5.1 Hz, H-2), 4.43 (2H, d, J = 5.1 Hz, H-10), 3.61 (2H, s, H-17), 3.58 
(2H, s, H-19), 2.14 (3H, s, H-18), 1.27 (1H, s, NH); δC (CDCl3, 75.5 MHz) 152.0 (C-1), 
150.2 (Arqu), 149.3  (Arqu), 137.4 (Arqu), 137.2 (Arqu), 137.1 (Arqu), 134.5 (Arqu), 132.0 (C-
15), 130.5 (ArC-H), 129.9 (C-12), 129.9 (ArC-H),128.4 (C-21 / 25), 128.4 (C-22 / 24), 127.9 
(C-8), 127.6 (ArC-H), 124.7 (C-6), 122.2 (C-5), 117.8 (Arqu), 99.0 (C-2), 61.9 (C-17), 61.0 
(C-19), 46.6 (C-10), 41.9 (C-18);  (Found: C, 74.56; H, 6.07; N, 10.08%. C25H24N3Cl 
requires C, 74.71; H, 6.02; N, 10.45%). 
 
General procedure for synthesis of the α, α'-2, 3 and 4 azido-bromo xylenes (GP1) 
 
Sodium azide (1.0 equiv.) was added to a stirred solution of the appropriate α, α'-
dibromoxylene (o, m or p) in anhydrous DMF under N2, and the reaction allowed stirring 
at room temperature overnight. The reaction mixture was diluted with ethyl acetate (100 
ml) and the organic layer washed with saturated brine (3 x 50 ml), dried (MgSO4) and 
concentrated in vacuo. The crude product was obtained as a mixture of the mono- and 
di-substituted as well as the unreacted α, α'-dibromoxylene, with approximately 65% of 
the crude product being the desired mono-substituted azidobromoxylene as evaluated 






























To a stirred solution of crude meta- α, α' -azidobromoxylene (0.22 g, 0.99 mmol) 
synthesized as outlined in GP1 and  K2CO3 (0.27 g, 2.00 mmol) in anhydrous acetonitrile 
(25 ml) at 0 °C, was added N-benzylmethylamine (0.19 ml, 1.49 mmol) and the reaction 
heated and allowed to progress under reflux overnight. Acetonitrile was then removed 
under reduced pressure, saturated aqueous Na2CO3 added and the organic product 
extracted into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and 
concentration in vacuo furnished  a residue, which was purified by column 
chromatography using mixtures of ethyl acetate: hexane (10:90) to (20:80) as eluent to 
give 13 (0.15 g, 57% over 2 steps.) as a yellow oil; δH (CDCl3, 300 MHz) 7.40 - 7.14 (9H, 
m, ArH), 4.35 (2H, s, H-1), 3.57 (2H, s, H-8), 3.57 (2H, s, H-10), 2.22 (3H, s, H-9); δC 
(CDCl3, 75.5 MHz) 140.0 (Arqu), 138.9 (Arqu), 135.3 (Arqu), 128.9 (ArC-H), 128.9 (C-12 / 
16), 128.7 (ArC-H), 128.7 (ArC-H), 128.2 (C-13 / 15), 127.0 (ArC-H), 126.8 (ArC-H), 61.8 (C-
8), 61.5 (C-10), 54.8 (C-1), 42.1 (C-9); HRMS (ES): Found 266.14947 (M+). C16H18N4 























To a stirred solution of 13 (0.44 g, 1.65 mmol) in THF (4.50 ml) under N2, was added 
PPh3 (0.44 g, 1.66 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water was added (1.50 ml, 83.3 mmol) and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
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MeOH: NEt3 (90: 5: 5) as eluent to give 24 (0.35 g, 88%) as a dark-yellow oil; vmax/cm
-1 
(DMSO) 3567 - 3374, 3273, 2840, 2784, 2149, 2056, 1968, 1711, 1661, 1579; δH 
(CD3OD, 300 MHz) 7.60 (1H, s, H-3), 7.44 - 7.24 (8H, m,  ArH), 4.10 (2H, s, H-1), 3.67 
(2H, s, H-8), 3.67 (2H, s, H-10), 2.23 (3H, s, H-9); δC (CD3OD, 75.5 MHz) 139.6 (Arqu), 
138.3 (Arqu), 136.1 (Arqu), 131.0 (ArC-H), 131.0 (ArC-H), 130.7 (C-12 / 16), 130.1 (ArC-H), 
129.5 (C-13 / 15), 129.1 (ArC-H), 128.7 (ArC-H), 62.6 (C-8), 62.1 (C-10), 44.5 (C-1), 41.9 
(C-9); HRMS (ES): Found 239.13034 (M+). C16H17NO (M



























A stirred solution of 24 (0.15 g, 0.63 mmol) in excess ethyl formate (2.50 ml, 31.5 mmol) 
under N2 was refluxed overnight. The excess ethyl formate was removed under reduced 
pressure and the crude product purified by column chromatography using mixtures of 
ethyl acetate: hexane (50:50) to (95:5) as eluent to give 35 (0.16 g, 95%) as a thick-
yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 (DMSO) 3591 - 3275, 2587, 
2321, 2137, 2070, 1988, 1904, 1655 ; δH (CDCl3, 300 MHz) 8.25 (1H, s, H-1), 7.38 - 7.16 
(9H, m, ArH), 6.02 (1H, br s, NH), 4.48 (2H, d, J = 5.9 Hz, H-2), 3.57 (2H, s, H-9), 3.54 
(2H, s, H-11), 2.20 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 161.0 (C-1), 139.3 (Arqu), 138.3 
(Arqu), 137.7 (Arqu), 129.1 (C-13 / 17), 128.7 (ArC-H), 128.4 (ArC-H), 128.4 (ArC-H), 128.3 
(C-14 / 16), 127.2 (ArC-H), 126.6 (ArC-H), 61.8 (C-9), 61.5 (C-11), 42.1 (C-2), 42.0 (C-10); 
HRMS (ES): Found 268.15763 (M+). C17H20N2O (M









































To a stirred solution of 24 (0.50 g, 2.08 mmol) in anhydrous N-methyl-2-pyrrolidone (5 
ml) under N2, were added triethylamine (1.45 ml, 10.4 mmol), K2CO3 (0.57 g, 4.16 mmol) 
and 4,7-dichloroquinoline (2.06 g, 10.4 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 130 °C overnight. After the mixture was allowed to cool to 
room temperature, it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4) and concentrated in vacuo to afford a crude product, which was purified by 
column chromatography using mixtures of ethyl acetate: hexane (50:50) to (90:10) as 
eluent to give 46 (0.19 g, 23%) as a colourless solid, m.p. (EtOAc:Hex) 103-104 ºC; 
vmax/cm
-1 (DMSO) 3582, 3395 - 3279, 2596, 2143, 2060, 1972, 1660, 1579; δH (CDCl3, 
300 MHz) 8.51 (1H, d, J = 5.1 Hz, H-1), 7.98 (1H, d, J = 2.6 Hz, H-8), 7.69 (1H, d, J = 
9.0 Hz, H-5), 7.37 (1H, dd, J = 2.6, 9.0 Hz, H-6), 7.34 - 7.20 (9H, m, ArH), 6.45 (1H, d, J 
= 5.1 Hz, H-2), 5.43 (1H, br t, J = 5.1 Hz, NH), 4.51 (2H, d, J = 5.1 Hz, H-10), 3.53 (2H, 
s, H-17), 3.51 (2H, s, H-19), 2.19 (3H, s, N-CH3); δC (CDCl3, 75.5 MHz) 152.1 (C-1), 
149.5 (Arqu), 149.2 (Arqu), 140.4 (Arqu), 139.1 (Arqu), 137.2 (Arqu), 134.9 (Arqu), 128.9 (ArC-
H), 128.8 (ArC-H), 128.8 (C-21 / 25), 128.5 (ArC-H), 128.2 (C-22 / 24); 127.9 (C-8), 126.9 
(ArC-H), 126.1 (ArC-H), 125.4 (C-6), 120.9 (C-5), 117.2 (Arqu), 99.7 (C-2), 61.9 (C-17), 61.6 
(C-19), 47.6 (C-10), 42.3 (N-CH3). (Found: C, 74.53; H, 5.76; N, 9.87%. C25H24N3Cl 































To a stirred solution of crude para- α, α' -azidobromoxylene (0.50 g, 2.25 mmol), 
synthesized as outlined in GP1 and  K2CO3 (0.61, 4.50 mmol) in anhydrous acetonitrile 
(50 ml) at 0 °C, was added N-benzylmethylamine (0.43 ml, 3.40 mmol) and the reaction 
heated and allowed to progress under reflux overnight. Acetonitrile was then removed 
under reduced pressure, saturated aqueous Na2CO3 added and the organic product 
extracted into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and 
concentration in vacuo furnished  a residue, which was purified by column 
chromatography using mixtures of ethyl acetate: hexane (10:90) to (20:80) as eluent to 
give 17 (0.35 g, 59% over 2 steps.) as a yellow oil; δH  (CDCl3, 400 MHz) 7.43 - 7.26 (9H, 
m, ArH), 4.35 (1H, s, H-1), 3.56 (2H, s, H-8), 3.56 (2H, s, H-10), 2.22 (3H, s, H-9); δC 
(CDCl3, 100.6 MHz) 139.7 (Arqu), 139.2 (Arqu), 134.1 (Arqu), 129.4 (2 x ArC-H), 129.0 (2 x 
ArC-H), 128.3 (2 x ArC-H), 128.2 (2 x ArC-H), 127.0 (ArC-H), 61.9 (C-8), 61.5 (C-10), 54.7 (C-
1), 42.1 (C-9); HRMS (ESI): Found 267.1605(M+ +1). C16H18N4 (M

























To a stirred solution of 17 (0.70 g, 2.63 mmol) in THF (7.20 ml) under N2, was added 
PPh3 (0.84 g, 3.16 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.39 ml, 133 mmol) was added and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
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MeOH: NEt3 (90: 5: 5) as eluent to give 28 (0.56 g, 89%) as a dark-yellow oil; vmax/cm
-1 
(DMSO) 3531 - 3408, 3273, 2131, 2057, 1973, 1659, 1612, 1512; δH (CD3OD, 400 MHz) 
7.21 – 7.10 (9H, m, ArH), 3.73 (2H, s, H-1), 3.38 (2H, s, H-8), 3.37 (2H, s, H-10), 2.03 
(3H, s, H-9); δC (CD3OD, 100.6 MHz) 140.3 (Arqu), 139.8 (Arqu), 139.2 (Arqu), 130.7 (C-13 
/ 15), 130.3 (C-12 / 16); 129.3 (C-4 / 6), 128.8 (C-3 / 7), 128.3 (C-14), 62.7 (C-8), 62.4 





























A stirred solution of 28 (150 mg, 0.63 mmol) in excess ethyl formate (2.50 ml, 31.5 
mmol) under N2 was refluxed overnight. The excess ethyl formate was removed under 
reduced pressure and the crude product purified by column chromatography using 
mixtures of ethyl acetate: hexane (50:50) to (95:5) as eluent to give 39 (149 mg, 89%) as 
a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 (DMSO) 3532 - 
3413, 3300, 2582, 2363, 2325, 2262, 2215, 2101, 1994, 1903; δH (CDCl3, 400 MHz) 8.15 
(1H, s, H-1), 7.34 - 7.20 (9H, s, ArH), 6.36 (1H, br s, NH), 4.41 (2H, d, J = 5.9 Hz, H-2), 
3.50 (2H, s, H-9), 3.49 (2H, s, H-11), 2.17 (3H, s, H-10); δC (CDCl3, 100.6 MHz) 161.2 
(C-1), 139.2 (Arqu), 138.8 (Arqu), 136.4 (Arqu), 129.3 (C-14 / 16), 128.9 (C-13 / 17), 128.3 
(C-5 / 7), 127.7 (C-4 / 8), 127.0 (C-15), 61.8 (C-11), 61.5 (C-9), 42.2 (C-2), 41.9 (C-10); 
HRMS (ES). Found 268.15756 (M+). C17H20N2O (M













































To a stirred solution of 28 (0.35 g, 1.46 mmol) in anhydrous N-methyl-2-pyrrolidone (3.5 
ml) under N2, were added triethylamine (1.02 ml, 7.25 mmol), K2CO3 (0.57 g, 4.16 mmol) 
and 4,7-dichloroquinoline (2.06 g, 10.4 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 90 °C for 48 hours. After the mixture was allowed to cool to 
room temperature it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (90:10) as eluent to 
give 50 (0.19 g, 32%) as a colourless solid, m.p. (EtOAc:Hex) 120-122 ºC; vmax/cm
-1 
(DMSO) 3603, 3394 - 3225, 2598, 2349, 2140, 2056, 1969, 1903, 1657; δH (CDCl3, 300 
MHz) 8.53 (1H, d, J = 5.1 Hz, H-1), 7.98 (1H, d, J = 1.9 Hz, H-8), 7.68 (1H, d, J = 8.3 Hz, 
H-5), 7.41 - 7.22 (9H, m, ArH), 7.28 (1H, dd, J = 1.9, 8.3 Hz, H-6), 6.46 (1H, d, J = 5.1 
Hz, H-2), 5.29 (1H, br s, NH), 4.49 (2H, d, J = 5.1 Hz, H-10), 3.53 (2H, s, H-17), 3.51 
(2H, s, H-19), 2.19 (3H, s, H-18); δC (CDCl3, 75.5 MHz) 152.1 (C-1), 149.5 (Arqu), 149.2  
(Arqu), 139.5 (Arqu), 139.3 (Arqu), 135.8 (Arqu), 134.9 (Arqu), 129.5 (C-21 / 25), 129.0 (C-
23), 128.8 (C-22 / 24), 128.2 (C-13 / 15), 127.6 (C-12 / 16), 127.0 (C-8), 125.5 (C-6), 
120.9 (C-5), 117.1 (Arqu), 99.6 (C-2), 61.9 (C-17), 61.4 (C-19), 47.4 (C-10), 42.3 (C-18). 
























To a stirred solution of 4-chlorobenzyl chloride (3.00 g, 18.6 mmol) in THF (300 ml) 
under N2 at 0 °C, was added methylamine solution in water (40% v/v) (9.0 ml, 93.4 
mmol) and the reaction allowed to progress at room temperature overnight. The solvent 
was removed on the rotorevaporator with the water removed by azeotroping with 
toluene. The crude product was purified directly by column chromatography using EtOAc 
(100%) followed by EtOAc: MeOH: NEt3 (92: 5: 3) as eluent to give 7 (2.35 g, 81%) as a 
yellow oil; δH (CDCl3, 300 MHz) 7.25 - 7.18 (4H, m, ArH), 3.66 (2H, s, H-7), 2.38 (3H, s, 
H-8), 1.65  ( 1H, s, NH); δC (CDCl3, 100.6 MHz) 138.6 (Arqu), 132.6 (Arqu), 129.5 (C-2 / 
6), 128.4 (C-3 / 5), 55.2 (C-7), 35.8 (C-8); HRMS (ESI): Found 156.0580 (M+). C8H10NCl 
























To a stirred solution of 7 (0.60 g, 3.85 mmol) and K2CO3 (0.71 g, 5.14 mmol.) in 
anhydrous acetonitrile (150 ml) under N2 at 0 °C, was added crude ortho- α, α' -
azidobromoxylene (0.58 g, 2.57 mmol), synthesized as outlined in GP1 and the reaction 
heated and allowed to progress under reflux for 6 hours. Acetonitrile was then removed 
under reduced pressure, saturated aqueous Na2CO3 added and the organic product 
extracted into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and 
concentration in vacuo furnished  a residue, which was purified by column 
chromatography using mixtures of ethyl acetate: hexane (5:95) to (20:80) as eluent to 
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give 10 (0.45 g, 58% over 2 steps.) as a yellow oil; δH (CDCl3, 400 MHz) 7.39 - 7.26 (9H, 
m, ArH), 4.55 (2H, s, H-1), 3.58 (2H, s, H-8), 3.50 (2H, s, H-10), 2.13 (3H, s, H-9); δC 
(CDCl3, 75.5 MHz) 137.4 (Arqu), 137.1 (Arqu), 134.7 (Arqu), 132.7 (Arqu), 130.7 (ArC-H), 
130.2 (C-12 / 16), 129.6 (ArC-H), 128.3 (C-13 / 15), 128.1 (ArC-H), 127.7 (ArC-H), 61.5 (C-
10), 59.9 (C-8), 52.0 (C-1), 41.9 (C-9); HRMS (ESI):  Found 301.1220 (M+). C16H18N4 Cl 
























To a stirred solution of 10 (0.40 g, 1.33 mmol) in THF (3.60 ml) under N2, was added 
PPh3 (0.42 g, 1.60 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water was added (1.20 ml, 66.7 mmol) and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
MeOH: NEt3 (90: 5: 5) as eluent to give 21 (0.34 g, 93%) as a yellow oil; δH (CDCl3, 300 
MHz) 7.35 - 7.16 (9H, m, ArH), 3.87 (2H, s, H-1), 3.55 (2H, s, H-8), 3.52 (2H, s, H-10), 
2.07 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 141.3 (Arqu), 136.7 (Arqu), 136.4 (Arqu), 133.0 
(Arqu), 131.1 (ArC-H), 130.6 (C-12 / 16), 129.4 (ArC-H), 128.5 (C-13 / 15), 128.2 (ArC-H), 
127.1 (ArC-H), 61.7 (C-10), 60.7 (C-8), 44.1 (C-1), 41.4 (C-9); HRMS (ESI): Found 
275.1315 (M+). C16H20N2Cl (M






































A stirred solution of 21 (100 mg, 0.36 mmol) in excess ethyl formate (1.44 ml, 18.3 
mmol) under N2 was heated to reflux overnight. The excess ethyl formate was removed 
under reduced pressure and the crude product purified by column chromatography using 
mixtures of ethyl acetate: hexane (50:50) to (100%) as eluent to give 32 (98 mg, 89%) 
as a thick-cream paste and predominantly as a s-trans rotamer; vmax/cm
-1 (DMSO) 3627-
3228, 2597, 2146, 2060, 1976, 1903, 1661; δH (CDCl3, 300 MHz) 8.09 (1H, s, H-1), 8.05 
(1H, br s, NH), 7.39 - 7.14 (9H, m, ArH), 4.65 (2H, d, J = 5.4 Hz, H-2), 3.57 (2H, s, H-9), 
3.51 (2H, s, H-11), 2.10 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 160.3 (C-1), 137.7 (Arqu), 
136.5 (Arqu), 136.4 (Arqu), 133.3 (Arqu), 131.6 (ArC-H), 130.6 (C-13 / 17), 130.4 (ArC-H), 
128.6 (C-14 / 16), 128.6 (ArC-H), 128.5 (ArC-H), 127.7 (ArC-H), 61.4 (C-11), 61.1 (C-9), 41.2 









































To a stirred solution of 21 (0.20 g, 0.73 mmol) in anhydrous N-methyl-2-pyrrolidone (2 
ml) under N2, were added triethylamine (0.58 ml, 4.17 mmol), K2CO3 (0.23 g, 1.46 mmol) 
and 4,7-dichloroquinoline (0.82 g, 4.14 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature, it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4) and concentrated in vacuo to afford a crude product, which was purified by 
column chromatography using mixtures of ethyl acetate: hexane (50:50) to (80:10) as 
eluent to give 43 (98 mg, 31%) as a yellow oil; vmax/cm
-1 (DMSO) 3595, 3378-3231, 
2142, 2067, 1975, 1657; δH (CDCl3, 300 MHz) 8.53 (1H, d, J = 5.4 Hz, H-1), 7.91 (1H, d, 
J = 2.4 Hz, H-8), 7.41 - 7.12 (8H, m, ArH), 7.26 (1H, d, J = 9.0 Hz, H-5), 6.98 (1H, dd, J 
= 2.4, 9.0 Hz, H-6), 6.52 (1H, d, J = 5.4 Hz, H-2), 5.29 (1H, s, NH), 4.44 (2H, d, J = 3.0 
Hz, H-10), 3.60 (2H, s, H-17), 3.54 (2H, s, H-19), 2.16 (3H, s, H-18); δC (CDCl3, 75.5 
MHz) 151.9 (C-1), 150.1 (Arqu), 149.1 (Arqu), 137.1 (Arqu), 136.9 (Arqu), 135.9 (Arqu), 
134.8 (Arqu), 133.5 (Arqu), 132.0 ((ArC-H), 131.1 (C-21 / 25), 130.5 (ArC-H), 128.6 (C-22 / 
24), 128.5 (ArC-H), 128.4 (ArC-H), 128.0 (C-8), 124.9 (C-6), 121.8 (C-5), 118.0 (Arqu), 99.1 
(C-2), 61.4 (C-19), 60.8 (C-17), 46.5 (C-10), 42.0 (C-18); HRMS (ESI): Found 436.1347 
(M+). C16H20N2Cl (M
























To a stirred solution of 7 (0.80 g, 5.13 mmol) and K2CO3 (0.95 g, 6.85 mmol) in 
anhydrous acetonitrile (200 ml) at 0 °C, was added crude meta-α, α' -azidobromoxylene 
(0.77 g, 3.43 mmol), synthesized as outlined in GP1, and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
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mixtures of ethyl acetate: hexane (5:95) to (20:80) as eluent to give 14 (0.63 g, 61% over 
2 steps.) as a yellow oil; δH (CDCl3, 300 MHz) 7.36 - 7.31 (7H, m, ArH), 7.22 (1H, m, H-
3), 4.35 (1H, s, H-1), 3.54 (2H, s, H-8), 3.50 (2H, s, H-10), 2.19 (3H, s, H-9); δC (CDCl3, 
75.5 MHz) 139.4 (Arqu), 137.7 (Arqu), 135.3 (Arqu), 132.6 (Arqu), 130.1 (C-12 / 16), 128.8  
(C-13 / 15), 128.7 (ArC-H), 128.6 (ArC-H), 128.3 (ArC-H), 126.9 (ArC-H), 61.5 (C-8), 61.0 (C-


























To a stirred solution of 20 (0.60 g, 2.00 mmol) in THF (5.40 ml) under N2, was added 
PPh3 (0.63 g, 2.40 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water was added (1.80 ml, 100 mmol) and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
MeOH: NEt3 (90: 5: 5) as eluent to give 25 (0.51 g, 93%) as a light-orange oil; vmax/cm
-1 
(DMSO) 3547-3399, 3271, 2835, 2783, 2144, 2048, 1707, 1663, 1605, 1491; δH (CDCl3, 
300 MHz) 7.31 - 7.18 (8H, m, ArH), 3.85 (2H, s, H-1), 3.49 (2H, s, H-8), 3.46 (2H, s, H-
10), 3.02 (2H, br s, NH2), 2.15 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 142.0 (Arqu), 139.3 
(Arqu), 137.7 (Arqu), 132.4 (Arqu), 130.0 (C-12 / 16), 128.3 (ArC-H), 125.8  (ArC-H), 128.2 (C-
13 / 15), 127.6 (ArC-H), 127.4  (ArC-H), 61.6 (C-8), 61.0 (C-10), 45.8 (C-1), 42.0 (C-9); 
HRMS (ESI): Found 275.1315    (M+). C16H20N2Cl (M



































A stirred solution of 25 (100 g, 0.36 mmol) in excess ethyl formate (2.88 ml, 36.5 mmol) 
under N2 was heated and allowed to reflux overnight. The excess ethyl formate was 
removed under reduced pressure and the crude product purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (100%) as eluent to 
give 36 (93 mg, 84%) as a thick-yellow oil and predominantly as a s-trans rotamer; 
vmax/cm
-1 (DMSO) 3628-3257, 2592, 2147, 2065, 1982, 1906, 1658; δH (CDCl3, 400 
MHz) 8.25 (1H, s, H-1), 7.26 - 7.23 (7H, m, ArH), 7.15 (1H, m, H-4), 6.05 (1H, br s, NH), 
4.42 (2H, d, J = 6.0 Hz, H-2), 3.48 (2H, s, H-9), 3.43 (2H, s, H-11), 2.13 (3H, s, H-10); δC 
(CDCl3, 75.5 MHz) 161.0 (C-1), 140.0 (Arqu), 137.7 (Arqu), 137.6 (Arqu), 132.6 (Arqu), 
130.1 (C-13 / 17), 128.7 (ArC-H), 128.3 (C-14 / 16), 128.1 (ArC-H), 128.1 (ArC-H), 126.4 
(ArC-H), 61.6 (C-9), 61.1 (C-11), 42.2 (C-2), 42.1 (C-10); HRMS (ESI): Found 303.1264 
(M+). C17H20N2 OCl (M


































To a stirred solution of 25 (0.45 g, 1.64 mmol) in anhydrous N-methyl-2-pyrrolidone (4 
ml) under N2, were added triethylamine (1.16 ml, 8.32 mmol), K2CO3 (0.46 g, 3.33 mmol) 
and 4,7-dichloroquinoline (1.65 g, 8.32 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature, it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
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ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4) and concentrated in vacuo to afford a crude product, which was purified by 
column chromatography using mixtures of ethyl acetate: hexane (50:50) to (90:10) as 
eluent to give 47 (0.19 g, 27%) as a colourless solid, m.p. (DCM:Hex) 103-104 ºC; 
vmax/cm
-1 (DMSO) 3620, 3372-3193, 2594, 2345, 2150, 2054, 1971, 1911, 1676, 1626; 
δH (CDCl3, 300 MHz) 8.48 (1H, d, J = 5.3 Hz, H-1), 7.97 (1H, d, J = 2.4 Hz, H-8), 7.16 
(1H, d, J = 8.7 Hz, H-5), 7.37 - 7.23 (9H, m, H-6 and ArH), 6.42 (1H, d, J = 5.3 Hz, H-2), 
5.62 (1H, br s, NH), 4.51 (2H, d, J = 4.8 Hz, H-10), 3.50 (2H, s, H-17), 3.45 (2H, s, H-
19), 2.15 (3H, s, H-18); δC (CDCl3, 75.5 MHz) 151.5 (C-1), 149.8  (Arqu), 149.8 (Arqu), 
140.1 (Arqu), 137.6 (Arqu), 137.2 (Arqu), 135.1 (Arqu), 132.6 (Arqu), 130.0 (C-21 / 25), 128.9 
(C-8), 128.4 (ArC-H), 128.4 (ArC-H), 128.3 (C-22 / 24), 127.8 (ArC-H), 126.2 (ArC-H), 125.5 
(C-6), 121.2 (C-5), 117.1 (Arqu), 99.6 (C-2), 61.6 (C-17), 61.0 (C-19), 47.5 (C-10), 42.2 
(C-18); HRMS (ESI): Found 436.1335 (M+). C16H20N2Cl (M


























To a stirred solution of 7 (1.00 g, 6.41 mmol) and K2CO3 (1.19 g, 8.60 mmol.) in 
anhydrous acetonitrile (300 ml) at 0 °C, was added crude para- α, α' -azidobromoxylene 
(0.96 g, 4.25 mmol) synthesized as outlined in GP1, and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (5:95) to (20:80) as eluent to afford 18 (0.83 g, 63% 
over 2 steps.) as a light-yellow oil; δH (CDCl3, 400 MHz) 7.44 - 7.31 (8H, m, ArH), 4.35 
(2H, s, H-1), 3.56 (2H, s, H-8), 3.52 (2H, s, H-10), 2.22 (3H, s, H-9); δC (CDCl3, 75.5 
MHz) 139.3 (Arqu), 137.7 (Arqu), 134.0 (Arqu), 132.4 (Arqu), 130.0 (C-13 / 15); 129.1 (C-12 
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/ 16), 128.2 (C-4 / 6), 128.0 (C-3 / 7); 61.3 (C-8), 61.0 (C-10), 54.4 (C-1), 42.0 (C-9); 
HRMS (ESI): Found 301.1220 (M+). C16H18N4 Cl (M

























To a stirred solution of 18 (0.80g, 2.67 mmol) in THF (7.20 ml) under N2, was added 
PPh3 (0.92 g, 3.20 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.40 ml, 133 mmol) was added and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
MeOH: NEt3 (90: 5: 5) as eluent to give 29 (0.68 g, 93%) as a dark-orange oil; vmax/cm
-1 
(DMSO) 3551-3388, 3287, 2790, 2138, 2063, 1957, 1708, 1662, 1513, 1490; δH (CDCl3, 
300 MHz) 7.32 - 7.24 (8H, m, ArH), 3.83 (2H, s, H-1), 3.48 (2H, s, H-8), 3.44 (2H, s, H-
10), 3.05 (2H, br s, NH2), 2.14 (2H, s, H-9); δC (CDCl3, 75.5 MHz) 137.7 (Arqu), 132.3 
(Arqu), 131.7 (Arqu), 129.9 (C-13 / 15), 128.9 (C-12 / 16), 128.1 (C-4 / 6); 127.7 (Arqu), 
127.0 (C-3 / 7), 61.3 (C-8), 60.7 (C-10), 45.5 (C-1), 41.9 (C-9); HRMS (ESI): Found 
275.1315 (M+). C16H20N2Cl (M




























A stirred solution of 29 (100 mg, 0.36 mmol) in excess ethyl formate (2.88 ml, 36.5 
mmol) under N2 was refluxed overnight. The excess ethyl formate was removed under 
reduced pressure and the crude product purified by column chromatography using 
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mixtures of ethyl acetate: hexane (50:50) to (100%) as eluent to give 40 (94 mg, 86%) 
as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 (DMSO) 3630 - 
3180, 2592, 2143, 2053, 1972, 1909, 1659; δH (CDCl3, 400 MHz) 8.21 (1H, s, H-1), 7.31 
- 7.14 (8H, m, ArH), 6.15 (1H, br s, NH), 4.40 (2H, d, J = 4.5 Hz, H-2), 3.45 (2H, s, H-9), 
3.42 (2H, s, H-11), 2.11 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 161.0 (C-1), 138.6 (Arqu), 
137.7 (Arqu), 136.3 (Arqu), 132.5 (Arqu), 130.0 (C-14 / 16), 129.3 (C-13 / 17), 128.3 (C-5 / 
7), 127.6 (C-4 / 8), 61.3 (C-9), 61.0 (C-11), 42.1 (C-10), 41.8 (C-2); HRMS (ESI): Found 
303.1264 (M+). C17H20N2OCl (M






































To a stirred solution of 29 (0.57 g, 2.08 mmol) in anhydrous N-methyl-2-pyrrolidone (6 
ml)) under N2, were added triethylamine (1.45 ml, 10.4 mmol), K2CO3 (0.57 g, 4.16 
mmol) and 4,7-dichloroquinoline (2.06 g, 10.40 mmol). The mixture was heated under 
pressure in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to 
cool to room temperature it was poured into saturated brine (20 ml) and extracted with 
ethyl acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 
50 ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (90:10) as eluent to 
give 51 (0.19 g, 21%) as a colourless crystalline solid, m.p. (DCM:Hex) 101-104 ºC; 
vmax/cm
-1 (DMSO) 3607, 3362-3195, 2344, 2146, 2059, 1947, 1905, 1677, 1627; δH 
(CDCl3, 300 MHz) 8.47 (1H, d, J = 5.4 Hz, H-1), 7.95 (1H, d, J = 1.8 Hz, H-8), 7.37 - 7.25 
(1H, d, J = 9.0 Hz, H-5), 7.32 (9H, m, H-6 and ArH), 6.40 (1H, d, J = 5.4 Hz, H-2), 5.73 
(1H, br s, NH), 4.48 (2H, d, J = 3.9 Hz, H-10), 3.50 (2H, s, H-17), 3.47 (2H, s, H-19), 
2.17 (3H, s, H-18); δC (CDCl3, 75.5 MHz) 151.6 (C-1), 149.8  (Arqu), 149.8  (Arqu), 139.0 
(Arqu), 137.8 (Arqu), 135.8 (Arqu), 135.0 (Arqu), 130.1 (C-21 / 25), 129.4 (C-22 / 24), 128.4 
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(Arqu), 128.3 (C-13 / 15), 127.5 (C-8), 127.5 (C-12 / 16), 125.4 (C-6), 121.2 (C-5), 117.1 
(Arqu), 99.5 (C-2), 61.4 (C-17), 61.0 (C-19), 47.3 (C-10), 42.2 (C-18); HRMS (ESI): 
Found 436.1335 (M+). C16H20N2Cl (M

















To a stirred solution of 4-methoxybenzyl chloride (3.00 g, 19.7 mmol) in THF (350 ml) 
under N2 at 0 °C, was added methylamine solution in water (40% v/v) (9.30 ml, 95.9 
mmol) and the reaction allowed to progress at room temperature overnight. The solvent 
was removed on the rotorevaporator with the water removed by azeotroping with 
toluene. The crude product was purified directly by column chromatography using EtOAc 
(100%) followed by EtOAc: MeOH: NEt3 (92: 5: 3) as eluent to give 8 (2.61 g, 87%) as a 
yellow oil; δH (CDCl3, 300 MHz) 7.27 (2H, d, J = 6.6 Hz, H-3 / 5), 6.87 (2H, d, J = 6.6 Hz, 
H-2 / 6), 3.75 (3H, s, H-9), 3.64 (2H, s, H-7), 2.33  ( 3H, s, H-8); δC (CDCl3, 75.5 MHz) 
159.0 (Arqu), 132.5 (Arqu), 129.6 (C-3 / 5), 113.8 (C-2 / 6), 54.9 (C-9 / C-7), 35.1 (C-8); 
HRMS (ESI): Found 152.1070 (M+). C9H14NO (M

























To a stirred solution of 8 (1.00 g, 6.61 mmol) and K2CO3 (1.22 g, 8.87 mmol.) in 
anhydrous acetonitrile (300 ml) at 0 °C, was added crude ortho- α, α' -azidobromoxylene 
(0.99 g, 4.38 mmol) synthesized as outlined in GP1, and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
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into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (10:90) to (25:75) as eluent to give 11 (0.83 g, 64% 
over 2 steps.) as a yellow oil; δH (CDCl3, 300 MHz) 7.42 - 7.31 (4H, m, ArH), 7.29 (2H, d, 
J = 8.9 Hz, H-12 / 16), 6.91 (2H, d, J = 8.9 Hz, H-13 / 15), 4.56 (2H, s, H-1), 3.83 (3H, s, 
H-17), 3.57 (2H, s, H-8), 3.51 (2H, s, H-10), 2.15 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 
159.1 (Arqu), 137.8 (Arqu), 135.1 (Arqu), 131.3 (Arqu), 131.1 (ArC-H), 130.5 (C-12 / 16), 
129.7 (ArC-H), 128.3 (ArC-H), 128.3 (ArC-H), 114.0 (C-13 / 15), 62.1 (C-8), 60.0 (C-10), 55.5 



























To a stirred solution of 11 (0.80 g, 2.70 mmol) in THF (7.29 ml) under N2, was added 
PPh3 (0.85 g, 3.24 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.45 ml, 135 mmol) was added and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and the solvent removed on 
the rotorevaporator with the water removed by azeotroping with toluene. The crude 
product was purified directly by column chromatography using EtOAc (100%) followed 
by EtOAc: MeOH: NEt3 (93: 5: 2) as eluent to give 22 (0.61 g, 83%) as a light-brown oil; 
vmax/cm
-1 (DMSO) 3592-3324, 2593, 2142, 2061, 1981, 1664, 1510; δH (CDCl3, 300 
MHz) 7.32 - 7.15 (6H, m, ArH), 6.83 (2H, d, J = 8.4 Hz, H-13 /15), 3.85 (2H, br s, H-1), 
3.77 (3H, s, H-17), 3.53 (2H, s, H-8), 3.49 (2H, s, H-10), 3.40 (2H, br s, NH2), 2.09 (3H, 
s, H-9); δC (CDCl3, 75.5 MHz) 158.7 (Arqu), 142.1 (Arqu), 136.7  (Arqu), 131.0 (ArC-H), 
130.5 (Arqu), 130.4 (C-12 / 16), 129.1 (ArC-H), 128.0 (ArC-H), 127.0 (ArC-H), 113.6 (C-13 / 



































A stirred solution of 22 (100 mg, 0.37 mmol) in excess ethyl formate (2.92 ml, 37.0 
mmol) under N2 was heated to reflux overnight. The excess ethyl formate was removed 
under reduced pressure and the crude product purified by column chromatography using 
mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0: 97:3) as eluent to give 33 
(87 mg, 79%) as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 
(DMSO) 3593-3257, 2593, 2146, 2063, 1978, 1905, 1658; δH (CDCl3, 400 MHz) 8.50 
(1H, br s, NH), 8.15 (1H, s, H-1), 7.39 - 7.12 (6H, m, ArH), 7.14 (2H, d, J = 8.8 Hz, H-13 / 
17), 6.85 (2H, d, J = 8.8 Hz, H-14 / 16), 4.43 (2H, d, J = 6.0 Hz, H-2), 3.80 (3H, s, H-18), 
3.55 (2H, s, H-9), 3.49 (2H, s, H-11), 2.09 (3H, s, H-10); δC (CDCl3, 100.6 MHz) 160.6 
(C-1), 159.3 (Arqu), 138.1 (Arqu), 137.1 (Arqu), 131.9 (ArC-H), 131.0 (Arqu), 130.8 (C-13 / 
17), 130.0 (ArC-H), 128.8 (ArC-H), 127.9 (ArC-H), 114.1 (C-14 / 16), 61.4 (C-9), 61.8 (C-11), 
55.5 (C-18), 41.3 (C-2), 41.0 (C-10); HRMS (ESI): Found 299.1760 (M+). C18H23N2O2 

















































To a stirred solution of 22 (0.35 g, 1.30 mmol) in anhydrous N-methyl-2-pyrrolidone (3.50 
ml) under N2, were added triethylamine (0.91 ml, 6.50 mmol), K2CO3 (0.54 g, 3.90 mmol) 
and 4, 7-dichloroquinoline (2.06 g, 10.4 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature, it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (100:0) as eluent to 
give 44 (0.12 g, 21%) as a dark-yellow oil; vmax/cm
-1 (DMSO) 3618, 3376-3177, 2633, 
2595, 2548, 2149, 2059, 1972, 1903, 1681; δH (CDCl3, 400 MHz) 8.53 (1H, d, J = 5.4 Hz, 
H-1), 7.91 (1H, d, J = 2.3 Hz, H-8), 7.62 (1H, s, NH), 7.34 – 7.31 (4H, m, ArH), 7.27 (1H, 
d, J = 9.0 Hz, H-5), 7.09 (2H, d, J = 8.9 Hz, H-21 / 25), 6.92 (1H, dd, J = 2.3, 9.0 Hz, H-
6), 6.75 (2H, d, J = 8.9 Hz, H-22 / 24), 6.53 (1H, d, J = 5.4 Hz, H-2), 4.42 (2H, s, H-10), 
3.77 (3H, s, H-26), 3.61 (2H, s, H-17), 3.53 (2H, s, H-19), 2.16 (3H, s, H-18); δC (CDCl3, 
75.5 MHz) 159.1 (Arqu), 151.7 (C-1), 150.3 (Arqu), 149.0  (Arqu), 137.2 (Arqu), 137.1 (ArC-
H), 134.6 (Arqu), 132.0 (ArC-H), 131.0 (C-21 / 25), 130.5 (Arqu), 129.3 (Arqu), 128.3 (ArC-H), 
128.1 (ArC-H), 127.9 (C-8), 124.7 (C-6), 122.3 (C-5), 117.8 (Arqu), 113.8 (C-22 / 24), 99.0 
(C-2), 61.5 (C-17), 60.9 (C-19), 55.2 (C-26), 46.5 (C-10), 41.7 (C-18); HRMS (ESI): 
Found 432.1860 (M+). C26H27N3OCl (M





























To a stirred solution of 8 (1.00 g, 6.61 mmol) and K2CO3 (1.22 g, 8.87 mmol.) in 
anhydrous acetonitrile (300 ml) at 0 °C, was added crude meta- α, α' -azidobromoxylene 
(0.99 g, 4.38 mmol) synthesized as outlined in GP1, and the reaction heated and 
allowed to progress under reflux for 5 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (10:90) to (25:75) as eluent to give 15 (0.79 g, 61% 
over 2 steps.) as a yellow oil; δH (CDCl3, 300 MHz) 7.35 - 7.18 (4H, m, ArH), 7.28 (2H, d, 
J = 8.4 Hz, H-12 / 16), 6.87 (2H, d, J = 8.4 Hz, H-13 / 15), 4.34 (2H, s, H-1), 3.81 (3H, s, 
H-17), 3.53 (2H, s, H-8), 3.49 (2H, s, H-10), 2.18 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 
158.7 (Arqu), 140.1 (Arqu), 135.3 (Arqu), 131.0 (Arqu), 130.1 (C-12 / 16), 128.9 (ArC-H), 
128.7 (ArC-H), 128.7 (ArC-H), 126.8 (ArC-H), 113.6 (C-13 / 15), 61.3 (C-8), 61.2 (C-10), 55.2 



























To a stirred solution of 15 (0.75 g, 2.53 mmol) in THF (7.0 ml) under N2, was added 
PPh3 (0.80 g, 3.04 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water was added (2.30 ml, 127.0 mmol) and the reaction heated at reflux 
for 6 hours. The reaction was then cooled to room temperature and solvent removed on 
the rotorevaporator with the water removed by azeotroping with toluene. The crude 
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product was purified directly by column chromatography using EtOAc (100%) followed 
by EtOAc: MeOH: NEt3 (93: 5: 2) as eluent to give 26 (0.60 g, 88%) as a dark-yellow oil; 
vmax/cm
-1 (DMSO) 3531- 3410, 3286, 2137, 2060, 1986, 1661, 1611, 1511; δH (CDCl3, 
400 MHz) 7.29 - 6.80 (8H, m, ArH), 4.53 (2H, br s, NH2), 3.73 (2H, s, H-1), 3.77 (3H, s, 
H-18), 3.46 (2H, s, H-8), 3.43 (2H, s, H-10), 2.13 (3H, s, H-9); HRMS (ESI): Found 
271.1810 (M+). C17H23N2 O (M






























A stirred solution of 26 (100 mg, 0.37 mmol) in excess ethyl formate (2.92 ml, 37.03 
mmol) under N2 was heated and allowed to reflux overnight. The excess ethyl formate 
was removed under reduced pressure and the crude product purified by column 
chromatography using mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0:97:3) 
as eluent to give 37 (84 mg, 76%) as a thick-yellow oil and predominantly as a s-trans 
rotamer; vmax/cm
-1 (DMSO) 3599-3278, 2592, 2140, 2066, 1982, 1904, 1660; δH (CDCl3, 
400 MHz) 8.28 (1H, s, H-1), 7.33 - 7.17 (6H, m, ArH), 6.87 (2H, d, J = 8.8 Hz, H-14 / 16), 
5.85 (1H, br s, NH), 4.50 (2H, d, J = 6.4 Hz, H-2), 3.81 (3H, s, H-18), 2.19 (2H, s, H-9), 
2.18 (2H, s, H-11), 2.18 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 160.9 (C-1), 158.7 (Arqu), 
140.1 (Arqu), 137.5 (Arqu), 131.1 (Arqu), 130.1 (C-13 / 17), 128.7 (ArC-H), 128.3  (ArC-H), 
128.3  (ArC-H), 126.4 (ArC-H), 113.6 (C-14 / 16), 61.4 (C-11), 61.3 (C-9), 55.2 (C-18), 42.1 












































To a stirred solution of 26 (0.40 g, 1.48 mmol) in anhydrous N-methyl-2-pyrrolidone (4.0 
ml) under N2, were added triethylamine (1.04 ml, 7.40 mmol), K2CO3 (0.61 g, 4.44 mmol) 
and 4, 7-dichloroquinoline (1.47 g, 7.40 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature, it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (90:10) as eluent to 
give 48 (0.13 g, 20%) as a light-brown oil; vmax/cm
-1 (DMSO) 3600, 3363 - 3169, 2599, 
2350, 2148, 2059, 1973, 1907, 1679, 1618; δH (CDCl3, 300 MHz) 8.51 (1H, d, J = 5.4 Hz, 
H-1), 7.98 (1H, d, J = 2.0 Hz, H-8), 7.70 (1H, d, J = 9.0 Hz, H-5), 7.40 - 7.24 (4H, m, 
ArH), 7.36 (1H, dd, J = 2.0, 9.0 Hz, H-6), 7.21 (2H, d, J = 8.7 Hz, H-21 / 25), 6.80 (2H, d, 
J = 8.7 Hz, H-22 / 24), 6.45 (1H, d, J = 5.4 Hz, H-2), 5.44 (1H, br s, NH), 4.51 (2H, d, J = 
5.4 Hz, H-10), 3.78 (3H, s, H-26), 3.50 (2H, s, H-17), 3.45 (2H, s, H-19), 2.17 (3H, s, H-
18); δC (CDCl3, 75.5 MHz) 158.6 (Arqu), 152.0 (C-1), 149.6 (Arqu), 149.1  (Arqu), 140.4 
(Arqu), 137.2 (Arqu), 134.9 (Arqu), 131.0 (Arqu), 130.0 (C-21 / 25), 128.8 (C-8), 128.7 (ArC-
H), 128.5 (ArC-H), 128.0 (ArC-H), 126.1 (ArC-H), 125.4 (C-6), 121.1 (C-5), 117.2 (Arqu), 113.6 
(C-22 / 24), 99.6 (C-2), 61.4 (C-17), 61.2 (C-19), 55.2 (C-26), 47.5 (C-10), 42.1 (C-18); 
HRMS (ESI): Found 432.1843 (M+). C26H27N3OCl (M
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To a stirred solution of 8 (1.00 g, 6.61 mmol) and K2CO3 (1.22 g, 8.87 mmol.) in 
anhydrous acetonitrile (300 ml) at 0 °C, was added crude para- α, α' -azidobromoxylene 
(0.99 g, 4.38 mmol), synthesized as outlined in GP1 and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (10:90) to (25:75) as eluent to afford 19 ( 0.74 g, 57% 
over 2 steps.) as a yellow oil; δH (CDCl3, 400 MHz) 7.43 (2H, d, J = 8.4 Hz, H-12 / 16), 
7.35 - 7.32 (4H, m, ArH),  6.92 (2H, d, J = 8.4 Hz, H-13 / 15), 4.37 (2H, s, H-1), 3.77 (3H, 
s, H-17), 3.52 (2H, s, H-8), 3.48 (2H, s, H-10), 2.15 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 
159.2 (Arqu), 140.2 (Arqu), 134.6 (Arqu), 131.6 (Arqu),  130.2 (C-4 / 6),  128.5 (C-3 / 7), 
129.4 (C-12 / 16), 113.9 (C-13 / 15), 61.4 (C-8), 61.4 (C-10), 54.9 (C-17), 54.4 (C-1), 
41.8 (C-9); HRMS (ESI): Found 297.1715 (M+). C17H21N4 O (M


























To a stirred solution of 19 (0.70 g, 2.36 mmol) in THF (6.40 ml) under N2, was added 
PPh3 (0.74 g, 2.84 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.1 ml, 118 mmol) was added and the reaction heated at reflux for 6 
hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
Experimental 
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MeOH: NEt3 (92: 5: 3) as eluent to give 30 (0.57 g, 89%) as a light-brown oil; vmax/cm
-1 
(DMSO) 3374-3272, 2833, 2785, 2145, 2056, 1978, 1903, 1662, 1610, 1583; δH (CDCl3, 
300 MHz) 7.32 - 7.27 (4H, m, ArH), 7.23 (2H, d, J = 8.8 Hz, H-12 / 16), 6.85 (2H, d, J = 
8.8 Hz, H-13 / 15), 4.53 (2H, br s, NH2), 3.83 (2H, s, H-1), 3.77 (3H, s, H-17), 3.46 (2H, 
s, H-8), 3.43 (2H, s, H-10), 2.13 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 158.5 (Arqu), 138.6 
(Arqu), 138.4  (Arqu), 131.0 (Arqu), 129.9 (C-12 / 16), 129.1 (C-4 / 6), 127.4 (C-3 / 7), 113.5 






























A stirred solution of 30 (100 mg, 0.37 mmol) in excess ethyl formate (2.90 ml, 37.0 
mmol) under N2 was refluxed overnight. The excess ethyl formate was removed under 
reduced pressure and the crude product purified by column chromatography using 
mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0:97:3) as eluent to give 41 (87 
mg, 79%) as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 
(DMSO) 3582- 3295, 2595, 2137, 2067, 1983, 1906, 1660; δH (CDCl3, 400 MHz) 8.21 
(1H, br s, H-1), 7.35 - 7.17 (6H, m, ArH), 6.85 (2H, d, J = 8.7 Hz, H-14 / 16), 6.06 (1H, br 
s, NH), 4.44 (2H, d, J = 5.7 Hz, H-2), 3.77 (3H, s, H-17), 3.48 (2H, s, H-9), 3.45 (2H, s, 
H-11), 2.15 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 161.0 (C-1), 158.6 (Arqu), 138.8 (Arqu), 
136.2 (Arqu), 131.0 (Arqu), 130.0 (C-13 / 15), 129.3 (C-5 / 7), 127.7 (C-4 / 8), 113.6 (C-14 
/ 16), 61.1 (C-9), 61.1 (C-11), 55.2 (C-18), 42.0  (C-2 / 10), 41.9 (C-10 / 2); HRMS (ESI): 
Found 299.1760 (M+). C18H23N2O2 (M













































To a stirred solution of 30 (0.50 g, 1.85 mmol) in anhydrous N-methyl-2-pyrrolidone (5.00 
ml) under N2, were added triethylamine (1.30 ml, 9.25 mmol), K2CO3 (0.77 g, 5.55 mmol) 
and 4,7-dichloroquinoline (1.84 g, 9.25 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of ethyl acetate: hexane (50:50) to (100:0) as eluent to 
give 52 (0.19 g, 24%) as a dark-yellow oil; vmax/cm
-1 (DMSO) 3589, 3365 - 3255, 2148, 
2059, 1977, 1910, 1661; δH (CDCl3, 400 MHz) 8.46 (1H, d, J = 5.7 Hz, H-1), 7.94 (1H, d, 
J = 2.1 Hz, H-8), 7.69 (1H, d, J = 9.0 Hz, H-5), 7.38 - 7.25 (7H, m, H-6 and ArH), 6.86 
(2H, d, J = 8.7 Hz, H-22 / 24), 6.40 (1H, d, J = 5.7 Hz, H-2), 5.57 (1H, br s, NH), 4.49 
(2H, d, J = 4.8 Hz, H-10), 3.76 (3H, s, H-26), 3.47 (2H, s, H-17), 3.44 (2H, s, H-19), 2.15 
(3H, s, H-18); δC (CDCl3, 100.6 MHz) 158.7 (Arqu), 151.5 (C-1), 149.9 (Arqu), 148.4  
(Arqu), 139.4 (Arqu), 135.7 (Arqu), 135.2 (Arqu), 131.1 (Arqu), 130.1 (C-22 / 24), 129.6 (C-13 
/ 15), 128.3 (C-8), 127.6 (C-12 / 16), 125.6 (C-6), 121.2 (C-5), 117.1 (Arqu), 113.7 (C-21 / 
25), 99.5 (C-2), 61.2 (C-17), 61.2 (C-19), 55.3 (C-26), 47.4 (C-10), 42.1 (C-18); HRMS 
(ESI): Found 432.1843 (M+). C26H27N3OCl (M
























To a stirred solution of 4-N, N-dimethylaminobenzaldehyde (3.00 g, 18.3 mmol) in 
acetonitrile (400 ml) under N2 at 0 °C was added methylamine solution in water (40% 
v/v) (10.0 ml, 103 mmol) and the reaction allowed to progress for 2 hours. NaCNBH3 
(3.46 g, 64.1 mmol) was then added and the reaction allowed to progress at room 
temperature for 4 hours. The solvent was removed on the rotorevaporator with the water 
removed by azeotroping with toluene. The crude product was purified directly by column 
chromatography using EtOAc (100%) followed by EtOAc: MeOH: NEt3 (92: 5: 3) as 
eluent to give 9 (2.20 g, 73%) as a yellow oil; δH (CDCl3, 300 MHz) 7.17 (2H, d, J = 8.7 
Hz, H-3 / 5), 6.70 (2H, d, J = 8.7 Hz, H-2 / 6), 3.59 (2H, s, H-7), 2.88 (6H, s, H-9 / 10), 
2.34  ( 3H, s, H-8); δC (CDCl3, 100.6 MHz) 150.0 (Arqu), 129.1 (Arqu), 129.1 (C-3 / 5), 
112.7 (C-2 / 6), 55.6 (C-7), 40.3 (C-8), 35.6 (C-9 / 10); HRMS (ESI): Found 165.1392 
(M+ +1). C10H17N2 (M

























To a stirred solution of 9 (1.00 g, 6.06 mmol) and K2CO3 (1.25 g, 9.09 mmol) in 
anhydrous acetonitrile (150 ml) at 0 °C, was added crude ortho- α, α' -azidobromoxylene 
(1.14 g, 5.05 mmol), synthesized as outlined in GP1 and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
Experimental 
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into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (05:95) to (30:70) as eluent to give 12 (0.89 g, 57% 
over 2 steps.) as a yellow oil; δH (CDCl3, 400 MHz) 7.48 - 7.42 (4H, m, ArH), 7.40 (2H, d, 
J = 8.7 Hz , H-12 / 16), 6.90 (2H, d, J = 8.7 Hz, H-13 / 15), 4.69 (2H, s, H-1), 3.69 (2H, s, 
H-8), 3.64 (2H, s, H-10), 3.09 (6H, s, C-17 / 18), 2.31 (3H, s, H-9); δC (CDCl3, 75 MHz) 
149.7 (Arqu), 137.4 (Arqu), 134.7 (Arqu),130.5 (ArC-H), 129.8 (C-12  / 16), 129.7 (ArC-H),  
127.6 (ArC-H), 127.2 (ArC-H), 126.4 (Arqu), 112.2 (C-13  / 15), 61.8 (C-10), 59.4 (C-8), 51.6 



























To a stirred solution of 12 (0.80 g, 2.58 mmol) in THF (7.20 ml) under N2, was added 
PPh3 (0.81 g, 3.10 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.40 ml, 133 mmol) was added and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and the solvent removed on 
the rotorevaporator with the water removed by azeotroping with toluene. The crude 
product was purified directly by column chromatography using EtOAc (100%) followed 
by EtOAc: MeOH: NEt3 (93: 5: 2) as eluent to give 23 (0.61 g, 83%) as a light-brown oil; 
vmax/cm
-1 (DMSO) 3550 - 3401, 3293, 2132, 2068, 1980, 1663, 1613, 1522; δH (CDCl3, 
300 MHz) 7.31 - 7.17 (6H, m, ArH), 6.71 (2H, d, J = 9.0 Hz, H-13 / 15), 4.05 (2H, br s, 
NH2), 3.85 (2H, s, H-1), 3.53 (2H, s, H-8), 3.48 (2H, s, H-10), 2.92 (6H, s, H-17 / 18), 
2.07 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 149.9 (Arqu),  141.3 (Arqu), 137.0 (Arqu), 131.1 
(ArC-H), 130.3 (C-12 / 16), 129.5 (ArC-H), 128.0 (ArC-H), 127.0  (ArC-H), 125.8 (Arqu), 112.5 
(C-13 / 15), 62.1 (C-8), 60.5 (C-10), 44.2 (C-1), 41.2 (C-9), 40.6 (C-17 / 18); HRMS 
(ESI): Found 284.2127 (M+). C18H26N3 (M
































A stirred solution of 23 (100 mg, 0.35 mmol) in excess ethyl formate (3.00 ml, 38.1 
mmol) under N2 was heated to reflux overnight. The excess ethyl formate was removed 
under reduced pressure and the crude product purified by column chromatography using 
mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0: 93:7) as eluent to give 34 
(90 mg, 82%) as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 
(DMSO) 3606 - 3245, 2587, 2147, 2067, 1981, 1903, 1659; δH (CDCl3, 400 MHz) 8.71 
(1H, br s, NH), 8.08 (1H, s, H-1), 7.39 - 7.18 (4H, m, ArH), 7.09 (2H, d, J = 8.2 Hz, H-13 / 
17), 6.68 (2H, d, J = 8.2 Hz, H-14 / 16), 4.42 (2H, d, J = 5.2 Hz, H-2), 3.55 (2H, s, H-9), 
3.46 (2H, s, H-11), 2.93 (6H, s, H-18 / 19), 2.08 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 
160.6 (C-1), 160.6 (Arqu), 138.2 (Arqu), 137.0 (Arqu), 132.0 (ArC-H), 130.9 (ArC-H), 130.6 (C-
13 / 17), 129.4 (Arqu), 128.7 (ArC-H), 127.8 (ArC-H), 112.6 (C-14 / 16), 62.0 (C-11), 61.4 (C-
9), 41.2 (C-2), 41.0 (C-10), 40.8 (C-18 / 19); HRMS (ESI): Found 312.2076 (M+). 
C19H26N3O (M



















































To a stirred solution of 23 (400 mg, 1.41 mmol) in anhydrous N-methyl-2-pyrrolidone 
(4.00 ml) under N2, were added triethylamine (1.00 ml, 7.19 mmol), K2CO3 (0.58 g, 4.23 
mmol) and 4, 7-dichloroquinoline (1.39 g, 7.04 mmol). The mixture was heated under 
pressure in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to 
cool to room temperature it was poured into saturated brine (20 ml) and extracted with 
ethyl acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 
50 ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0:90:10) 
as eluent to give 45 (112 mg, 18%) as a dark-yellow oil; vmax/cm
-1 (DMSO) 3633, 3360 - 
3104, 2706, 2641, 2598, 2342, 2147, 2056, 1970, 1901; δH (CDCl3, 300 MHz) 8.54 (1H, 
d, J = 5.4 Hz, H-1), 7.89 (1H, d, J = 2.1 Hz, H-8), 7.79 (1H, br s, NH), 7.42 (1H, m, ArH), 
7.31 (3H, m, ArH), 7.24 (1H, d, J = 9.0 Hz, H-5), 7.04 (2H, d, J = 8.6 Hz, H-21 / 25), 6.88 
(1H, dd, J = 2.1, 9.0 Hz, H-6), 6.57 (2H, d, J = 8.6 Hz, H-22 / 24), 6.54 (1H, d, J = 5.4 Hz, 
H-2), 4.41 (2H, s, H-10), 3.61 (2H, s, H-17), 3.50 (2H, s, H-19), 2.92 (6H, s, H-26 / 27), 
2.14 (3H, s, H-18); δC (CDCl3, 75.5 MHz) 152.0 (C-1), 150.3 (Arqu), 150.0 (Arqu), 149.2  
(Arqu), 137.4 (Arqu,), 137.4 (Arqu,), 134.4 (Arqu), 132.0 (ArC-H), 130.8 (C-21 / 25), 130.5 
(ArC-H), 128.2 (C-8), 128.0 (ArC-H), 127.8  (ArC-H), 124.8 (Arqu), 124.7 (C-6), 122.6 (C-5), 
117.9 (Arqu), 112.3 (C-22 / 24), 98.8 (C-2), 61.6 (C-19), 61.0 (C-17), 46.5 (C-10), 41.5 




























To a stirred solution of 9 (1.00 g, 6.06 mmol) and K2CO3 (1.25 g, 9.09 mmol) in 
anhydrous acetonitrile (150 ml) at 0 °C, was added crude meta- α, α' -azidobromoxylene 
(1.14 g, 5.05 mmol), synthesized as outlined in GP1 and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (05:95) to (30:70) as eluent to give 16 (0.95 g, 61% 
over 2 steps.) as a yellow oil; δH (CDCl3, 300 MHz) 7.35 - 7.26 (4H, m, ArH), 7.23 (2H, d, 
J = 8.9 Hz, H-12 / 16), 6. 73 (2H, d, J = 8.9 Hz, H-13 / 15), 4.34 (2H, s, H-1), 3.52 (2H, s, 
H-8), 3.47 (2H, s, H-10), 2.94 (6H, s, H-18 / 19), 2.19 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 
149.9 (Arqu), 140.4 (Arqu), 135.2 (Arqu), 129.9 (C-12 / 16), 128.9 (ArC-H), 128.7 (ArC-H), 
128.6 (ArC-H), 126.8 (Arqu), 126.7 (ArC-H), 113.6 (C-13 / 15), 61.4 (C-8), 61.2 (C-10), 54.8 



























To a stirred solution of 16 (0.80 g, 2.58 mmol) in THF (7.20 ml) under N2, was added 
PPh3 (0.81 g, 3.10 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.40 ml, 133 mmol) was added and the reaction heated at reflux for 
Experimental 
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6 hours. The reaction was then cooled to room temperature and solvent removed on the 
rotorevaporator with the water removed by azeotroping with toluene. The crude product 
was purified directly by column chromatography using EtOAc (100%) followed by EtOAc: 
MeOH: NEt3 (93: 5: 2) as eluent to give 27 (0.59 g, 81%) as a light-brown oil; vmax/cm
-1 
(DMSO) 3531- 3410, 3286, 2137, 2060, 1986, 1661, 1611, 1511; δH (CDCl3, 300 MHz) 
7.29 – 7.18 (6H, m, ArH), 6.86 (2H, d, J = 8.7 Hz, H-13 / 15), 3.86 (2H, s, H-1), 3.79 (6H, 
s, H-18 / 19), 3.49 (2H, s, H-8), 3.47 (2H, s, H-10), 2.50 (2H, br s, NH2), 2.16 (3H, s, H-
9); δC (CDCl3, 75.5 MHz) 158.6 (Arqu), 142.4 (Arqu), 139.6 (Arqu), 131.1 (Arqu), 130.0 (C-
12 / 16), 128.3 (ArC-H), 127.6 (ArC-H), 127.5 (ArC-H), 125.7 (ArC-H), 113.5 (C-13 / 15), 61.5 






























A stirred solution of 27 (100 mg, 0.35 mmol) in excess ethyl formate (3.00 ml, 38.1 
mmol) under N2 was heated to reflux overnight. The excess ethyl formate was removed 
under reduced pressure and the crude product purified by column chromatography using 
mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0: 93:7) as eluent to give 38 
(97 mg, 89%) as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 
(DMSO) 3599-3278, 2592, 2140, 2066, 1982, 1904, 1660; δH (CDCl3, 400 MHz) 8.21 
(1H, s, H-1), 7.30 - 7.27 (3H, m, ArH), 7.21 (2H, d, J = 8.8 Hz, H-13 / 17), 7.15 (1H, m, 
H-4), 6.72 (2H, d, J = 8.8 Hz, H-14 / 16), 6.22 (1H, br s, NH), 4.45 (2H, d, J = 6.0 Hz, H-
2), 3.49 (2H, s, H-9), 3.46 (2H, s, H-11), 2.94 (6H, s, H-18 / 19), 2.17 (3H, s, H-10); δC 
(CDCl3, 100.6 MHz) 161.1 (C-1), 149.9 (Arqu), 140.1 (Arqu), 137.5 (Arqu), 130.0 (C-13 / 
17), 129.9 (Arqu), 128.6 (ArC-H), 128.4  (ArC-H), 128.4  (ArC-H), 126.4 (ArC-H), 113.6 (C-14 / 
16), 61.4 (C-9), 61.3 (C-11), 42.0 (C-2), 42.0 (C-10), 40.7 (C-18 / 19); HRMS (ESI): 
Found 312.2063 (M+). C19H26N3O (M






































To a stirred solution of 27 (0.40 g, 1.41 mmol) in anhydrous N-methyl-2-pyrrolidone (4.00 
ml) under N2, were added triethylamine (1.00 ml, 7.19 mmol), K2CO3 (0.58 g, 4.23 mmol) 
and 4,7-dichloroquinoline (1.39 g, 7.04 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0:90:10) 
as eluent to give 49 (0.14 g, 22%) as a dark-yellow oil; vmax/cm
-1 (DMSO) 3363 - 3169, 
2599, 2350, 2148, 2059, 1973, 1907, 1679, 1618; δH (CDCl3, 400 MHz) 8.47 (1H, d, J = 
5.2 Hz, H-1), 7.95 (1H, d, J = 2.0 Hz, H-8), 7.70 (1H, d, J = 8.8 Hz, H-5), 7.38 - 7.21 (4H, 
m, ArH), 7.31 (1H, dd, J = 2.0, 8.8 Hz, H-6), 7.13 (2H, d, J = 8.6 Hz, H-21 / 25), 6.61 
(2H, d, J = 8.6 Hz, H-22 / 24), 6.41 (1H, d, J = 5.2 Hz, H-2), 5.58 (1H, br s, NH), 4.47 
(2H, d, J = 4.8 Hz, H-10), 3.47 (2H, s, H-17), 3.40 (2H, s, H-19), 2.88 (6H, s, H-26 / 27), 
2.15 (3H, s, H-18); δC (CDCl3, 100.6 MHz) 152.4 (Arqu), 152.0 (C-1), 149.9 (Arqu), 149.6  
(Arqu), 140.7 (Arqu), 137.2 (Arqu), 135.0 (Arqu), 130.1 (Arqu), 129.8 (C-21 / 25), 128.8 (C-8), 
128.8 (ArC-H), 128.6 (ArC-H), 128.1 (ArC-H), 126.1 (ArC-H), 125.5 (C-6), 121.0 (C-5), 117.2 
(Arqu), 112.5 (C-22 / 24), 99.7 (C-2), 61.3 (C-17), 61.3 (C-19), 47.7 (C-10), 42.2 (C-19), 
40.7 (C-26 / 27); HRMS (ESI): Found 445.2159 (M+). C27H30N4Cl (M
































To a stirred solution of 9 (1.00 g, 6.06 mmol) and K2CO3 (1.25 g, 9.09 mmol) in 
anhydrous acetonitrile (150 ml) at 0 °C, was added crude para- α, α' -azidobromoxylene 
(1.14 g, 5.05 mmol), synthesized as outlined in GP1 and the reaction heated and 
allowed to progress under reflux for 6 hours. Acetonitrile was then removed under 
reduced pressure, saturated aqueous Na2CO3 added and the organic product extracted 
into EtOAc (3 × 100 ml). Drying (MgSO4) of the organic extracts and concentration in 
vacuo furnished  a residue, which was purified by column chromatography using 
mixtures of ethyl acetate: hexane (5:95) to (30:70) as eluent to give 20 (0.99 g, 63% over 
2 steps.) as a yellow oil; δH (CDCl3, 400 MHz) 7.40 - 7.25 (4H, m, ArH), 7.23 (2H, d, J  = 
8.6 Hz, H-12/ 16), 6.72 (2H, d, J  = 8.6 Hz, H-13 / 17), 4.32 (2H, s, H-1), 3.51 (2H, s, H-
8), 3.46 (2H, s, H-10), 2.92 (6H, s, H-17 / 19), 2.15 (3H, s, H-9); δC (CDCl3, 75.5 MHz) 
149.8 (Arqu), 139.9 (Arqu), 133.8 (Arqu), 129.8 (ArC-H), 129.3 (C-12 / 16), 128.1 (ArC-H), 
126.9 (Arqu), 112.5 (C-13 / 15), 61.4 (C-10), 61.1 (C-8), 54.6 (C-1), 42.1 (C-9), 40.7 (C-
17 / 18); HRMS (ESI): Found 310.2032 (M+). C18H24N5 (M


























To a stirred solution of 20 (0.80 g, 2.58 mmol) in THF (7.20 ml) under N2, was added 
PPh3 (0.81 g, 3.10 mmol) and the reaction mixture allowed to stir for 30 minutes at room 
temperature. Water (2.40 ml, 133 mmol) was added and the reaction heated at reflux for 
6 hours. The reaction was then cooled to room temperature and the solvent removed on 
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the rotorevaporator with the water removed by azeotroping with toluene. The crude 
product was purified directly by column chromatography using EtOAc (100%) followed 
by EtOAc: MeOH: NEt3 (93: 5: 2) as eluent to give 31 as a light-brown oil (0.65 g, 89%); 
vmax/cm
-1 (DMSO) 3545 - 3385, 3285, 2582, 2141, 2066, 1985, 1904, 1661, 1521; δH 
(CDCl3, 400 MHz) 7.31 – 7.21 (4H, m, ArH), 7.19 (2H, d, J = 8.8 Hz, H-12 / 16), 6.69 
(2H, d, J = 8.8 Hz, H-13 / 15), 3.81 (2H, s, H-1), 3.46 (2H, s, H-8), 3.43 (2H, s, H-10), 
2.91 (6H, s, NMe2), 2.49 (2H, br s, NH2), 2.14 (3H, s, N-CH3); δC (CDCl3, 75.5 MHz) 
149.8 (Arqu),141.2 (Arqu), 138.0 (Arqu), 129.8 (C-4 / 6), 129.2 (C-12 /16), 127.0 (C-3 / 7); 
126.8 (Arqu), 112.5 (C-13 / 15), 61.2 (C-8 or C-10), 61.1 (C-8 or C-10), 46.0 (C-1), 41.9 






























A stirred solution of 31 (100 mg, 0.35 mmol) in excess ethyl formate (3.00 ml, 38.1 
mmol) under N2 was heated to reflux overnight. The excess ethyl formate was removed 
under reduced pressure and the crude product purified by column chromatography using 
mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0: 93:7) as eluent to give 42 
(85 mg, 78%) as a thick-yellow oil and predominantly as a s-trans rotamer; vmax/cm
-1 
(DMSO) 3615 - 3235, 2595, 2142, 2061, 1973, 1901, 1657; δH (CDCl3, 400 MHz) 8.16 
(1H, s, H-1), 7.32 -7.20 (4H, m, ArH), 7.19 (2H, d, J = 8.8 Hz, H-13 / 17), 6.69 (2H, d, J = 
8.8 Hz, H-14 / 16), 5.41 (1H, br s, NH), 4.41 (2H, d, J = 5.7 Hz, H-2), 3.51 (2H, s, H-9), 
3.47 (2H, s, H-11), 2.90 (6H, s, H-18 / 19), 2.14 (3H, s, H-10); δC (CDCl3, 75.5 MHz) 
161.1 (C-1), 149.9 (Arqu), 138.0 (Arqu), 136.4 (Arqu), 130.0 (C-5 / 7), 129.5 (C-13 / 17), 
127.6 (C-4 / 8) , 125.6 (Arqu), 112.4 (C-14 / 16), 60.9 (C-9 or 11), 60.6  (C-9 or 11), 41.8 













































To a stirred solution of 31 (0.40 g, 1.41 mmol) in anhydrous N-methyl-2-pyrrolidone (4.00 
ml) under N2, were added triethylamine (1.00 ml, 7.19 mmol), K2CO3 (0.58 g, 4.23 mmol) 
and 4,7-dichloroquinoline (1.39 g, 7.04 mmol). The mixture was heated under pressure 
in a cyclo-addition tube at 120 °C overnight. After the mixture was allowed to cool to 
room temperature it was poured into saturated brine (20 ml) and extracted with ethyl 
acetate (3 × 50 ml). The organic layer was further washed with saturated brine (5 × 50 
ml) to ensure removal of any traces of the pyrrolidone. The organic layer was dried 
(Na2SO4), concentrated in vacuo and the resulting crude product was purified by column 
chromatography using mixtures of hexane: ethyl acetate: methanol (50:50:0) to (0:90:10) 
as eluent to give 53 (0.16 g, 26%) as a dark-yellow oil; vmax/cm
-1 (DMSO) 3616, 3378 - 
3212, 2596, 2150, 2062, 1977, 1904, 1674, 1635; δH (CDCl3, 400 MHz) 8.43 (1H, d, J = 
5.4 Hz, H-1), 7.92 (1H, d, J = 2.0 Hz, H-8), 7.70 (1H, d, J = 9.0 Hz, H-5), 7.34 - 7.28 (4H, 
m, ArH), 7.26 (1H, dd, J = 2.4, 9.0 Hz, H-6), 7.19 (2H, d, J = 8.4 Hz, H-21 / 25), 6.68 
(2H, d, J = 8.4 Hz, H-22 / 24), 6.37 (1H, d, J = 5.4 Hz, H-2), 5.82 (1H, br s, NH), 4.43 
(2H, d, J = 4.8 Hz, H-10), 3.46 (2H, s, H-17), 3.42 (2H, s, H-19), 2.89 (6H, s, H-26 / 27), 
2.15 (3H, s, H-18); δC (CDCl3, 75.5 MHz) 151.7 (C-1), 149.7 (Arqu), 149.7 (Arqu), 148.8 
(Arqu), 139.2 (Arqu), 135.6 (Arqu), 134.8 (Arqu), 129.7 (C-13 / 15), 129.3 (C-21 / 25), 128.3 
(C-8), 127.3 (C-12 / 16), 126.7 (Arqu), 125.2 (C-6), 121.3 (C-5), 117.1 (Arqu), 112.4 (C-22 
/ 24), 99.5 (C-2), 61.2 (C-17 or 19), 61.0 (C-17 or 19), 47.1 (C-10), 42.0 (C-18), 40.6 (C-
26 / 27); HRMS (ESI): Found 445.2159 (M+). C27H30N4 Cl (M
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V Z_ UC T _0 80 61 8 _1 2b   1 8 (0 .1 9 7) Cn  (C en ,4, 8 0.00 , Ar); S m  (S G , 1x 3 .0 0); Sb  (1 ,40 .00  ); C m  (18 :27 -10 1:1 42 ) T O F M S  ES + 





















































































































V Z_ UC T _0 80 6 18 _3 2   1 36  (1 .43 5 ) C n (C en ,4, 80 .00 , A r); S m  (S G , 1x 3 .0 0 ); S b (1,4 0.0 0 ); C m  (1 3 2:14 2 -1 :11 ) T O F M S  E S + 


































V Z_ UC T _0 80 6 18 _4 2   4 3 (0.4 58 ) Cn  (C e n,4 , 8 0.0 0, Ar); Sm  (SG , 1 x3 .00 ); S b  (1 ,4 0 .0 0  ); Cm  (43 :51-1:5 ) T O F M S  E S + 
1.5 5e 3432 .1825
368 .1531








































































HRMS (ES) spectra for (51): Found 436.1335 (M+). C25H24N3Cl2 requires 436.1347. 
 
 
 
 
 
 
 
 
 
